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1  Zusammenfassung
Ein Hauptmerkmal eukaryoter Zellen ist ihre räumliche wie funktionelle Unterteilung in den
Zellkern und das Zytoplasma. Im Gegensatz zu den Prokaryonten, die nur ein einziges
zelluläres Kompartiment besitzen, können somit eine Vielzahl zelluläre Prozesse besser
reguliert,  und  somit  eine  weitaus  komplexere  Ebene  an  intra-  und  interzellulärer
Kommunikation erreicht werden. Dies erfordert jedoch die Existenz eines hoch spezifischen
und effizienten Transportsystems, welches den Austausch von Makromolekülen zwischen
den beiden Kompartimenten vermittelt.
Ziel dieser Arbeit war es, die Bedeutung des Kern-Zytoplasma-Transports für die biologische
Funktion von Transkriptionsfaktoren sowie von Proteinen, welche am programmierten Zelltod
beteiligt sind, aufzuklären. Zusätzlich sollten zelluläre Testsysteme entwickelt werden, die
eine Identifizierung von molekularen Werkzeugen zur Interferenz mit dem Kern-Zytoplasma-
Transport von Proteinen erlauben.
Um  essentielle  biologische  Prozesse  wie  die  der  Signaltransduktion,  Transkription  und
Translation zeitlich und räumlich effizient kontrollieren zu können, sind der Zellkern und das
Zytoplasma durch die Kernhülle voneinander getrennt. Der Substanzaustausch durch die
Kernhülle wird durch die kanalartigen, dynamischen Kernporenkomplexe vermittelt, welche
aus lektinbindenden Proteinen, den so genannten Nukleoporinen aufgebaut sind (Übersicht
in Pante, 2004). Es wird angenommen, daß neben Ionen und Metaboliten Makromoleküle bis
zu  einem  Molekulargewicht  von  60  kDa  die  Kanäle  der  Kernporen  einem
Konzentrationsgradienten folgend mittels freier Diffusion passieren können. Makromoleküle
von  mehr  als  60  kDa  werden  hauptsächlich  mittels  eines  aktiven  Transportprozesses
transportiert,  welcher  signalspezifisch  und  energieabhängig  auch  gegen  ein
Konzentrationsgefälle erfolgen kann, wobei der Kernporenkomplex als selektiver Transporter
fungiert  (Übersicht  in  Pemberton  &  Paschal,  2005).  Der  Transport  wird  durch
Transportrezeptoren vermittelt, die ihre Substrate über spezifische Sequenzmotive erkennen
und binden können, und selbst zwischen dem Zellkern und dem Zytoplasma wandern. Die
Nukleoporine  dienen  hierbei  hauptsächlich  als  stationäre  Phase,  an  denen  die  mit
Transportsubstraten  beladenen  Rezeptoren  transient  binden.  Je  nach  Richtung  der
Translokation wird bei den Erkennungssequenzen zwischen nukleären Importsignalen (NLS)
und nukleären Exportsignalen (NES) unterschieden. „Klassische“ NLSe bestehen aus einer
Anhäufung  basischer  Aminosäuren  (zur  Übersicht  siehe  Bednenko et al.,  2003)  und
vermitteln über die Bindung an die Transportrezeptoren Importin-α und -β den Kernimport.
Für  eine  Reihe  von  Transportsubstraten  wird  jedoch  auch  ein  Kernimport  direkt  durchZUSAMMENFASSUNG
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Importin-β oder durch alternative Importrezeptoren diskutiert.
Im Gegensatz zum Kernimport ist der Kernexport molekular weniger gut verstanden. Die am
besten charakterisierten Kernexportsignale sind reich an hydrophoben Aminosäuren, wie
Leucin oder Isoleucin (zur Übersicht siehe Bednenko et al., 2003). Leucin-reiche NESe
vermitteln als Komplex mit Ran-GTP die Bindung an den Exportrezeptor Exportin-1 (CRM1).
Die  Bindung  der  Transportsignale  sowie  die  anschließende  Freisetzung  der
Transportrezeptoren  wird  durch  die  asymmetrische  Verteilung  von  Ran  in  seinen
verschiedenen nukleotid-gebundenen Formen reguliert. In neueren Arbeiten sind eine Reihe
weiterer Exportrezeptoren identifiziert worden, denen eine Selektivität für gewisse Proteine
und RNA-Spezies zugeschrieben werden.
Für  eine  Vielzahl  von  Molekülen  ist  der  koordinierte  und  effiziente  Ablauf
nukleozytoplasmatischer Transportprozesse essentiell für die Ausübung ihrer biologischen
Aufgaben. Insbesondere für Transkriptionsfaktoren stellt die Regulation ihrer subzellulären
Lokalisation einen attraktiven Mechanismus zur Kontrolle ihrer Aktivität dar. Die komplexen
Expressionsmuster  der  Homeobox-Gene  in  der  embryonalen  Retina  erfordern  ein
ausgeklügeltes regulatorisches Netzwerk von Transkriptionsfaktoren (Ohtoshi et al., 2004).
Um eine mögliche Regulation der Aktivität dieser Transkriptionsfaktoren durch aktiven Kern-
Zytoplasma-Transport  zu  untersuchen,  wurde  im  Rahmen  dieser  Arbeit  das  intra-  und
interzelluläre Transportverhalten der sogenannten „paired-like CVC Homeodomain“ Proteine
(PLC-HDPs)  auf  molekularer  Ebene  analysiert  (Knauer  et  al.,  2005a).  Mittels
Deletionsmutagenese,  Mikroinjektionsexperimenten  und  biochemischer  Analysen  konnte
gezeigt werden, daß die Mitglieder der PLC-HDP Familie über den CRM1-Signalweg aus
dem Kern exportiert werden und ein evolutionär konserviertes Leucin-reiches NES enthalten.
Der Kernexport regulierte durch den verstärkten proteasomalen Proteinabbau im Zytoplasma
die intrazelluläre Konzentration und extrazelluläre Sekretion der PLC-HDPs, und beeinflußte
somit  die  transkriptionelle  Aktivität  der  PLC-HDPs.  Die  hauptsächlich  nukleäre
Gleichgewichtslokalisation der PLC-HDPs wurde durch ein aktives NLS vermittelt, welches in
der PLC-HDP Familie zu 100% konserviert ist. Die hohe Homologie des NLS zu bekannten
Protein-Transduktionsdomänen  (PTD)  konnte  auch  funktionell  verifiziert  werden.  Die
Integrität beider Signale, NES und NLS/PTD, erscheint somit als Grundvoraussetzung für die
Funktion  der  PLC-HDPs  als  mobile  nukleozytoplasmatische  „shuttle“-Proteine  mit  dem
Potential  zur  unkonventionellen  Sekretion  und  zum  interzellulären  Transfer.  Neben  der
Kontrolle auf der Ebene der Transkription, scheint der Kern-Zytoplasma-Transport somit
einen zusätzlichen konservierten Kontrollmechanismus für die präzise Feinregulation der
transkriptionellen Aktivität der PLC-HDPs darzustellen, um das komplexe Expressionsmuster
innerhalb der Retina-Entwicklung zu gewährleisten.ZUSAMMENFASSUNG
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Neben  intrazellulären  Transportsignalen  können  auch  posttranslationelle  Modifikationen
einen regulatorischen Einfluß auf die Lokalisation von Proteinen haben. Beispielsweise wird
der  nukleozytoplasmatische  Transport  der  STAT  Transkriptionsfaktoren  durch
Phosphorylierungen reguliert (McBride & Reich, 2003), und auch andere Modifizierungen wie
Sumoylierung (Endter et al., 2001) und Acetylierung (Yuan et al., 2005) können einen Einfluß
auf den Kerntransport von Proteinen haben. Das Gleichgewicht zwischen der Acetylierung
und Deacetylierung von Proteinen wird durch die sogenannten Histon-Acetyltransferasen
(HATs) und Histon-Deacetylasen (HDACs) reguliert (Kouzarides, 1999). Chemische HDAC-
Inhibitoren (HDACi) können das Expressionsmuster verschiedenster Gene beeinflussen,
deren Genprodukte wichtige regulatorische Funktionen während der Differenzierung, des
Zellzyklus,  der  Apoptose  oder  der  Signaltransduktion  ausüben.  Um  die  molekularen
Wirkmechanismen der HDACi zu verstehen, wurde in der vorliegenden Arbeit (Krämer et al.,
2005)  der  Einfluß  von  HDACi  auf  Signaltransduktionskaskaden  und  auf  die
Apoptoseinduktion untersucht. Es zeigte sich, daß die durch HDACi verursachte Apoptose
mit der Expression des STAT1-Proteins korrelierte, und die ektope Expression von STAT1 in
STAT1-defizienten  Zellen  die  HDACi  vermittelte  Apoptose  auslösen  konnte.  HDACi
induzierten  nicht  nur  die  STAT1-Expression,  sondern  bewirkten  außerdem  dessen
Acetylierung. Acetyliertes STAT1 zeigte eine verbesserte Bindung an NF-κB p65, und die
STAT1/NF-κB p65 Komplexe wiesen eine verminderte nukleäre Lokalisation und reduzierte
DNA-Bindung auf, was letztendlich eine verminderte Expression anti-apoptotischer Zielgene
zur Folge hatte. Diese Arbeit zeigte, daß die Interaktion zwischen STAT1 und dem NF-κB
Signaltransduktionsweg durch HDACi-induzierte Änderungen im Acetylierungszustand von
STAT1 reguliert werden, und durch Beeinflussung der intrazellulären Lokalisation letztendlich
die biologische Aktivität von Signaltransduktionswegen verändert werden kann.
Nicht nur indirekt über die Aktivierung von Signaltransduktionsketten, sondern auch direkt
spielt  der  Kern-Zytoplasma-Transport  eine  wichtige  Rolle  innerhalb  der  Apoptose.  Der
programmierte Zelltod kann sowohl durch interne als auch durch externe Stimuli ausgelöst
werden  (Übersicht  in  Krammer,  2000),  und  erfordert  letztendlich  den  Zugang  von
Effektorproteinen zum Zellkern. Deregulierte Apoptosevorgänge spielen eine wichtige Rolle
bei  einem  breiten  Spektrum  humaner  Erkrankungen  einschließlich  Krebs.  Neben  den
Mitgliedern der Bcl-2 Proteinfamilie (Cory & Adams, 2002) kann die enzymatische Aktivität
der Caspasen auch durch die sog. „Inhibitoren der Apoptose" Proteine (IAPe) (Deveraux &
Reed, 1999) reguliert werden. Besondere Beachtung fand in den letzten Jahren das IAP
Survivin, welches in den meisten Tumoren stark exprimiert wird und an der Resistenz von
Tumoren gegenüber Radio- und Chemotherapie beteiligt zu sein scheint (Altieri, 2003d).ZUSAMMENFASSUNG
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Neben seiner anti-apoptotischen Aktivität spielt Survivin außerdem als sog. „chromosomal
passenger“ eine wichtige Rolle während der Zellteilung (Lens et al., 2003). Diese duale Rolle
weist Survivin als ein attraktives Ziel für die Entwicklung neuer Krebstherapeutika aus.
In der vorliegenden Arbeit wurde daher untersucht, ob und in welcher Weise der Kern-
Zytoplasma-Transport eine Rolle für die biologische Funktion von Survivin spielt (Knauer et
al.,  2005b).  Die  Überexpression  von  Survivin  konnte  in  Kopf-Hals-Tumoren  und  in
kolorektalen Karzinomen sowohl auf RNA als auch auf Proteinebene verifiziert werden.
Dabei  zeigte  sich,  daß  Survivin  sowohl  im  Zytoplasma  als  auch  im  Zellkern  von
Tumorproben detektiert werden konnte, was auf eine dynamische intrazelluläre Lokalisation
hinwies. Diese Annahme konnte durch die Identifizierung eines evolutionär konservierten
CRM1-abhängigen  Leucin-reichen  NESs  bestätigt  werden.  Interessanterweise  war  die
Integrität des NES essentiell für eine geordnete Zellteilung, da Survivin durch die NES-
vermittelte  Interaktion  mit  CRM1  an  die  Mitosemaschinerie  lokalisiert  wurde.  Zusätzlich
zeigte sich, daß der Kernexport wichtig für den durch Survivin vermittelten Schutz gegenüber
Chemo-  und  Radiotherapie  induzierter  Apoptose  war,  da  die  NES-vermittelte
zytoplasmatische  Lokalisation  von  Survivin  eine  optimale  Interaktion  mit  der
Apoptosemaschinerie zu ermöglichen scheint. Die klinische Relevanz dieser Ergebnisse
wurde durch die Beobachtung untermauert, daß eine vorwiegend nukleäre Lokalisation von
Survivin, welche durch Störung des nukleären Exports in Zellkulturexperimenten induziert
werden konnte, mit einer längeren Überlebensdauer in Kolonkarzinompatienten korrelierte.
Somit scheint der Kernexport essentiell für die duale biologische und auch tumorfördernde
Aktivität von Survivin zu sein. Die spezifische Interferenz mit dem Kernexport von Survivin
stellt daher einen vielversprechenden Ansatz für die Entwicklung neuer Anti-Krebs-Therapien
dar.
Die Ergebnisse dieser Studie und eine Vielzahl von Beispielen aus der Literatur belegen,
daß nukleozytoplasmatische Transportprozesse essentiell für die biologische Funktionen von
Proteinen sind, welche eine zentrale Rolle für eine Reihe von Krankheitsprozessen spielen.
Der  Ansatz,  die  gerichtete  Modulation  nukleozytoplasmatischer  Transportprozesse  als
therapeutische Strategie zu verfolgen, rückte daher in den letzten Jahren vermehrt in das
Interesse  von  akademischer  und  industrieller  Forschung  (Kau et al.,  2004).  In  diesem
Zusammenhang ist die Verfügbarkeit zellbasierte Testsysteme von besonderer Bedeutung,
um eine effiziente Identifizierung und Validierung von Inhibitoren dynamischer intrazellulärer
Prozesse zu gewährleisten.ZUSAMMENFASSUNG
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Im Rahmen dieser Arbeit wurden neuartige Biosensoren generiert, welche es ermöglichen,
den signal-spezifischen Kern-Zytoplasma-Transport molekular zu charakterisieren, und die
zugleich als Grundlage für die Entwicklung zell-basierter Testsysteme zur Identifizierung
chemischer  Transportinhibitoren  dienen  können.  (Knauer  et  al.,  2005c).  Die
autofluoreszierenden Translokations-Biosensoren setzten sich aus Glutathion-S-Transferase
(GST), Mutanten des grün-fluoreszierenden Proteins (GFP) sowie rationalen Kombinationen
aus nukleären Import- und Exportsignalen zusammen. Diese hauptsächlich im Zytoplasma
lokalisierten Indikatormoleküle wandern kontinuierlich zwischen Kern- und Zytoplasma. Die
Inhibition des Kernexports führte zu einer quantitativen nukleären Translokation, welche
fluoreszenzmikroskopisch bereits in lebenden Zellen detektiert und automatisch quantifiziert
werden konnte. Dieses System erlaubt es nicht nur, den Einfluß der Expression oder der
siRNA-vermittelten  Degradation  von  Proteinen  auf  den  Kern-Zytoplasma-Transport  zu
untersuchen,  sondern  auch  chemische  Substanzen  auf  deren  inhibitorische  Aktivität  zu
testen bzw. Inhibitoren aus Substanzbibliotheken zu identifizieren.
Zudem  wurden  die  Transport-Biosensoren  zu  Protein-Translokations-Biosensoren  (PTB)
weiterentwickelt, welche es erlauben, Protease-Aktivität sowie Protein-Protein-Interaktionen
in vivo zu erforschen.
Zur Generierung der Protease-Biosensoren wurde in die Transport-Biosensoren zusätzlich
eine  Proteasespaltstelle  vor  dem  NES  integriert.  Intrazelluläre  Proteasen  bewirken  die
proteolytische Abspaltung des NES, wodurch die Kernakkumulation des Biosensors induziert
wird. Die Funktionalität des Systems als Apoptose-Sensor konnte durch die Integration der
Casapase-3 Schnittstelle experimentell verifiziert werden.
Eine  dritte  Anwendung  des  Translokationsprinzips  stellt  das  sog.  „Two-Hybrid“  Protein-
Interaktions-System  dar.  Ein  primär  zytoplasmatisch  lokalisiertes  „Beute“-GFP-
Fusionsprotein, welches kontinuierlich zwischen Zytoplasma und Zellkern wandert, beinhaltet
die zu testenden Proteindomäne. Durch Koexpression mit dem am Nukleolus verankertem
„Köder“-BFP-Fusionsprotein, welches eine zweite Proteindomäne enthält, findet im Falle
einer  effizienten  in  vivo  Protein-Interaktion  eine  Translokation  des  „Beute“-GFP-
Fusionsprotein an den Nukleolus statt, die fluoreszenzmikroskopisch bereits in lebenden
Zellen detektiert werden kann. Die Spezifität sowie die generelle Anwendbarkeit der PTB
wurde durch die Analyse unterschiedlicher Klassen von Protein-Interaktionsdomänen (ID),
wie  z.B.  der  „Leucin-Zipper“-ID  der  Transkriptionsfaktoren  Jun  und  Fos,  der  basischen
„Helix-loop-Helix-Zipper“ ID der Transkriptionsfaktoren Myc und Max sowie der „coiled-coil“
ID der leukämieassoziierten Bcr-Abl-Proteinkinase nachgewiesen (Knauer et al.,  2005c;
Knauer & Stauber, 2005). Das Translokations-System erlaubt neben der Verifizierung der inZUSAMMENFASSUNG
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vivo Protein-Interaktion auch eine effiziente Kartierung von ID, wie am Beispiel der Proteine
p53 und Mdm2 gezeigt werden konnte (Knauer & Stauber, 2005). Im Gegensatz zu auf
Enzym-Komplementation  basierenden  Testsystemen  erwies  sich  das  PTB-System  als
effizient und reversibel, und somit auch zur systematischen Identifizierung synthetischer
Protein-Protein-Interaktions-Inhibitoren geeignet.
Die  im  Rahmen  dieser  Arbeit  entwickelten  Biosensoren  nutzen  somit  die  nukleäre
Akkumulation der vormals zytoplasmatischen Indikatormoleküle als gemeinsamen „Read-
out". Durch die gerichtet Integration regulatorischer Sequenzen konnten drei Klassen von
Biosensoren  entwickelt  werden,  welche  zum  Studium  von  Kerntransportprozessen,  der
Aktivität intrazellulärer Proteasen und von Protein-Protein-Wechselwirkungen angewendet
werden können. Die vorgestellten Testsysteme erscheinen auch für die Entwicklung von
zellbasierten  Testsystemen  geeignet,  um  eine  systematische  Identifizierung  von
niedermolekularen potentiell therapeutisch relevanten Inhibitoren durchzuführen.
Die vorliegende Arbeit unterstreicht nicht nur die allgemeine zellbiologische Bedeutung des
nukleozytoplasmatischen  Transports,  sondern  verdeutlich  auch  dessen  Potential  zur
Entwicklung neuer Therapien gegen Krankheiten.INTRODUCTION
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2  Introduction
One defining key feature of eukaryotic cells is their spatial and functional division into the
nucleus  and  the  cytoplasm.  In  contrast  to  prokaryotes  that  only  possess  one  cellular
compartment,  numerous  fundamental  biological  processes  can  be  regulated  more
sophisticatedly,  and  thus  a  much  more  complex  level  of  intra-  and  intercellular
communication can be achieved. To efficiently control fundamental biological processes like
signal transduction, transcription and translation in a time and space dependent manner, the
nucleus, comprising most of the cell’s genetic material, and the cytoplasm, where protein
synthesis takes place, are separated by the nuclear envelope and transport occurs through
the nuclear pore complexes. This type of regulation requires the existence of a highly specific
and efficient transport machinery for the controlled transport of macromolecules between
both  compartments.  Ordered  regulation  of  bidirectional  nucleo-cytoplasmic  transport  is
critical for normal cell function and essential for cellular homeostasis. Deregulation of nucleo-
cytoplasmic  transport  has  been  observed  in  many  disease  conditions,  and  the  cellular
transport machinery is also taken advantage of by intracellular parasites, such as viruses.
Thus, besides the academic interest in a detailed understanding of the molecular regulation
of nucleo-cytoplasmic transport, targeted intervention with transport is now considered also
an attractive opportunity for the development of novel therapeutics.
Therefore, this work aimed to unreveal the impact of nucleo-cytoplasmic transport on the
biological function of transcription factors as well as proteins involved in programmed cell
death.  Additionally,  cell-based  assay  systems  should  be  developed,  which  allow  the
identification of molecular tools for the interference with nucleo-cytoplasmic transport of
proteins.NUCLEO-CYTOPLASMIC TRANSPORT
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3  Nucleo-cytoplasmic transport
All nucleo-cytoplasmic transport processes take place through the nuclear pores that are
embedded in the nuclear envelope (reviewed in Fahrenkrog et al., 2004; Pante, 2004). Ions,
metabolites, and other small molecules up to a size of 60 kDa are able to passively diffuse
through  the  pore  channels,  whereas  larger  molecules  or  complexes  must  be  actively
transported in an energy-dependent manner (Pante & Kann, 2002). This active transport can
also occur against a concentration gradient, and is mediated by soluble transport factors, that
in turn shuttle between the nucleus and the cytoplasm. Importantly, even molecules that are
theoretically small enough for passive diffusion are actively and selectively transported, and
often play crucial roles for cellular homeostasis (Görlich & Kutay, 1999), since regulated
transport appears to be more efficient and more amendable for specific regulation.
3.1  Composition and structure of the nuclear pore complex
The complex macromolecular structure that acts as the passageway for transport is a large
dynamic multi-protein assembly called the nuclear pore complex (NPC) (Pante, 2004). It is
embedded in the double membrane of the nuclear envelope and has an estimated molecular
mass  of  125  MDa  in  vertebrates (Reichelt et al., 1990).  Although  the  NPC  performs  a
function analogous to membrane channels, it does not span the individual bilayers but
instead forms an aqueous channel at the site where the inner and outer nuclear membrane
are continuous. Figure 3.1.1.A shows an electron microscopical (EM) cross-section of a
vertebrate  nuclear  pore  (Stoffler et al.,  1999)  with  a  double-layered  nuclear  membrane
around the pore and a high electron density in the central plane of the nuclear membrane. It
extends approximately 120 nm in width and 200 nm in heights (figure 3.1.1.A). In vertebrates
the NPC is composed of about 30 different proteins that are collectively termed nucleoporins
(NUPs) (reviewed in Fahrenkrog et al., 2004; Pante, 2004). Owing to the eight-fold rotational
symmetry of the NPC and the relatively small number of proteins that build up the nuclear
pore, it can be assumed that most of the NUPs are present at a copy number of either 8 or
an integer multiple of 8 per pore. The 8-fold symmetry around a central axis can also be
observed in the conventional transmission electron microscopical (CTEM) top view of nuclear
pores shown in figure 3.1.1.B (Reichelt et al., 1990). The schematic organization of the
nuclear  pore  complex  is  depicted  in  figure  3.1.1.C.  It  is  composed  of  a  central  bodyNUCLEO-CYTOPLASMIC TRANSPORT
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consisting of eight spoke-like segments sandwiched between nucleoplasmic and cytoplasmic
rings. The spokes project radially from the wall of the pore membrane and surround a central
tube called the central transporter. Each spoke is composed of numerous struts and attached
to  its  neighbors  by  four  coaxial  rings:  an  outer  spoke-ring  in  the  lumen  of  the  nuclear
envelope adjacent to the pore membrane, a nucleoplasmic ring, a cytoplasmic ring, and an
inner spoke-ring surrounding the central transporter. A considerable portion of each spoke
traverses the pore membrane and resides in the lumen of the nuclear envelope. Together
these structures comprise the central core. Peripheral elements project from this core toward
the nucleoplasm and cytoplasm. These include numerous proximal filaments on both faces
of  the  cylindrical  central  core,  whose  presence  is  inferred  from  the  large  number  of
symmetrically  disposed  filamentous  nucleoporins.  In  addition,  fibers  extend  into  both
cytoplasm and nucleus. The eight cytoplasmic filaments are attached at the cytoplasmic ring,
and the nuclear filaments originate at the nuclear ring and conjoin distally to form a basket-
like  structure  below  the  body  of  the  NPC,  reaching  approximately  120  nm  into  the
nucleoplasm (figure 3.1.1.A), thus connecting with elements of the nucleoskeleton. The body
of the NPC thereby forms a central channel through which macromolecules are transported.NUCLEO-CYTOPLASMIC TRANSPORT
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Figure 3.1.1. Structure of the nuclear pore complex. (A) EM cross-section of a vertebrate
NPC (Xenopus  laevis) and the respective schematic comparison (Stoffler  et  al., 1999)  (B)
CTEM top view of negatively stained vertebrate NPCs (Xenopus laevis) (Reichelt et al., 1990).
(C) Organization of a vertebrate NPC. Structural elements are marked by arrows (Rout &
Aitchison, 2001). See text for further explanations.
Nucleoporins can be assigned to two different groups: NUPs without phenylalanine-glycine
(FG)-repeats, which form the basic scaffold of the nuclear pore (Doye & Hurt, 1997), and FG-
repeat  containing  NUPs  (see  table  3.1.).  Those  interact  with  the  transport  receptors,
importins (IMPs) and exportins (EXPs), and are considered to guide the transport receptor-
cargo complexes through the pore.
Investigations  on  the  composition  of  the  NPC  revealed  distinct  subcomplexes  of
nucleoporins. The relative positions of individual NUPs in the NPC structure have been
determined by immuno-electron microscopy (Fahrenkrog et al., 2000; Rout et al.,  2000;
Stoffler et al., 1999), revealing a defined network of NUP-NUP subcomplexes. Thus, the
NUPs seem to have specific substructural localizations within the NPC architecture, with
distinct protein compositions on the cytoplasmic and the nucleoplasmic faces (see table 3.1.
and figure 3.1.2.), which may reflect distinct functions during NPC assembly and transport
(reviewed in Suntharalingam & Wente, 2003).NUCLEO-CYTOPLASMIC TRANSPORT
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Table 3.1. NPC Components in Vertebrates.
Nucleoporin Localization Motif(s)
NUP153b Nuclear FXFG
NUP62 Symmetric FG, FXFG
NUP50b Nuclear-biased FXFG
NLP1/hCG1 (45) Cytoplasmic FG
NUP58, NUP45 Symmetric FG
NUP35 Symmetric
NUP35 Symmetric
NUP54 Symmetric FG
NUP88 Cytoplasmic
NUP107 Symmetric
NUP75/NUP85 Symmetric
NUP93 Symmetric
NUP98b Cytoplasmic-biased GLFG
NUP98b Cytoplasmic-biased FG, GLFG
NUP98b Nuclear-biased GLFG
NUP160 Symmetric
NUP133 Symmetric
NUP96 Symmetric
NUP155 Symmetric
NUP155 Symmetric
NUP214/CAN Cytoplasmic FG
NUP188 Symmetric
NUP205 Symmetric
hGle1b,d (85) Cytoplasmic-biased
Rae1/Gle2b (41) Symmetric WD
Tpr (266) Nuclear
Tpr (266) Nuclear
Seh1 (40) Symmetric WD
Pom121 Pore membrane FG, TM
Gp210 Pore membrane TM
NUP358/RanBP2 Cytoplasmic FXFG
ALADIN (60) ? WD
NUP37 ? WD
NUP43 ? WD
Table  based  on  the  general  NUP  nomenclature.  The  numerical  designation  reflects  the
predicted mass in kDa. For a subset where this is not the case, the predicted mass is in
parentheses. A NUP having two different names is indicated by “/”.NUCLEO-CYTOPLASMIC TRANSPORT
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Figure 3.1.2. NUP Subcomplexes in Vertebrate NPCs. The boxes show the reported NUP-
NUP subcomplexes. Defined NUP-NUP interactions are indicated by the dashes, whereas
commas  indicate  that  the  association  network  is  not  fully  known.  Their  relative  surface-
accessible localizations are indicated: purple or green box: asymmetric, only on the designated
side;  blue  box:  symmetric  with  two  sets,  one  on  each  side.  Figure  adapted  from
(Suntharalingam & Wente, 2003). See text for further explanations.
3.2  The Ran-GTPase cycle
As the process of active transport is mediated by mobile transport receptors interacting with
NUPs, it additionally needs diverse soluble factors that are able to shuttle between the
nucleus and the cytoplasm as well. One of these soluble factors, which plays an important
role in conferring directionality to nucleo-cytoplasmic transport events, is the small Ras-like
GTPase (guanosine-5'-triphosphatase) Ran (Izaurralde et al., 1997; Nachury & Weis, 1999).
Furthermore,  Ran  acts  in  diverse  cellular  processes  like  mitotic  spindle  assembly,  the
regulation of cell cycle progression, and post-mitotic nuclear assembly (Dasso, 2002). In
contrast to the majority of the members of Ras superfamily, Ran localizes predominantly to
the nucleus. Similar to other Ras-like GTPases, Ran occurs in to different bound states
inside the cell (reviewed in Görlich & Kutay, 1999; Kuersten et al., 2001). Either it is bound to
guanosine triphosphate (GTP), or it is complexed to guanosine diphosphate (GDP) (figure
3.2.). A steep Ran-GTP/Ran-GDP gradient has been measured across the nuclear envelope,
being  the  key  for  dictating  the  bidirectionality  of  transport.  This  gradient  with  nuclearlyNUCLEO-CYTOPLASMIC TRANSPORT
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enriched Ran-GTP is generated by the cellular compartmentalization of the regulators of the
Ran cycle. The existence of these specific factors is necessary because of the low intrinsic
GTP-hydrolysis  und  nucleotide  exchange  activity.  Specifically,  the  guanine-nucleotide
exchange factor of Ran (RanGEF or RCC1), which regenerates Ran-GTP, is nuclear and
associated with the chromatin (Azuma & Dasso, 2000; Dasso, 2001). In contrast, the main
GTPase-activating protein (RanGAP) and its co-activators, the Ran-binding proteins RanBP1
and RanBP2, which stimulate GTP to GDP + Pi hydrolysis, localize to the cytoplasm (Dasso,
2001). As a direct consequence, nuclear Ran is predominantly bound to GTP whereas
cytoplasmic Ran is immediately converted to a GDP-bound state. Interestingly, an increase
of Ran-GTP levels in the cytoplasm of permeabilized HeLa cells could partially invert the
direction of transport (Nachury & Weis, 1999).
It was also suggested that, in addition to the Ran cycle, the NPC itself could provide a further
mechanism  to  ensure  transport  directionality  (Ben-Efraim  &  Gerace,  2001).  Given  that
several  nucleoporins  implicated  in  binding  to  importins  and  exportins  have  distinctive
locations in the structure of the NPC, the asymmetric design of the NPC may also be
important to efficiently drive nuclear import and export.
Figure 3.2. The Ran-GTP/GDP cycle. Figure modified from (Kuersten et al., 2001). See text for
details.NUCLEO-CYTOPLASMIC TRANSPORT
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3.3  The protein family of karyopherins
Most  nucleo-cytoplasmic  transport  processes  are  mediated  by  a  group  of  homologous
transport receptors, the karyopherins. They belong to the family of importin-β-like proteins,
named after the first characterized member importin-β (Görlich et al., 1995). In vertebrates,
there exist at least 20 different karyopherins (table 3.3.), which recognize their various
cargoes via transport signals present in them (reviewed in Pemberton & Paschal, 2005).
Depending  on  the  direction  of  transport,  karyopherins  are  divided  into  importins  und
exportins, with the potential to recognize either substrates with an nuclear import/localization
(NLS)  or  nuclear  export  signal  (NES),  respectively.  Importins  bind  their  cargo  in  the
cytoplasm and transfer it to the nucleus, whereas exportins interact with their substrates in
the  nucleus  and  mediate  their  export  to  the  cytoplasm.  Human  importin-13  takes  an
exceptional position within the karyopherins (Mingot et al., 2001), mediating both export and
import of its substrates, and is therefore also called transportin. All karyopherins consist of a
N-terminal Ran-GTP-binding site and a C-terminal domain mediating the interaction with their
cargoes. At the same time, the karyopherins can interact with the FG-repeats of the NUPs
and  thereby  enable  the  translocation  of  the  complexes  through  the  pore.  Despite  their
detailed characterization, the exact molecular mechanism how specificity and activity of the
karyopherin-cargo interaction is achieved and controlled is still not completely understood.NUCLEO-CYTOPLASMIC TRANSPORT
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Table 3.3. Members of the human karyopherin-β family.
Karyopherin Cargo
Import
Importin-β1 Many cargoes, cargoes with basic NLSs via karyopherin-α,
UsnRNPs via snurportin
Karyopherin-β2 hnRNPA1, histones, ribosomal proteins
Transportin SR1 SR proteins
Transportin SR2 HuR
Importin 4 Histones, ribosomal proteins
Importin 5 Histones, ribosomal proteins
Importin 9 Histones, ribosomal proteins
Importin 7 HIV RTC, Glucocorticoid receptor, ribosomal proteins
Importin 8 SRP19
Importin 11 UbcM2, rpL12
Export
CRM1/Exportin 1 Leucine-rich NES cargoes
Exportin-t tRNA
CAS Karyopherin α
Exportin 4 eIF-5 A
Exportin 5 microRNA precursors
Exportin 6 Profilin, actin
Exportin 7 p50Rho-GAP, 14-3-38
Import/Export
Importin 13/Transportin Rbm8, Ubc9, Pax6, hnRNPA1 (import); elF-1 A (export)
Uncharacterized
RanBP6 undefined
RanBP17 undefined
Table adapted from (Pemberton & Paschal, 2005).NUCLEO-CYTOPLASMIC TRANSPORT
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3.4  Energetics of nucleo-cytoplasmic transport
In the past, it has been suggested that the translocation through the pore needs hydrolysis of
adenosine or guanosine triphosphate (ATP or GTP, respectively). In the meantime, this
assumption was refuted by different findings. E.g., for the import of a classical NLS by
importin-α und importin-β  (see  3.5.1),  no  hydrolysis  of  GTP  appears  to  be  required
(Schwoebel et al., 1998). The NES-mediated export (see 3.5.2) by the export receptor CRM1
obliges Ran-GTP, but not Ran-GTP hydrolysis (Englmeier et al., 1999). However, this does
not apply to the whole export and import cycle. Thus, the reloading of Ran with GTP appears
to be essential for the release of the export cargo from its exportin via Ran-GTP-hydrolysis,
for  the  reimport  of  Ran-GDPs  by  the  nuclear  transport  factor  NTF2  as  well  as  for  the
dissociation of the import complex, each exhausting one molecule of GTP. The energy
needed for nucleo-cytoplasmic transport could by supplied indirectly via the hydrolysis of
Ran-GTP. Other energy-consuming steps are suspected during the transport of very large
macromolecules, like mRNA containing ribonucleoproteins (mRNPs) or ribosomes. e.g. Also
processes like the unwinding of the RNA or other conformational changes of the transport
substrates, as well as the detachment of proteins not to be cotransported, could for example
demand  energy  (Adam,  1999;  Görlich  &  Kutay,  1999;  Vasu  &  Forbes,  2001). Clearly,
additional  work  has to be performed  to clarify  the energy  requirements  of general  and
substrate specific transport processes.
3.5  Mechanisms of translocation through the nuclear pore
Any NPC translocation model will have to account for the observation that the same NPC is
strongly bidirectional in vivo, mediating both import and export. Moreover, the mechanism will
need to accommodate for rapid transport rates of up to 1000 macromolecules per second per
NPC  (Suntharalingam  &  Wente,  2003).  At  present,  different  translocation  models  are
discussed, most of them assume a facilitated diffusion that is controlled via the association
and dissociation of the transport complexes with FG-repeat containing NUPs (reviewed in
Suntharalingam & Wente, 2003).
The first step is the recognition of the cargo, followed by docking of the transport factor-cargo
complex at the NPC. The key tenets of all the proposed NPC translocation models are based
on the transport factors having dual interactions with the cargo and the NPC.NUCLEO-CYTOPLASMIC TRANSPORT
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The  FG-containing  NUPs  may  form  the  physical  and  mechanistic  basis  of  the  NPC
permeability barrier. The FG repeat domains have remarkably unstructured and random coil
properties (Denning et al., 2003), resulting in a dynamic meshwork of filaments that excludes
macromolecules that do not directly interact (figure 3.5.A). The specific interactions may
facilitate random movement through the network and the NPC.
Debate has centered on several discrete models that propose either affinity-gating, selective
phase partitioning, or affinity-gradient mechanisms. In the affinity-gating scenario (Rout &
Aitchison, 2001), passive diffusion into the narrow NPC central region is sterically prevented
by the FG-rich filaments. The FG binding sites at the NPC create a high concentration of
transport complexes, thereby increasing the probability that the complex will enter into the
NPC, overcome the entropic barrier, and translocate through the NPC by Brownian-based
random diffusion. Molecules with no affinity for FG NUPs would not achieve an effective
concentration at the NPC, and thus be excluded. The model assumes the binding of the
transport receptor to the FG-repeats to be necessary and sufficient for the subsequent
translocation through the pore. It doesn’t explain however, how larger objects that actually
exceed the physical size of the narrow pore channel are able to pass.
A key difference in the selective phase model (figure 3.5.B) is the assumption that the
diameter of the central channel is large enough to also allow passage of large receptor-
substrate complexes (Pante & Kann, 2002; Ribbeck & Görlich, 2002). The channel is not
completely open, but is protected by a so called selective phase that is composed of the
NUPs in this model. A hydrophobic network results from weak interactions between the FG
domains themselves, thereby building a permeability border (figure 3.5.B, inset). The FG
binding sites on the shuttling receptors allow selective passage through the hydrophobic
environment, excluding hydrophilic macromolecules. However, by binding the FG repeats,
the transport factor/cargo complexes would locally dissolve the hydrophobic network and
selectively partition into and through the central region of the NPC, rendering the barrier
permeable. These sequential association and dissociation of the transport complex to and off
the different NUPs then mediates the direction of transport. What argues against this model
is  the  fact  that  the  translocation  process  itself  is  fully  reversible  and  mediated  in  both
directions (Ribbeck & Görlich, 2001). In the affinity gradient model (figure 3.5.C), the FG-
NUPs would provide a series of sequential binding sites of progressively increasing affinities
for the translocating macromolecules from one NPC side to the other (Ben-Efraim & Gerace,
2001). Again, molecules that do not interact with FG-NUPs would not engage in such cycles
of association and dissociation, and would thus not be transportedNUCLEO-CYTOPLASMIC TRANSPORT
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Figure 3.5. Different NPC translocation models (A) Dynamic filamentous network model
(Denning et al., 2003). (B) Selective phase model (Ribbeck & Görlich, 2001). (C) Affinity-
gradient model (Ben-Efraim & Gerace, 2001). Not specifically shown is the affinity-gating model
(Rout & Aitchison, 2001). See text for explanations.
3.5.1  Import processes
Protein  translocation  through  the  NPC  is  thought  to  occur  by  an  essentially  similar
mechanism for all importin-β related receptors, except for the fact that, in some situations,
additional  adaptors  are  required  to  bridge  the  cargo/receptor  interaction  (reviewed  in
Goldberg, 2004; Harel & Forbes, 2004; Pemberton & Paschal, 2005). Import processes can
be  divided  into  classical  NLS-mediated  protein  import,  the  import  of  RNA-binding  and
ribosomal proteins.
The  most-studied  pathway  is  the  import  of  classical  NLS-containing  proteins.  Classical
protein import is mediated by one or two clusters of basic amino acids (aa), the simple or
classical basic nuclear localization signal, and the bipartite NLS (Kalderon et al., 1984;
Robbins et al., 1991). E.g., the simian virus 40 (SV40) large T-antigen harbors a classical
NLS, consisting of the aa-sequence PKKKRKV. An example for a bipartite NLS can be found
in the protein nucleoplasmin, with the recognition sequence KRPAAIKKAGQAKKKK. The two
groups of basic amino acids (shown underlined) are separated by a 9 aa spacer in this case
(Görlich & Mattaj, 1996). The import of many nuclear proteins is thought to be mediated by
the basic NLS. Both types of classical import signals are recognized by the heterodimeric
importin-β/importin-α complex in the cytoplasm. Thereby, importin-α  acts  as  an  adaptor
between  the  NLS-bearing  protein  and  importin-β,  recognizing  and  binding  the  NLS-
containing cargo and importin-β in the cytoplasm. The binding of importin-α to importin-β is
thereby mediated via its N-terminal importin-β binding domain (IBB) (Görlich & Kutay, 1999).
After formation of the trimeric complex, importin-β mediates docking at the NPC via directNUCLEO-CYTOPLASMIC TRANSPORT
19
interaction with the FG-repeat sequences of the NUPs. Translocation of the complex occurs
in the presence of Ran-GDP and free GTP, and is terminated via binding of Ran-GTP to
importin-β  in  the  nucleus,  which  releases  the  complex  from  the  NPC  and  dissociates
importin-α  from  importin-β.  Free  importin-α has a lower affinity for the NLS cargo, and
release from importin-β is therefore believed to trigger release of the NLS cargo as well.
Thereafter, the importin-β-Ran-GTP complex as well as importin-α bound to its exportin
(CAS) together with Ran-GTP, are re-exported to the cytoplasm for another round of import.
Figure 3.5.1. Schematic representation of the transport cycles of importin-α and -β. Figure
modified from (Kau et al., 2004). See text for further explanations.
In higher eukaryotes, several importin-β homologues exist, some of which interestingly show
a tissue- and development-specific expression. Additionally, they reveal different binding
specificities to NLS-bearing cargo proteins (Nachury et al., 1998). This suggests that import
processes  can  be  regulated  specifically  for  different  tissue  types.  In  addition,  there  is
increasing evidence that active import of cargos containing basic NLSs can be mediated by
importin-β in the absence of importin-α (Palmeri & Malim, 1999; Strom & Weis, 2001). For
example, uridine-rich small nuclear ribonuclear proteins (UsnRNPs), which are polymerase
type II transcripts from small nuclear RNA (snRNA) that are synthesized inside the nucleus
and thereafter exported into the cytoplasm for maturation, are reimported into the nucleus viaNUCLEO-CYTOPLASMIC TRANSPORT
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a bipartite NLS by an importin-β-dependent mechanism that does not involve importin-α
(Palacios et al., 1997).
Another example for a complex nuclear translocation process is the import of heterogeneous
nuclear ribonucleoproteins (hnRNPs). The so called “M9 domain” of hnRNP A1 not only
serves as a recognition sequence essential for import, but also has been postulated to also
mediate re-export. Spanning 38 aa, the M9 signal exceeds the length of the classical SV40
NLS (Siomi & Dreyfuss, 1995). The receptor recognizing this transport signal, transportin,
also belongs to the importin-β family (see also table 3.3.) (Pollard et al., 1996). Similar to
importin-β/-α-mediated  transport,  the  import  complex,  consisting  of  hnRNPA1  and
transportin, is dissociated by Ran-GTP inside the nucleus (Izaurralde et al., 1997). Thus, a
continuous shuttling of hnRNPA1 between the nucleus and the cytoplasm occurs, with the
involved exportin not yet identified.
Also ribosomal proteins, which are synthesized in the cytoplasm, must be transported into
the nucleus and afterwards directed to the nucleolus. To date, it is still unclear whether these
proteins are imported individually or as preformed complexes, and whether they contain
distinct nuclear import and also nucleolar localization sequences (Rosorius et al., 2000).
3.5.2  Export processes
As one hallmark of nucleo-cytoplasmic transport is the bidirectionality, the existing import
reactions into the nucleus face a comparable amount of export processes into the cytoplasm.
These transport processes in the reverse direction are mediated by exportins, and are
regulated in a converse manner (reviewed in Goldberg, 2004; Kau et al., 2004; Pemberton &
Paschal, 2005).
Since  in  eukaryotes  transcription  and  translation  are  taking  place  in  two  different
compartments, the RNA molecules synthesized in the nucleus have to be exported into the
cytoplasm. As most RNAs are transported as ribonucleoprotein particles, it was assumed
that export is mediated via RNA-binding proteins containing nuclear export signals. The best
characterized signal mediating export is the leucine-rich NES, which was first discovered
within the Rev-protein of the human immunodeficiency virus type 1 (HIV-1) (Fischer et al.,
1995). The HIV-1 Rev protein is an essential viral protein responsible for the efficient export
of  unspliced  and  partially  spliced  viral  mRNAs  required  for  the  production  of  the  viral
structural proteins.NUCLEO-CYTOPLASMIC TRANSPORT
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Leucine-rich NESs conform to the still loosely defined consensus sequence Ω-x2-3-Ω-x2-3-Ω-
x-I/L, (Ω = V,F,M or W; x is any amino acid) (Fornerod & Ohno, 2002; La Cour et al., 2004).
The  presence  of  regularly  spaced,  large  hydrophobic  amino  acids  such  as  leucine  or
isoleucine as well as the spacing itself are critical features of the signals. Leucine-rich NESs
have been identified in an increasing number of disease relevant cellular and viral proteins
(table 3.5.2.) (Heger et al., 2001; La Cour et al., 2004; Rosorius et al., 1999), implicated in
transcription control, cell cycle control and RNA transport.
Table 3.5.2. Examples of viral and vertebrate leucine-rich NESs.
Protein NES-sequence
Minute virus of mice (MVM) NS2 MTKKF–GTLTI
Protein kinase inhibitor PKI LALKL–AGLDI
HIV-1 Rev L–PPL–ERLTL
HTLV-1 Rex LSAQLYSSLSL
MAP kinase kinase MAPKK LQKKL–EELEL
Adenovirus type 5 E1B-55K LYPELRRILTI
Tumor suppressor protein p53 MFRELNEALEL
Double minute 2 Mdm2 ISLSFDESLAL
Inhibitor of NF-κB I-κBα MVKEL–QEIRL
Cyclin B1 LCQAF–SDVIL
Transcription factor IIIA TFIIIA L–PVL–ENLTL
Signal transducer and activator of transcription STAT1 LAAEF-RHLQL
NES consensus Ωx2-3Ωx2-3ΩxL/I
Conserved hydrophobic aa residues reported to be essential for function are marked in bold.
Ω denotes amino acids V,F,M or W; x is any aa.
A major step towards the identification of the export receptor of leucine-rich NESs was the
observation that the fungicide antibiotics leptomycin B (LMB) blocks export of Rev (Wolff et
al., 1997).  LMB,  a  Streptomyces  metabolite,  inhibits  the  cellular  target  protein  CRM1
(chromosome region maintenance) by direct binding (Fornerod, 1997; Fukuda et al., 1997).
The inhibition of CRM1 by LMB depends on the highly conserved nucleophilic cysteine
residue 528 (Cys528), to which LMB covalently binds in a "Michael-type" reaction (figure
3.5.2.1.) (Kudo et al., 1999). Thus, LMB serves as a potent tool to identify proteins that are
exported via the CRM1-pathway.NUCLEO-CYTOPLASMIC TRANSPORT
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Figure 3.5.2.1. Michael-type addition of LMB with the Cys528 of CRM1. Figure taken from
(Kau et al., 2004).
Mechanistically, CRM1 binds to substrates containing a leucine-rich NES in the nucleus,
forming a trimeric complex with Ran-GTP. This complex is then transferred to the cytoplasm
by  a  mechanism  involving  binding  of  CRM1  to  the  NPC.  Once  in  the  cytoplasm,  GTP
hydrolysis results in the dissociation of Ran from the complex, allowing CRM1 to release its
cargo. Free CRM1 then reenters the nucleus to bind and export additional cargo molecules
(figure 3.5.2.2.).
Figure 3.5.2.2. Schematic representation of the transport cycles of CRM1. Figure modified
from (Kau et al., 2004). See text for further explanations.NUCLEO-CYTOPLASMIC TRANSPORT
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Although the orchestration of export is still unclear, NESs can be grouped into specific
classes according to their activity in vivo (Heger et al., 2001; Rosorius et al., 1999), although
most NESs bind to CRM1 with relatively low affinity in vitro (reviewed in Kutay & Guttinger,
2005). The different activities of the individual NESs can be regulated either by the NES-
conformation itself or by additional cofactors favoring the formation of specific NES-CRM1
complexes.  Efficient  binding  of  weak  NESs  to  CRM1  in  the  nucleus  was  for  example
suggested to be stimulated by a CRM1-specific cofactor, RanBP3, a nuclear Ran-GTP-
binding protein (Englmeier et al., 2001; Lindsay et al., 2001).
In addition to leucine-rich NESs, also other nuclear export signals appear to exist, since
nuclear export has been described for proteins lacking leucine-rich NESs. For example, the
Ran binding protein Yrb1 in yeast, not harboring a leucine-rich NES, is exported via binding
to the yeast CRM1 homologue (Künzler et al., 2000). Another protein that uses the CRM1
export pathway for recycling and does not contain a classical leucine-rich NES is Snurportin,
a factor involved in small nuclear ribonucleoprotein (snRNP) import (Paraskeva et al., 1999).
However, since the definition of active nuclear export still awaits a standardized experimental
definition, some of these reports have to be considered with caution.
3.6  Regulation of nuclear transport
Nuclear transport is regulated at multiple levels, via a diverse range of mechanisms, and in
response to a variety of signals such as hormones, cytokines and growth factors, cell-cycle
signals, developmental signals, immune challenge and stress (see Poon & Jans, 2005 and
references therein). Although several mechanisms have been suggested through which the
regulation of nuclear import and export pathways can occur, the complex orchestration and
specificity of transport is not yet understood.
Post-translational modifications and masking/unmasking of the specific transport signals can
modulate the accessibility and affinity of target signal recognition by the transport receptors,
and thus appear to contribute to the coordinated control of nucleo-cytoplasmic transport
(Poon & Jans, 2005). In addition, alterations in the expression levels of components of the
nuclear transport machinery also appear to be a determinant of transport efficiency, having
central importance in development, differentiation and transformation.
Post-translational  modification  of  signaling  molecules  through
phosphorylation/dephosphorylation  can  be  mediated  by  kinases/phosphatases.  As
kinases/phosphatases can be regulated by many different cellular signals, signal-responsive
phosphorylation/dephosphorylation to modulate subcellular localization represents a directNUCLEO-CYTOPLASMIC TRANSPORT
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link between extracellular signals or signals within the cell, and response in terms of nuclear
import or export of specific signaling molecules such as cell-cycle regulators, kinases and
transcription factors. A key step by which the efficiency of nuclear transport may be regulated
is that of importin-NLS/exportin-NES interactions. Intra- or intermolecular masking of NLSs/
NESs within cargo proteins to prevent importin/exportin recognition appears to be a common
mechanism to regulate the efficiency of nuclear transport. Intramolecular masking occurs
when the accessibility of the NLS/NES is inhibited by the charge or conformation of the
NLS/NES-containing protein (Figure 3.6.A). Intramolecular masking can also be effected by
phosphorylation close to the targeting sequence, as it is the case for the NLSs of the nuclear
factor of activated T cells (NF-AT) 2. Intermolecular masking occurs when the binding of a
heterologous  protein  prevents  NLS-importin-  or  exportin-NES-interaction  (Figure  3.6.B).
Examples  are  the  transcription  factor  NF-AT4,  where  at  high  Ca
2+  concentrations,  the
phosphatase calcineurin binds to and masks the NES, or NF-κB p65, where the NLS is
masked due to binding of the specific inhibitor protein I-κB. Nuclear localization of the tumor-
suppressor p53 is regulated by a number of mechanisms, one of which is tetramerization in
the nucleus in response to DNA damage, resulting in masking of the NES in the tetramer.
Ligand binding can also mask NESs/NLSs, as shown for the NES of the androgen receptor,
which lies in the ligand binding domain of the molecule. Intermolecular masking of targeting
signals can also occur via RNA or DNA binding. In the case of the HIV-1 Rev protein, binding
of mRNA masks its NLS. This ensures mRNA release in the cytoplasm before another round
of Rev nuclear import to ferry HIV-1 mRNA out of the nucleus. The physiological role of this
may be an alternative mechanism to Ran-GTP-mediated cargo release in the nucleus, as it
also seems to be the case for STAT1 (Poon & Jans, 2005).
In addition to NLS/NES masking, the binding affinity of importins/exportins for NLSs/NESs
can be regulated positively by phosphorylation, where phosphorylation sites close to the
targeting signal enhance importin/exportin binding. E.g., this accounts for the NLS of the
SV40 T-Ag, the NLS of the Drosophila morphogen Dorsal, or the NES of the transcription
factor Pho4 (Figure 3.6.C). That importin-binding affinity is of critical importance in a human
context is demonstrated by the analysis of mutations within either one of the dual NLSs of
the sex-determining factor SRY (Harley et al., 2003) that lower the binding affinity, impair
SRY nuclear import and result in XY females (Swyer syndrome). Similarly, mutations in the
protein Dorsal that prevent phosphorylation and thereby enhancement of nuclear import are
lethal (Briggs et al., 1998). These studies underline the critical importance of regulated
importin-NLS interaction for developmental processes.NUCLEO-CYTOPLASMIC TRANSPORT
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Figure  3.6.  Mechanisms  of  nuclear  transport  regulation.  (A)  Selected  examples  of
intramolecular masking, where targeting signals are prevented from importin-(IMP)/exportin
(EXP) recognition by the conformation of the protein containing it. (B) Selected examples of
intermolecular masking, where targeting signals are protected from IMP/EXP recognition by
binding of a heterologous molecule. (C) Selected examples of the enhancement of IMPs/EXPs
binding to NLSs/NESs by phosphorylation. Figure modified from (Poon & Jans, 2005). See text
for further explanations.NUCLEO-CYTOPLASMIC TRANSPORT
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Another mechanism of regulating nuclear transport is through modulation of the binding of
NLS/NES-containing cargo to specific cytoplasmic or nuclear factors that serve to anchor or
retain cargoes in cytoplasmic or nuclear compartments, thereby preventing nuclear transport
and leading to cytoplasmic or nuclear retention. Proteins that are regulated via cytoplasmic
retention, are, for example, the glucocorticoid receptor (GR) complexed with the heat-shock
protein Hsp90, or the tumor-suppressor p53 bound to the ubiquitin ligase p53-associated
Parkin-like cytoplasmic protein (Parc). Binding interactions with both nuclear and cytoplasmic
anchor/retention  factors  may  contribute  to  signal  transduction-responsive  control  of  the
subcellular localization of signaling and other molecules in the nucleus (Poon & Jans, 2005).
As indicated above, the modulation of the expression level of components of the nuclear
transport machinery represents an additional regulatory mechanism. In particular importins
appear to be specialized to mediate the nuclear import of particular transport cargoes.
Further, it seems likely that importin/cargo complexes or proteins such as β-catenin or the
STAT proteins may take specific paths through the NPC by binding to only a subset of FG-
repeat-containing NUPs. Thus, the presence or absence of a particular importin or NUP may
determine whether specific nuclear import/export cargoes can efficiently enter or exit the
nucleus,  making  the  tissue/cell  type-specific  expression  of  components  of  the  nuclear
transport machinery a critical determinant of the nuclear import efficiency for a given cargo.
3.7  Functional implication of nucleo-cytoplasmic transport
The following chapter will give a brief introduction into several functional implications of
nucleo-cytoplasmic transport, focusing mainly on proteins and mechanism that have been
investigated in this work.
Active transport signals have been identified in an increasing number of cellular and viral
proteins  executing  heterogeneous  biological  functions  involving  RNA  transport  (Cullen,
2003b), transcription (Knauer et al., 2005a; McBride & Reich, 2003), apoptosis (Ferrando-
May, 2005), or cell cycle control (Phippard & Manning, 2003). Since nucleo-cytoplasmic
transport is crucial for normal cell function, defects in this process can also lead to various
disease conditions including cancer (reviewed in Kau et al., 2004; Poon & Jans, 2005).
However,  regulated  subcellular  transport  also  provides  an  attractive  way  to  control  the
activity and stability of regulatory proteins and RNAs. Recently, interfering with nucleo-
cytoplasmic transport in general as a novel therapeutic principle has attracted major interest
by academia and industry (reviewed in Kau et al., 2004; Pagliaro et al., 2004).NUCLEO-CYTOPLASMIC TRANSPORT
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3.7.1  RNA-transport
Eukaryotic cells transport the different classes of RNAs, like rRNAs, tRNAs, mRNAs and
snRNAs, by distinct but in some cases partially overlapping nuclear export pathways (see
Cullen, 2003b and references therein). In contrast to the export of proteins, which are mostly
transported  individually,  most  RNAs  are  transported  as  a  complex  with  appropriate
ribonucleoprotein particles (RNPs).
Virology has made several key contributions to our current understanding of how mRNAs are
exported from the nucleus (figure 3.7.1.). Initial evidence identifying the karyopherin CRM1
as a nuclear RNA export factor derived from efforts to identify the cellular cofactor for the
HIV-1 Rev protein, which is essential for the nuclear export of the incompletely spliced HIV-1
mRNA species expressed late in the viral life cycle (Pavlakis & Stauber, 1998). The HIV-1
replication requires the cytoplasmic expression of unspliced, singly spliced and fully spliced
viral mRNAs. In the absence of Rev function, only fully spliced viral mRNAs are exported
from the nucleus. In contrast, incompletely spliced viral mRNAs, encoding primarily the viral
structural proteins, are retained in the nucleus by cellular proteins that normally prevent the
nuclear export of cellular pre-mRNAs. However, Rev is responsible for the CRM1-mediated
export of the incompletely spliced viral mRNAs by binding to the cis-acting Rev response
element (RRE) present on these RNAs. In addition to HIV-1, other retroviruses and also
adenovirus encode adapter proteins that recruit CRM1 to late viral mRNAs, e.g., the human
T-cell leukemia virus (HTLV) Rex protein (Heger et al., 1999) or the adenovirus type 5 E1B-
55K protein (Krätzer et al., 2000). One common reason why these viruses exploit the CRM1
pathway  for  mRNA  transport  is  that  eukaryotic  cells  have  a  stringent  proofreading
mechanism to ensure nuclear retention of incompletely spliced RNAs, which has to be
overcome.
CRM1 also appears to be responsible for the export of cellular UsnRNAs and all rRNAs (see
Cullen, 2003b, and references within). The small nuclear ribonucleoprotein particles are
RNA-protein complexes that play a critical role in the splicing of nuclear pre-mRNAs. In
higher eukaryotes, the UsnRNA components of the snRNPs are synthesized in the nucleus,
then assembled into mature snRNPs in the cytoplasm and reimported into the nucleus by the
snurportin1/importin-β-heterodimer. The snRNAs that undergo this cytoplasmic assembly
step are cotranscriptionally 7-methylguanosine (m7G) capped, whereas the cap serves as
the critical export signal. For export, the m7G cap is bound by the nuclear cap-binding
complex (CBC), consisting of the cap-binding proteins CBP20 and CBP80. This complexNUCLEO-CYTOPLASMIC TRANSPORT
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does not directly interact with CRM1, but with an additional factor, PHAX (phosphorylated
adapter for RNA export), which in a phosphorylated form binds Ran-GTP-bound CRM1.
Ribosomes are RNPs that consist of a large (60S) and a small (40S) subunit, and are
essential for protein synthesis inside the cytoplasm. The two subunits, each encompassing
different rRNAs and ribosomal proteins, are assembled and processed in the nucleolus, a
specialized subnuclear structure, and are then separately exported to the cytoplasm. Export
of both subunits depends on Ran, and nuclear export of the 60S pre-ribosomal subunit is
mediated by the Nmd3-dependent recruitment of CRM1. Nuclear export of the 40S pre-
ribosomal subunit is also CRM1 dependent, but neither Nmd3 nor CRM1 directly bind to the
40S  subunits.  Recruitment  of  CRM1  to  nuclear  40S  pre-ribosomal  subunits  therefore
probably depends on an hitherto unidentiﬁed adapter that has an analogous role to Nmd3.
In contrast, tRNA export is mediated by a own transportin of the importin-β family, exportin-t
or XPO-t. Exportin-t binds directly and speciﬁcally to mature tRNA molecules in the presence
of  Ran-GTP,  but  very  poorly  to  tRNAs  that  bear  incorrect  5'-  or  3'-ends,  or  that  are
inappropriately modiﬁed (Cullen, 2003b).
Recently, it has been discovered that eukaryotic cells transcribe a wide range of other small
non-coding RNAs. Recent advances have revealed that so called microRNAs (miRNAs)
function  in  a  variety  of  regulatory  pathways,  including  cell  proliferation,  apoptosis,
hematopoiesis and organogenesis (reviewed in Ambros, 2001; McManus, 2003). Recent
studies have shown that exportin-5 (Exp5), a Ran-dependent importin-β-related transport
receptor,  mediates  nuclear  export  of  miRNA  precursors  (pre-miRNAs)  (Kim,  2004),
resembling the transport of small viral RNAs, e.g., the adenovirus VA mRNA (Cullen, 2003a).
In contrast, mRNA export is generally mediated by a distinct nuclear export pathway that is
independent of the Ran system and karyopherins, and is both complex and still incompletely
understood (reviewed in Izaurralde, 2004). However, a few human mRNAs might be subject
to  nuclear  export  by  CRM1.  E.g.,  AU-rich  elements  (AREs)  that  are  present  in  the  3'-
untranslated regions of several genes involved in cell signaling, bind the protein HuR, which
in turn interacts with the nucleo-cytoplasmic shuttle protein APRIL, which contains a leucine-
rich NESs and interacts with CRM1. Functional analysis of members of the human nuclear
export family (NXF) has also suggested that some cellular mRNAs might be exported by
CRM1.
The key mediator of bulk mRNA export is instead a heterodimer of the tip associating TAP
and a small cofactor termed NXT. RNA binding is achieved via recruitment of the protein
UAP56,  which  in  turn  binds  to  ALY  that  then  interacts  with  TAP  and  its  partner  NXT.NUCLEO-CYTOPLASMIC TRANSPORT
29
Although UAP56, TAP and NXT are all essential for poly(A)+ RNA export, ALY appears to be
dispensable, thus suggesting the existence of other intermediate factor(s). TAP differs from
CRM1 in not being a member of the karyopherin family, and TAP-mediated nuclear export
does not require its interaction with any karyopherin nor the Ran-GTPase as a cofactor.
Thus, these findings explained the previous observation that, in contrast to all other nuclear
RNA-export pathways, nuclear mRNA export was independent of Ran function. Instead, the
TAP-NXT heterodimer interacts directly with components of the NPC via an essential domain
located at the C terminus of TAP. Although TAP is ubiquitously expressed, a closely related
protein, NXF3, displays a highly tissue-specific expression pattern. Although NXF3, like TAP,
is a nucleocytoplasmic shuttle protein that can export nuclear mRNAs when tethered via a
heterologous RNA-binding motif, NXF3 lacks the C-terminal NPC-binding domain that is
crucial for TAP function. This conundrum was resolved by the demonstration that NXF3,
unlike TAP, contains a leucine-rich NES that binds CRM1. NXF3 associates with poly(A)+
mRNA in vivo and, therefore, might function as a tissue-specific CRM1-dependent nuclear
mRNA-export factor.
Figure 3.7.1. Karyopherin-mediated nuclear RNA export pathways. This depiction provides
an overview of the key factors involved in mediating the nuclear export of different classes of
RNA. Hypothetical factors that remain to be identified are indicated by ‘X’. Figure modified from
(Cullen, 2003a; Cullen, 2003b). See text for details.NUCLEO-CYTOPLASMIC TRANSPORT
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3.7.2  Transcriptional activation
A key juncture in the control of cell differentiation and growth is found at the level of gene
expression. Transcription factors are gene regulatory proteins endowed with sequence-
specific DNA recognition and protein interaction motifs, and as such have the ability to
positively  or  negatively  influence  the  rate  and  efficiency  of  transcript  initiation.  Since
transcription  factors  lie  at  the  heart  of  almost  every  fundamental  developmental  and
homeostatic organismal process, defects in transcription factor function can lead to various
types of malignancy. On the other hand, transcription factors also represent prime targets for
disruption in malignancy. Often, transcription factors are latent in the cytoplasm and are
transported into the nucleus upon signal mediated activation. Thus, modulating their nucleo-
cytoplasmic  transport  as  well  as  their  interactions  with transcription regulatory proteins
provides  a  multistep  mechanism  for  controlling  and  interfering  with  gene  expression  in
eukaryotes.
3.7.2.1.  Homeodomain proteins
Ordered development depends on the fine-tuned activity of transcription factors in a temporal
and spatial controlled manner. Among other mechanisms, regulated stability and subcellular
localization provides an intracellular way to control the activity of transcription factors (Affolter
et al., 1999). Homeodomain proteins (HDPs) have been shown to exert key developmental
functions since defects in the evolutionary conserved homeobox genes were shown to cause
many  human  disorders  and  aberrant  animal  phenotypes  (Zhao  &  Westphal,  2002).
Homeobox-containing genes  encode  transcription  factors and  are  characterized  by  the
homeodomain (HD), a motif that directs specific DNA binding to regulate the expression of
target genes. Homeodomain proteins (HDPs) are grouped into several subclasses according
to the primary structure of their HD and its flanking sequences (Galliot et al.,  1999  and
references  therein).  In  concordance  with  their  role  as  transcriptional  regulators,
homeoproteins localize predominantly to the nucleus, although several reports characterize
HDPs also as nucleo-cytoplasmic shuttle proteins (Affolter et al., 1999). For example, Maizel
et  al.  suggested  that  nuclear  export  of  the  Engrailed  protein  influenced  intracellular
localization and also extracellular secretion (Maizel et al., 2002).NUCLEO-CYTOPLASMIC TRANSPORT
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3.7.2.2.  The STAT family of transcription factors
The STAT family of transcription factors, named after their dual role as signal transducers
and activators of transcription (reviewed in Levy & Darnell, 2002) are characterized by a
modulatory structure comprising a coiled-coil domain for protein interaction, a DNA-binding
domain recognizing the GAS family of enhancers, an SH2 (src homology 2) domain for
dimerization,  and  a  transactivation  domain  (TAD).  The  STAT  proteins  are  latent  in  the
cytoplasm until they are activated by extracellular signaling proteins that bind and activate
specific cell-surface receptors, the Janus kinases (Jaks), which in turn phosphorylate STAT
proteins. Phosphorylated and thereby activated STAT proteins dimerize, and are transported
into the nucleus via importin-α5 to drive transcription. In the nucleus, dephosphorylation of
STATs is thought to trigger conformational changes that expose the NES and induce export
back to the cytoplasm, thereby terminating target gene expression. As STAT proteins are
often deregulated  in malignancies  (Levy & Darnell,  2002), nucleo-cytoplasmic  transport
processes that affect their transcriptional regulation are currently considered a highly relevant
target for therapeutic intervention (McBride & Reich, 2003).
3.7.2.3.  Nuclear factor-κB
Transcriptional modulators of the nuclear factor-κB (NF-κB)/Rel family hold a central role in
the inducible expression of a high number of genes involved in inflammation, host defense,
cell  survival,  proliferation,  and  thus  also  tumorigenesis  (Perkins,  2004).  Their  common
characteristic is a so-called Rel homology domain, which is responsible both for binding to a
consensus DNA sequence and for homo- or heterodimerization. The most abundant forms of
NF-κB are p65/p50 heterodimers and p65/p65 homodimers. In most cases, NF-κB dimers
are kept inactive by cytoplasmic retention due to binding to the inhibitors of NF-κB (I-κBs),
mostly I-κBα. I-κBα is thought to mask the NLS of NF-κB, thereby preventing the interaction
of NF-κB with the nuclear import machinery. Moreover, the non-conventional NLS of I-κBα
itself, located within the second ankyrin repeat, appears to be blocked when I-κBα is bound
to NF-κB. Thus, the NLS of NF-κB is unmasked upon degradation of its inhibitor and the
transcription factor can be imported into the nucleus, where it binds to specific promoter
elements. Besides a number of other genes, NF-κB is also inducing the transcription of DNA
encoding its own inhibitor. After translation in the cytosol, I-κBα  is imported into the nucleus,
where it is assumed to dissociate NF-κB from promoter regions. The newly formed NF-κB/I-NUCLEO-CYTOPLASMIC TRANSPORT
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κBα complex is then transported back to the cytosol by the means of a classical NES of I-
κBα (Tam et al., 2000). However, it was also postulated that NF-κB contains a NES by itself,
which would allow an I-κBα-independent nuclear export. The finding that both molecules
apparently contain NLS as well as NES domains still raise the question how the intracellular
distribution  of  these  proteins  is  regulated  functionally  in  the  course  of  activation  and
deactivation of the signaling pathway. This regulatory network became even more complex
upon  the  demonstration  that  posttranslational  modifications  (e.g.,  phosphorylation,
acetylation) and/or binding to regulatory proteins can influence the trafficking, stability and
activity of the NF-κB and/or NF-κB/I-κBα complexes (Kiernan et al.,  2003;  Zhong et al.,
2002).
3.7.2.4.  The Myc/Max/Mad network of transcription factors
The  Myc/Max/Mad  network  of  transcription  factors  regulates  many  cellular  functions,
including proliferation, differentiation, and apoptosis. These proteins belong to the helix-loop-
helix-zipper (bHLH-ZIP) family of transcriptional regulators and can form dimers in multiple
combinations  through  interactions  mediated  by  the  helix-loop-helix  leucine  zipper
dimerization interface. Different members of the Myc/Max/Mad family have distinct biological
functions.  Myc  proteins  promote  cell  proliferation,  whereas  Mad  family  proteins  limit
proliferation (reviewed in Hurlin & Dezfouli, 2004). Genes encoding Myc family proteins are
mutated or deregulated in many types of cancer, whereas Mad family proteins can inhibit cell
transformation. Myc and Mad family proteins form dimers with Max, and dimerization with
Max is essential for the regulatory functions of Myc and Mad family proteins. Interestingly, a
NES  has  been  identified  in  the  Mad4  protein  (Grinberg et al., 2004) and suggests that
regulated subcellular localization might be an additional factor influencing the stoichiometry
of Myc/Max and Mad/Max complex formation, which ultimately may have an profound impact
on the cellular response.
3.7.2.5.  The AP1 transcription factor
Likewise,  it  has  been  suggested  that  the  transcription  factors  c-jun  and  c-fos,  which
constitute the AP1 transcription factor, are actively imported into the nucleus via a Ran/Imp-
β-mediated mechanism, which however does not require importin-α (Forwood et al., 2001).
AP1 is involved in regulation of gene transcription linked to cell proliferation and is thought toNUCLEO-CYTOPLASMIC TRANSPORT
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be associated with the development of a more malignant cancer phenotype (van Dam &
Castellazzi, 2001). Like the bHLH family, the interactions between basic leucine zipper
(bZIP) family members are mediated by the coiled alpha helices. These factors can homo-
and heterodimerize, but only the Jun/Fos heterodimer displays a high affinity for the AP1 site
(Vogt, 2002).
3.7.2.6.  p53 and Mdm2
The p53 protein is a transcription factor regulating many cellular processes, including cell
cycle, DNA repair, apoptosis, angiogenesis, and thus acts as major tumor suppressor, with
loss of normal p53 function by mutation occurring in almost all cancers (Vogelstein et al.,
2000; Vousden & Prives, 2005).
Regulated nuclear export of p53 is a major mechanism governing its stability and ability to
promote G1 arrest and apoptosis (Vousden & Prives, 2005). However, although one NLS
and even two NESs have been identified in p53, the mechanisms that control p53 nucleo-
cytoplasmic transport have not been fully clarified (O'Brate & Giannakakou, 2003). Various
models for p53 nuclear export have been proposed, but recent data indicate that Mdm2-
mediated mono-ubiquitination of p53 promotes its nuclear export (Brooks et al., 2004), while
poly-ubiquitination promotes its degradation in the nucleus. Because p300 has been shown
to  promote  p53  poly-ubiquitination,  it  was  suggested  that  p300/CBP  binding,  besides
acetylation, regulates p53 nuclear export by controlling its ubiquitination (Xu & Massague,
2004).
Mdm2-mediated p53 degradation depends on the interaction between the two proteins, and
the ability of p53 to be exported is greatly enhanced by the action of Mdm2, potentially by an
additive effect of the Mdm2 NES (Gu et al., 2001). Thus, inhibition of Mdm2 nuclear export
stabilizes nuclear p53. Constant growth factor stimulation, which is evident in tumors, can
promote relocation of Mdm2 to the cytoplasm and thereby attenuate the ability of p53 to
induce cell cycle arrest and apoptosis (Vousden & Prives, 2005).
3.7.3  Apoptosis
Apoptosis  is  a  key  component  in  the  development  and  maintenance  of  tissues  within
multicellular  organisms,  providing  a  tightly  regulated  and  selective  mechanism  for  the
deletion  of  superfluous,  infected,  mutated  or  aged  cells.  Dysregulation  of  apoptosisNUCLEO-CYTOPLASMIC TRANSPORT
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contributes to a variety of pathologic conditions, including cancer (reviewed in Gerl & Vaux,
2005; Meier et al., 2000). As tumor cells show a disturbed equilibrium between proliferation
and apoptosis, conventional cancer therapies take advantage of this apoptotic mechanism by
employing  ionizing  radiation  or  chemotherapeutic  drugs  to  damage  DNA  and  induce
selective apoptosis of rapidly growing cells. Apoptosis consists of two main pathways, the
extrinsic and the intrinsic pathway (for reviews see Igney & Krammer, 2002; Jesenberger &
Jentsch,  2002).  The  functional  role  of  nucleo-cytoplasmic  transport  for  apoptosis  is
implicated at several levels. First, the apoptotic demolition of the nucleus is accomplished by
diverse pro-apoptotic factors, most of which are activated in the cytoplasm and have to gain
access to the nucleoplasm during the cell death process. Secondly, signals generated in the
nucleus by DNA damage have to propagate to all cellular compartments to ensure the
coordinated  execution  of  cell  demise.  The  nucleocytoplasmic  shuttling  of  signaling  and
execution factors is thus an integral part of the apoptotic programme. Several proteins
implicated in apoptotic cell death have been shown to shuttle between the nucleus and the
cytoplasm prior to or upon apoptosis induction. These include the apoptosis-inducing factor
(AIF), adapter molecules like FADD, TRADD and Apaf-1, but also the caspases, which
consist of a family of cysteine proteases that can be grouped into initiator (caspase-8 and -9)
and effector caspases (caspase-3, -6 and -7) (see Ferrando-May, 2005 and references
therein). The so-called caspase cascade, which is a sequence of subsequent proteolytic
caspase cleavages, leads to the activation of caspases that in turn cleave cytoskeletal and
nuclear proteins, finally resulting in cell death. Although an NLS has been identified in
caspase-2, a requirement for active import of all caspases is not clear since also the NPC is
an early target of caspase activity and thus caspases may gain indirectly access to the
nucleus.
In addition, pro- and anti-apoptotic factors, such as members of the Bcl-2 family and the
inhibitors of apoptosis (IAP) family, have been described to actively migrate between the
nucleus and the cytoplasm.
The evolutionarily conserved IAP family is characterized by a signature region of about 70 aa
termed baculovirus IAP repeat (BIR) domain and is mainly involved in anti-apoptosis.
Survivin, the smallest mammalian member of the IAP family (Salvesen & Duckett, 2002),
contains a single BIR domain and exists as a stable homodimer in solution (Sun et al., 2005).
A single-copy survivin gives rise to the four alternatively spliced survivin transcripts survivin-
2B, -3B, -∆Ex-3 and -2α (Altieri, 2003b; Caldas et al., 2005, and references within). Although,
the  low  molecular  weight  would  allow  survivin  to  access  intracellular  compartments  byNUCLEO-CYTOPLASMIC TRANSPORT
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passive diffusion, regulated subcellular localization has also been suggested for survivin
(reviewed in Altieri, 2004). Survivin is cell cycle regulated, and involved in both control of
apoptosis and regulation of cell division. It is undetectable in most normal adult tissues, but is
highly expressed in cancer. As its expression correlates with reduced tumor cell apoptosis,
abbreviated patient survival, accelerated rates of recurrences, and increased resistance to
chemo- and radiotherapy, major therapeutic and prognostic interest has been focused on
survivin (see Altieri, 2003a; Altieri, 2003d; Li, 2003, and references within). The protective
effect of survivin is supposed to be due to its caspase-binding capacity and to depend also
on its spindle  association  during  cell cycle progression  (Li et al., 1999; Li et al.,  1998).
However, critical gaps in the molecular understanding of the survivin pathway still exist that
have hampered its full exploitation for cancer therapeutics.
3.7.4  Cell cycle
The cell cycle is one of the most comprehensively studied biological processes, particularly
given  its  importance  for  growth  and  development  and  its  implication  in  many  human
disorders (for review see Harper & Brooks, 2005). The mammalian cell division cycle is
divided into two basic parts: interphase and mitosis, also called M-phase. Interphase is the
time during which replication of chromosomes and centrosomes and cell proliferation occur
in an orderly manner in preparation for cell division. While the cells double in size between
each mitotic step, the DNA is synthesized only during a portion of interphase. The timing of
DNA synthesis thus conventionally divides the cell cycle into four discrete phases - G1, S,
G2 and M phase (figure 3.7.4.1.A). The two most dramatic phases are the DNA synthesis (S)
phase, in which DNA replication takes place, and the chromosomes are faithfully duplicated,
and  mitosis  (M),  in  which  the  replicated  genome  is  divided  equally  between  two  new
daughter cells by the separation of the daughter chromosomes. Preparations for S and M
phase take place in the preceding G1 (gap 1) and G2 (gap 2) phase, respectively. Under
unfavorable environments, cells can exit the G1 phase and enter the quiescent G0 phase,
from where they can return to the cycle through the G1 phase when environmental cues
permit.
Mitosis comprises different steps - prophase, prometaphase, metaphase, anaphase and
telophase (figure 3.7.4.1.B) - and usually ends with cell division (cytokinesis). At prophase,
chromosome condensation begins, centrosomes separate and the nuclear envelope breaks
down. During prometaphase, chromosomes are captured by microtubules growing from theNUCLEO-CYTOPLASMIC TRANSPORT
36
separated centrosomes and bi-orient, congressing to the center of the spindle at metaphase.
Cromosome alignment is finished with the end of metaphase. Anaphase marks the loss of
cohesion between sister chromatids and their movement to opposite spindle poles, which
move apart to further separate daughter nuclei reforming in telophase (not shown) prior to
cytokinesis (not shown) and the return to interphase.
Figure 3.7.4.1. The mammalian cell cycle. (A) The phases of the cell cycle - G1, S, G2, and M
(mitosis). (B) The stages of mitosis illustrating microtubule reorganization and chromosome
translocation. Depiction modified from (Gadde & Heald, 2004). For further explanations see text.
To ensure that the original cell is copied with high fidelity, an elaborate control system using
so called checkpoints is employed, preventing cell cycle events to occur prematurely or in the
wrong order. Chromosome segregation is an important process in mitosis and must beNUCLEO-CYTOPLASMIC TRANSPORT
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performed correctly to ensure that the two resulting daughter cells have the same DNA
content. Missegregation of chromosomes results in aneuploidy, something that is frequently
found in cancers, suggesting that the machinery surveying the chromosome segregation
process has somehow been compromised during the development of these tumors. One of
the  cell  cycle  checkpoints,  the  mitotic  spindle  checkpoint,  has  also  been  shown  to  be
defective in cancers with chromosomal instability.
The proper passage through the cell cycle is regulated by phosphorylation and degradation
of cyclins and cyclin dependent kinases (CDK). While the cyclins C, D, and E are essential
for the progression of the cycle into S phase, and synthesized during G1, cyclins A and B,
are synthesized during S and G2 phases, which are essential for entry into mitosis. The
activity of cyclin-dependent kinases is regulated by temporal synthesis and binding of cyclins,
by  the  association  and  dissociation  of  CDK  inhibitors  (CDKIs),  and  by  inhibitory  and
activating phosphorylation events (reviewed in Miele, 2004; Sherr & Roberts, 2004). The
decision to continue cell cycle progression takes place in G2 phase, when cellular Ras
induces the elevation of cyclin D1 levels. These levels are maintained through G1 phase and
are required for the initiation of S phase, at which time cyclin D1 levels are automatically
reduced to low levels. This reduction is required for DNA synthesis, and forces the cell to
induce high cyclin D1 levels once again when it enters G2 phase. In this way, cyclin D1 is
proposed to serve as an active switch in the regulation of continued cell cycle progression.
Regulated nucleo-cytoplasmic transport has a profound impact on the intracellular activity of
cell cycle regulators. Controlled removal of cyclin D1 from the nucleus during S phase is
essential  for  regulated  cell  division.  GSK-3β-dependent  phosphorylation  of  cyclin  D1
promotes its interaction with CRM1 and thus, nuclear export (Alt et al., 2000). In addition, the
shuttling proteins p21 and p27 appear to be positive regulators of cyclin D1/CDK4 assembly
and nuclear accumulation via inhibition of cyclin D1/CRM1 interaction (Alt et al., 2002).
Disturbance of this regulatory network results in cellular transformation and promoted tumor
growth in mice (Alt et al., 2000). While cyclin B1 is capable of shuttling from the nucleus to
the cytoplasm throughout interphase, mitotic onset requires phosphorylation of cyclin B1 by
Polo-like kinase1, thereby enhancing import and inhibiting export of the cyclin B1-CDK1
complex (Porter & Donoghue, 2003). Connor et al. also showed that the cell cycle dependent
localization of p27 is regulated by CRM1/Ran-GTP-mediated nuclear export. This resulted in
the  incremental  activation  of  cyclin  E-CDK2  leading  to  cyclin  E-CDK2-mediated
phosphorylation  and  p27  proteolysis  in  late  G1  and  S  phase  (Connor et al.,  2003).
Interestingly, LMB did neither inhibit p27-CRM1 binding nor prevent p27 export.NUCLEO-CYTOPLASMIC TRANSPORT
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Strikingly, effectors and components of the nuclear transport machinery are not only active
during interphase but play additional crucial roles during mitosis. Mitosis involves a dramatic
reorganization of the nucleus, with changes in chromatin structure, assembly of the mitotic
spindle, and the breakdown of the nuclear envelope. Recent evidence suggest that the Ran-
GTPase/RCC1  system  also  controls  changes  in  microtubule  dynamics  and  chromatin
structure (Arnaoutov et al., 2005; Arnaoutov & Dasso, 2003; Weis, 2003). Generation of Ran-
GTP by RCC1 on chromosomes causes the release of so called spindle assembly factors
(SAFs) from inhibitory complexes with importins-α and -β that otherwise bind to a nuclear
localization sequence (NLS) on a SAF (figure 3.7.4.2.) (Clarke, 2005). Interestingly, Ran-
GTP can also function through CRM1, which interacts with kinetochores and recruits Ran-
BP2  and  Ran-GAP1.  Thus,  through  the  interactions  with  leucine-rich  nuclear  export
sequences, proteins are recruited as active complexes to the spindle via CRM1. CRM1,
which has originally been defined as a chromosome region maintenance in fission yeast
(Fornerod, 1997), can thereby function as a major nuclear export receptor during interphase
and as a regulator during mitosis.
Figure 3.7.4.2. Regulation of multiprotein complexes by Ran-GTP during mitosis. Figure
taken from (Clarke, 2005). For further explanations see text.NUCLEO-CYTOPLASMIC TRANSPORT
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3.7.5  Cancer
Cancer  is  a  complex  disease  generated  by  multiple  genetic  alterations  (for  review  see
Hanahan & Weinberg, 2000; Vogelstein & Kinzler, 2004). Malignant, invasive tumours are
characterized by self-sufficiency in growth signals, insensitivity to growth-inhibitory signals,
block of cellular differentiation, evasion of apoptosis, genetic instability, limitless replicative
potential,  sustained  angiogenesis,  tissue  invasion  and  metastatic  potential. As  nucleo-
cytoplasmic transport is an important aspect of normal cell function, defects in this process
can lead to disturbances of the cellular homeostasis, and thereby also contribute to cancer
formation (reviewed in Ferrando-May, 2005; Kau et al., 2004; Poon & Jans, 2005). On the
other  hand,  the  detailed  molecular  knowledge  of  how  nucleo-cytoplasmic  transport
contributes  to  disease  conditions  might  also  be  exploited  for  the  formulation  of  novel
therapeutic strategies specifically targeting transport processes.
There are different ways how nucleo-cytoplasmic transport can be deregulated contributing
also to malignant transformation.
First,  modification  of  the  cargo  can  in  turn  affect  its  ability  to  interact  with  its  cognate
transporter. Regulated modifications that affect nuclear transport include phosphorylation,
acetylation and ubiquitylation (see also 3.6.), mostly inducing conformational changes (see
Xu & Massague, 2004). Constitutive activation of signaling cascades leading to increased
phosphorylation and nuclear transport of downstream target molecules, such as the STAT
proteins, is observed in a variety of cancers.
On the other hand, dysregulation at the level of the transporters might also lead to cellular
transformation. Some karyopherins are expressed only in certain tissues and might transport
cargoes only during specific stages of development, or function in a particular cell type
(Görlich & Kutay, 1999). Components of the nuclear transport machinery also appear to be
differentially expressed in transformed cells, with strong proliferative signals leading to the
alteration of nuclear import (Sherr, 2004). For example, overexpression of CAS has been
reported in several different tumors and cancer cells (Kau et al., 2004). In this case, excess
CAS may lead to enhanced nuclear accumulation of nuclear acting factors that facilitate cell
proliferation or prevent apoptosis, through accelerated importin-α recycling.
Further  examples  of  an  altered  nuclear  transport  machinery  in  cancer  are  observed  in
patients with acute myelogenous leukemia, where chromosomal rearrangements can lead to
the fusion of NUPs such as NUP98 or NUP214 with HOXA9 or DEK, respectively. Although
these fusion proteins do not assemble into the NPC, their hydrophobic FG-repeat sequencesNUCLEO-CYTOPLASMIC TRANSPORT
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may enable them to bind to transport receptors and modify transport of certain cargos since
overexpression of FG-repeats has been shown to interfere with transport (Kau et al., 2004).
Finally,  the  nuclear  pore  itself  can  offer  an  added  level  of  regulation.  The  number  of
functional and/or specific pores may vary depending on the growth state of the cell, which in
turn affects the overall permeability of the nucleus.
Thus, modifications to cargo, changes in the nuclear transport machinery and alterations in
the NPC itself could markedly alter cellular functions and potentially promote tumorigenesis.
3.8  Targeting nucleo-cytoplasmic transport as a potential therapeutic principle
Drugs that target nucleo-cytoplasmic transport can be envisaged to be active at the different
levels described above. However, two important obstacles must be overcome - the problem
of specificity for tumour cells versus normal cells, and the difficulty in creating drugs that
interfere with protein-protein interactions (PPIs), in contrast to enzyme-substrate binding.
Drugs, which indirectly interfere with nuclear import/export by blocking posttranslational
modification  of  the  cargo  and  thereby  inhibiting  its  ability  to  interact  with  its  cognate
transporter has been described for several proteins. Mostly, these consist of protein kinase
inhibitors as exemplified by inhibitors of the PI3K/PTEN/Akt signal transduction pathway,
which affected export of the Forkhead family of transcription factors (Kau et al., 2003).
Although these compounds interfere with nuclear transport of proteins they clearly lack
specificity.
So far, no inhibitors have been described directed against components of the stationary
nuclear transport machinery. In contrast, the karyopherin transport factors – the karyopherin-
β proteins, in particular – represent a class of potential targets. Molecular structures of
several different karyopherins have been solved, making these proteins potential therapeutic
targets, since some of these factors might transport only a defined class of proteins (Kau et
al., 2004). For example Leptomycin B (LMB), which inhibits CRM1 export activity by covalent
binding and prevention of the CRM1-NES interaction, was identified as a HIV-1 inhibitor
(Wolff et al., 1997) and had also been suggested as a potential anti-cancer drug (Komiyama
et al., 1985; Vigneri & Wang, 2001). However, although LMB clearly inhibits export of the
HIV-1 Rev protein or the leukemia inducing Bcr-Abl kinase (Vigneri & Wang, 2001), LMB
blocks  all  NES  mediated  export  in  the  cell,  and  thus  its  cellular  toxicity  will  not  allow
therapeutic applications.NUCLEO-CYTOPLASMIC TRANSPORT
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Therefore, protein specific transport inhibitors are urgently needed. Since transport signals
can be grouped into specific categories according to their activity in vivo (Heger et al., 2001;
Rosorius et al.,  1999),  these  differences  may  represent  an  attractive  opportunity  to
selectively interfere with export and the biological functions of proteins by the generation of
NES/NLS-specific inhibitors.
Targeting the proteins that are involved in nuclear transport, in addition to the nuclear
transport of factors that have been associated with disease, could prove to be a promising
approach  for  controlling  cancer-cell  growth  as  well  as  infectious  diseases.  In  order  to
efficiently identify nuclear transport and protein-protein interaction small-molecule inhibitors,
high-content, cell-based screening assays are urgently required.CELL-BASED ASSAY SYSTEMS
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4  Cell-based assay systems
As any biochemical data or potential drug therapies must be effective at the cellular level,
isolated proteins cannot be regarded as representatives of complex biological systems, and
cell-based  assays  have  to  be  employed  to  complement  in vitro data. Traditional small-
molecule drug discovery focuses primarily on the activity of compounds against purified
targets, such as binding to cell-surface receptors or inhibition of the catalytic activity of
enzymes. While these approaches have led to the development of a large number of drugs,
they  clearly  have  limitations.  Because  of  the  complex  network  environment,  in  which
intracellular signaling occurs, it is advantageous to screen compounds in living cells to
reproduce the pathway and network context, in which the drug will eventually have to act. In
addition, unwanted cellular toxicity can thereby be recognized very early in the expensive
drug  discovery  process,  and  biosensors  will  help  to  ease  the  bottlenecks  in  the  drug
discovery  process.  High-content  screening  (HCS)  has  been  created  as  a  platform  for
measuring the temporal and spatial responses of cells to drug and biological treatments.
Subcellular localization of mislocalized proteins in cancer cells have been suggested as a
read-out to identify small molecules that redirect the proteins to the correct compartments
(Kau et al.,  2003).  Such  screening  approaches  could  lead  to  the  discovery  of  novel
compounds that provide new insights into the mechanisms of nucleo-cytoplasmic trafficking
and disease-regulatory pathways. However, any realistic application of high-content and
high-throughput CBAs critically depends on robust and reliable biological readout systems
with a high signal to noise ratio. Quantification of the translocations of molecules between
cellular compartments, including organelles, is considered an important parameter of HCS
(Giuliano et al., 2003b). Quantification can be performed in either a fixed end-point mode or a
kinetic  mode,  using  novel  computer-driven,  automated  image  acquisition  and  pattern-
recognition from the cellular images (Liebel et al., 2003). Cell-based assays that measure
translocation of green fluorescent protein tagged targets as the primary read-out have been
applied to identify inhibitors in the p38-MAP kinase (Almholt et al., 2004) or the PI3K/Akt
kinase pathway (Kau et al., 2003).
Live cell assays have also been applied to monitor protease activity and to screen for
protease inhibitors (Laxman et al., 2002; Lindsten et al., 2001). Site-specific proteases, which
catalyze cleavage of peptide bonds in specific amino acid sequences of target proteins, play
important  roles  in  various  biological  events,  and  dysregulation  of  these  site-specific
proteases can also lead to pathological consequences (reviewed in Patel et al., 2001). TheseCELL-BASED ASSAY SYSTEMS
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include, e.g., the prostate specific antigen (PSA), a serine protease in prostate cancer
patients, an Alzheimer-specific aspartic protease, matrix metalloproteinases (MMP), involved
in tumor invasion, metastasis, and angiogenesis as well as site-specific proteases involved in
blood clotting, such as Factor Xa and Thrombin. Dysregulation of apoptosis also contributes
to a variety of pathologic conditions, including cancer, with the main effectors, the caspases,
also being proteases. For several viruses including HIV, viral proteases are essential for
replication, and thus are crucial drug targets (Brik & Wong, 2003). Since nucleo-cytoplasmic
translocation depends on the activity of defined linear signals, it can be envisaged to develop
also translocation sensors into protease biosensors for the in vivo screening for protease
inhibitors.
The proper biological functions of cells are controlled by interacting proteins in metabolic and
signaling pathways, and in complexes such as the molecular machineries for transcription,
translation, intracellular transport and apoptosis. Much of modern biological research is
concerned with identifying proteins involved in these cellular processes. Because many of
the properties of complex systems seem to be more closely determined by their interactions
than by the characteristics of their individual components, identification and characterization
of specific protein interactions is one of the main goals of current research. In addition,
abolishing or inducing specific PPIs by molecular decoys may offer new opportunities for the
treatment of human diseases (see Berg, 2003; Pagliaro et al., 2004, and references within).
In cancer, cellular transformation and maintenance of the transformed phenotype often
depend upon the formation of specific complexes, and thus, inhibitors that prevent Jun-Fos,
Myc-Max or p53-Mdm2 interaction are currently under intense investigation as potential anti-
cancer drugs (Berg et al., 2002; Hermeking, 2003; Vassilev et al., 2004). Consequently,
many methods have been described to analyze PPIs, including numerous sophisticated
biochemical techniques or the yeast two-hybrid (YTH) system. Methods to study protein
interactions in living cells or even whole animals involve inter- and intramolecular FRET,
bimolecular fluorescence complementation (BiFC) (Hu & Kerppola, 2003), as well as protein
complementation assays, in which a signal is generated only when two interacting proteins
come together (referenced in Day & Schaufele, 2005; Pagliaro et al., 2004). Although these
approaches shows great promise, they still await successful adaption to and application in
high-throughput screening.CELL-BASED ASSAY SYSTEMS
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In conclusion, the living cell, with its amazing integrative abilities of environmental detection,
molecular signal amplification and processing, and repertoire of genome-level responses to
perturbation, represents a powerful test tube (Giuliano et al.,  2003a).  As  proteins  have
evolved to mediate intracellular chemical reactions, they are ideal candidates not only to
sense the dynamic distribution of specific reactions in cells, but also to act as reporters of
their own activities. An improved molecular understanding of protein-protein interactions as
well as of nucleo-cytoplasmic transport is required to learn more about biological processes
and their contributions to disease conditions. Exploitation of this knowledge in the context of
living cells will lead to chemical genetic assay systems for elucidating complex pathways in
biological systems and to the development of novel pharmaceuticals.SUMMARY OF PUBLICATIONS
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5  Summary of publications
The following section presents a brief summary of the publications achieved and specifies
my contributions to the individual reports.
The overall topic of the thesis was to investigate the significance of nucleo-cytoplasmic
transport for the biological fuctions of cellular proteins.
It  could  be  shown  that  regulated  nucleo-cytoplasmic  transport  of  a  subfamily  of  the
homeobox transcription factors could fine-tune their transcriptional activity (Knauer et al.,
2005a). Experimental procedures and data analysis in this work were predominantly carried
out by myself.
The work performed by Krämer et al. (Krämer et al., 2005) showed that acetylation of the
transcription factor Stat1 enhanced its interaction with NF-κB p65, which in turn influenced
subcellular localization, DNA-binding and transcriptional activation of apoptosis-inducing NF-
κB target genes. The main contributor, Oliver Krämer, performed most of the biochemical
assays, and I confirmed the results on the cellular level.
In  the  case  of  the  anti-apoptotic  protein  survivin,  it  could  be  demonstrated  that  the
evolutionary conservation of an export signal plays an important role for ist dual function,
apoptosis  inhibition  and  ordered  cell  division  (Knauer et al.,  2005b).  This  work  was
performed in collaboration with Oliver Krämer, who performed the caspase-3 activity assays.
Thomas Knösel, Knut Engels, Franz Rödel, Hartmut Walendzik, Adoriàn Kovács, Jürgen
Brieger,  Wolf  Mann  and  Iver  Petersen  provided  the  patient  material  and  performed
immunohistology stainings as well as the Kaplan-Meier survival analysis. RT-qPCR analysis
was performed by Negusse Habtemichael.
These findings indicated that the intervention with nucleo-cytoplasmic transport of disease-
relevant could be a potential therapeutic principle. To follow this approach, novel cell-based
assay systems were developed that allow the identification of transport inhibitors (Knauer et
al., 2005c). The work was performed in collaboration with Thorsten Berg, who provided
plasmids and chemical substance for screening procedures. Urban Liebel performed the
automated image acquisition and analysis on a fully automated high-throughput screening
microscope. In addition, the principle of nuclear translocation was exploited to establish
protease-  and  protein-interaction  biosensors  (Knauer  &  Stauber,  2005).  Experimental
procedures,  data  analysis  and  interpretation  presented  in  this  work  were  carried  out
predominantly by myself.SUMMARY OF PUBLICATIONS
46
5.1  Nuclear export is evolutionary conserved in CVC paired-like homeobox
proteins  and  influences  protein  stability,  transcriptional  activation  and
extracellular secretion
Shirley K. Knauer, Gert Carra and Roland H. Stauber
Ordered development depends on the activity of transcription factors in a controlled manner.
Among other mechanisms, regulated subcellular localization provides an attractive way to
control the activity of transcription factors, which has been, demonstrated for several key
players of signal transduction cascades (Cartwright & Helin, 2000, and references therein).
Homeodomain transcription factors control a variety of essential cell fate decisions during
development. To understand the developmental regulation by these transcription factors, we
investigated the intracellular trafficking of the paired-like CVC Homeodomain proteins (PLC-
HDPs) and analyzed its consequences for PLC-HDP function as transcriptional regulators.
The PLC-HDPs are characterized by a conserved CVC domain, can be grouped into the
Vsx-1 (visual system homeobox)  and  Vsx-2 family, and play a particular role in ocular
development (Ohtoshi et al., 2004, and references therein).
As representatives of the Vsx-1 and Vsx-2 group, we studied the zebrafish Vsx1 and the
murine Chx10 (Ceh-10 homologous homeobox)  protein  in  detail  (Knauer et al.,  2005a).
Nucleocytoplasmic  transport  was  investigated  by  interspecies  heterokaryon  assays,
microinjection  of  recombinant  transport  substrates,  and  the  use  of  chemical  transport
inhibitors. We could demonstrate that PLC-HDPs contain an evolutionary conserved CRM1-
dependent NES, previously described as the “octapeptide”.
Interestingly, preventing nuclear export by mutation of the NES resulted in a significantly
increased half-life for the export deficient Vsx-1 and Chx10 mutant proteins, indicating that
nuclear  export  is  continuously  supplying  substrate  for  the  proteasomal  degradation
machinery. Thus, by regulating the intracellular steady-state concentration, nuclear export
indirectly influenced PLC-HDP transcriptional activation, since the export deficient Vsx-1 and
Chx10 mutant proteins showed an increased stimulation of gene expression. In addition, we
found that the export-mediated continuous supply of cytoplasmic PLC-HDPs facilitated their
unconventional secretion required for the intercellular trafficking of PLC-HDP.
The predominant nuclear steady-state localization of PLC-HDPs was found to be mediated
by the presence of a 100% conserved active nuclear import signal. The high homology of thisSUMMARY OF PUBLICATIONS
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signal  to  known  protein  transduction  domains  (PTD)  could  be  verified  also  functional,
explaining the evolutionary conservation of this signal.
Based on our findings, we propose a model, in which the continuous nucleo-cytoplasmic
shuttling of PLC-HDPs contributes to the optimal and flexible execution of their transcriptional
activities (figure 5.1.). The evolutionarily conserved combination of a PTD, together with
active nuclear export and import signals, may allow the fine-tuning of intracellular protein
levels by the proteasome pathway and, in addition, also permits intercellular transfer.
The overlapping complex patterns of homeobox gene expression in the embryonic retina
require  a  complex  regulatory  network  of  transcription  factors.  Although  transcriptional
regulation of PLC-HDPs is an important control mechanism, PLC-HDPs may have additional
unexpected paracrine activity, thereby influencing and maintaining the complex expression
pattern during development.
Figure 5.1. (A) Organization  of  evolutionary  conserved  domains  in  PLC-HD  proteins
regulating cellular transport. (B) Model linking nucleo-cytoplasmic transport with PLC-
HDP activity. The predominantly nuclear localization of PLC-HD proteins is the net result of
import exceeding the rate of export due to the different activities of NES and NLS. Nuclear
export allows PLC-HD protein levels to be regulated by the proteasomal degradation pathway
and  continuously  supplies  cargo  for  extracellular  unconventional  secretion.  Intercellular
transport and trans-activation could be mediated by the protein transduction domain/NLS.SUMMARY OF PUBLICATIONS
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5.2  Acetylation of STAT1 modulates NF-κB signaling
Oliver H. Krämer, Daniela Baus, Shirley Knauer, Stefan Stein, Elke Jäger,
Roland Stauber, Manuel Grez, Edith Pfitzner and Thorsten Heinzel
The modulation of signaling events by histone deacetylase inhibitors (HDACi) can lead to the
induction  of  apoptosis  or  differentiation  of  carcinoma  cells.  The  molecular  mechanisms
underlying these processes are still under investigation but their understanding is crucial for
the efficient therapeutic application of HDACi. We found that sensitivity to HDACi correlated
with  STAT1  expression  in  human  melanoma  cell  lines  (Krämer et al.,  2005).  Ectopic
expression of STAT1 in resistant cells restored HDACi mediated induction of apoptosis. In
STAT1-positive cells, HDACi increased expression and acetylation of STAT1 and promoted
its  interaction  with  NF-κB  p65.  As  a  consequence,  NF-κB  p65  DNA-binding,  nuclear
localization and ultimately expression of anti-apoptotic NF-κB target genes decreased (figure
5.2.). We identified lysines 410 and 413 of STAT1 as acetylation sites. Mutation of these
residues to glutamine mimicked acetylation and rendered the interaction of STAT1 and NF-
κB p65 constitutive, whereas mutation to arginine precluded this interaction as well as
HDACi-induced  apoptosis.  Our  study  not  only  provides  an  additional  example  how
posttranslational modifications can influence protein localization, but also shows that the
crosstalk between STAT1 and NF-κB signaling pathways can be regulated by changes in the
acetylation status of STAT1.
Figure 5.2. Model for acetylation-dependent STAT1-NF-κB crosstalk.SUMMARY OF PUBLICATIONS
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5.3  Nuclear export is essential for the biological activity of survivin - Novel
aspects to target the survivin pathway in cancer
Shirley K. Knauer, Oliver H. Krämer, Thomas Knösel, Knut Engels, Franz
Rödel,  Hartmut  Walendzik,  Adoriàn  F.  Kovács,  Negusse  Habtemichael,
Jürgen Brieger, Wolf Mann, Thorsten Heinzel, Iver Petersen and Roland H.
Stauber
Evasion  from  apoptosis  as  well  as  enhanced  proliferation  are  invariant  molecular
characteristics of human cancer (Hanahan & Weinberg, 2000). Among several mechanisms,
escape from apoptosis can be the result of a deregulated overexpression of apoptosis
inhibitors (IAPs). A major therapeutic and prognostic interest has been focused on the IAP
survivin (Altieri, 2003a; Altieri, 2003d),  which  is  expressed  in  most  human  tumors  and
correlates with reduced tumor cell apoptosis, abbreviated patient survival, accelerated rates
of recurrences, and increased resistance to chemo- and radiotherapy (see Altieri, 2003c;
Altieri, 2003d; Li, 2003, and references within).
Since survivin was reported to function as an apoptosis inhibitor and a regulator of cell
division, i.e., functions executed in distinct intracellular compartments, we dissected the
molecular mechanism regulating the dynamic cellular localization of survivin and investigated
their functional consequences (Knauer et al., 2005b).
We  found  that  survivin  was  overexpressed  in  head  and  neck  tumors  and  colorectal
carcinomas and could be detected in both the cytoplasm and the nucleus. Nucleocytoplasmic
transport was investigated in cell culture systems by deletion mutagenesis, microinjection of
recombinant transport substrates, as well as biochemical assays resulting in the identification
of an evolutionary conserved CRM1 dependent leucine-rich NES in survivin, present also in
the splice variants 2B and 3B, but absent in the splice variants ∆Exon3 and 2α. In contrast,
neither survivin nor survivin splice variants harbor an active nuclear import signal, and thus
appear  to  enter  the  nucleus  by  passive  diffusion.  Importantly,  comparison  of  the  anti-
apoptotic activity of survivin and a NES-deficient survivin mutant revealed that nuclear export
was required for survivin mediated protection against chemo- and radiotherapy induced
apoptosis.  Since  the  activity  of  IAPs  is  assumed  to  be  mediated  predominantly  in  the
cytoplasm,  the  reduced  colocalization  of  the NES-mutant  with  Caspase-3  and  -9  could
account for the diminished anti-apoptotic activity of the survivin NES-mutant.SUMMARY OF PUBLICATIONS
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Interfering with nuclear export of survivin also manifested in an increase in multinuclear cells,
indicative for an impaired mitotic checkpoint control. We assume that survivin is tethered to
the chromosomal passenger complex via the NES-mediated interaction with CRM1, which is
an essential component of the mitotic machinery. Thus, nuclear export not only appears to
play a role in protection against cancer therapy induced apoptosis but also seems to be
required for proper cytokinesis.
The clinical relevance of our finding was supported by showing that preferential nuclear
localization of survivin correlated with enhanced survival in a cohort of colorectal cancer
patients. Cell culture experiments suggested interference with the nuclear export machinery
as one potential mechanism promoting survivin’s nuclear accumulation.
In conclusion, targeted interference with survivin’s nuclear export can be regarded as a
promising strategy for novel anti-cancer therapies.SUMMARY OF PUBLICATIONS
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5.4  Translocation  biosensors  to  study  signal  specific  nucleo-cytoplasmic
transport, protease activity & protein interactions
Shirley  K.  Knauer,  Sabrina  Moodt,  Thorsten  Berg,  Urban  Liebel,  Rainer
Pepperkok and Roland H. Stauber
Nucleo-cytoplasmic transport is crucial to  control  the  activity  and  stability  of  regulatory
proteins and RNAs, and thus interfering with nucleo-cytoplasmic transport in general as a
novel therapeutic principle has recently attracted major interest by academia and industry
(reviewed  in  Kau et al., 2004; Pagliaro  et  al.,  2004). In addition, regulated intracellular
localization is also essential for the controlled activity of site-specific proteases, which play
crucial roles in a variety of cellular functions, e.g. Thus, a great deal of interest has recently
focused on caspases as therapeutic targets for various disease processes (Los et al., 2003).
Besides for nucleo-cytoplasmic transport, protein  interaction  networks  are  critical  for  all
cellular events (Fahrenkrog & Aebi, 2003). In addition, modulating specific protein-protein
interactions by chemical compounds offers tremendous potential for the treatment of human
diseases.
As drug therapies must be effective at the cellular level, isolated proteins cannot be regarded
as representatives of complex biological systems, and cell-based assays (CBAs) have to be
employed. Recently, several methods have been developed to facilitate the implementation
of high-throughput CBAs (Hemmila & Hurskainen, 2002). However, any realistic applications
of high-throughput CBAs critically depend on robust and reliable biological readout systems
with a high signal to noise ratio. In this context, the spatial and functional division into the
nucleus and the cytoplasm marks two dynamic intracellular compartments that can easily be
distinguished by microscopy. Facing the clear need for improved CBAs, we exploited our
knowledge  of  regulated  nucleo-cytoplasmic  transport  resulting  in  the  development  and
application of modular biosensors tailored to investigate signal specific nuclear export and
import, protease activity and specific protein-protein interactions in living cells (Knauer et al.,
2005c).
The cellular biosensors were composed of the SV40 nuclear import signal, glutathione S-
transferase (GST), mutants of GFP and combinations of nuclear export signals. The fusion
proteins met essential requirements prerequisite to function as screening systems to identify
signal  specific  nucleo-cytoplasmic  translocation  inhibitors:  The  biosensors  1.  localized
predominantly to the cytoplasm. 2. were efficiently shuttling between the nucleus and theSUMMARY OF PUBLICATIONS
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cytoplasm. 3. accumulated in the nucleus following inhibition of nuclear export. 4. allowed the
modular exchange of transport signals. 4. were neither toxic nor affected by passive diffusion
or post-translational modifications in their intracellular localization.
We incorporated the NESs from PKI, from the HIV-1 Rev protein, from STAT1 and from Bcr-
Abl into the translocation sensors. The performance of the biosensors were systematically
investigated demonstrating that the designed transport sensors allowed to directly investigate
the effects of drug treatment or of over-expression/conditional knock-down of proteins on
general and signal-specific nucleo-cytoplasmic transport. Importantly, cytoplasmic to nuclear
translocation of the sensors could be accurately and reproducibly quantitated also on an
automated platform for high-throughput cell screening microscopy, which is an essential
requirement for their practical use in screening assays.
The principle of the translocation sensors was further exploited by the development into
protease biosensors. We incorporated the PARP (poly-(ADP-Ribose) polymerase ) cleavage
site for Caspase-3 N-terminal to the RevNES. The Casp3-sensor localized predominantly to
the cytoplasm, and induction of apoptosis resulted in the cleavage of the RevNES and the
subsequent nuclear accumulation of the Casp3-sensor.
Subsequently,  we  further  developed  the  transport  biosensor  system  into  a  “two-hybrid”
protein  interaction  assay  to  visualize  specific  protein-protein  interaction  in  vivo.  We
engineered a cassette that allows the expression of any ORF (open reading frame) X as a
NLS-GFP/GST-X-RevNES fusion protein (GFP-prey). Our previous work (Stauber et al.,
1998) demonstrated that a NES deficient HIV-1 Rev BFP fusion (RevM10-BFP) localized to
the nucleolus, and thus represented an ideal frame to express nucleolar anchored Y-BFP
fusion proteins (BFP-bait).
Having tested the leucine zipper protein interaction domains (ID) of Jun/Fos and Myc/Max as
well as for the ID of p53/Mdm2 in our assay, we finally concluded that the protein interaction
assay  fulfills  the  following  criteria:  1.  The  GFP-prey  molecule  containing  ID1,  although
continuously shuttling between the nucleus and the cytoplasm, localizes predominantly to the
cytoplasm. 2. The BFP-bait protein harboring ID2 is confined to the nucleolus. 3. Upon
specific protein interaction between ID1 and ID2, the GFP-prey redistributes to the nucleus
and colocalizes with the BFP-bait at the nucleolus. 4. The system is reversible and allows the
modular exchange of interaction domains. 5. Inhibitors of protein interactions can significantly
diminish the cytoplasmic to nuclear translocation.
In summary, the developed assays proved flexible, robust, facile and highly amenable to
academic  scale  screens  with  the  potential  to  be  employed  also  in  drug-screeningSUMMARY OF PUBLICATIONS
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applications. Efficient nuclear accumulation served as the common reliable indicator for all
biosensors (see figure 5.4.) and thus will facilitate fully automated image acquisition and data
analysis  using  microscopy  based  assay  platforms.  The  modular  composition  of  the
biosensors  guarantees  their  flexible  adoption  and  applications  in  numerous  biological
systems.
Figure  5.4.  Nuclear  translocation  of  the  biosensors  as  the  principle  for  cell-based
screening applications. The cellular biosensors are composed of GST, GFP and rational
combinations  of  nuclear  import  and  export  signals.  (A)  Addition  of  regulatory  sequences
resulted in three classes of biosensors applicable for the identification of signal specific nuclear
transport inhibitors, small molecules that interfere with protease activity and compounds that
modulate protein-protein interactions in living cells. (B) Nuclear accumulation of the cytoplasmic
biosensors serves as the indicator, which can be induced by interference with nuclear export,
induction of protease activity or formation of highly specific protein complexes.SUMMARY OF PUBLICATIONS
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5.5  Development  of  an  Autofluorescent  Translocation  Biosensor  System  to
Investigate Protein-Protein-Interactions in Living Cells
Shirley K. Knauer and Roland H. Stauber
Cellular homeostasis and communication strictly require regulated protein-protein interaction
networks.  Identification  of  these  interactions  and  characterization  of  their  physiological
significance is one of the main goals in a wide range of biological fields (Mendelsohn &
Brent, 1999; Ozawa et al., 2001). In cancer, cellular transformation and maintenance of the
transformed phenotype often strictly depend upon the formation of high molecular weight
complexes (HMWC). Thus, it has become clear that molecules, which inhibit specific protein-
protein interactions, have great potential as therapeutics with new modes of action (Arkin &
Wells, 2004). Consequently, numerous methods have been described to analyze protein-
protein interactions in vitro, in cell culture and in vivo including the yeast two-hybrid (YTH)
system, several split-enzyme complementation/reconstitution assays (Paulmurugan et al.,
2002, and references therein), fluorescence resonance energy-transfer (FRET) (Ozawa et
al., 2001; Wehrman  et  al.,  2002) as well as bimolecular fluorescence complementation
(BiFC) (see (Hu & Kerppola, 2003; Yu et al., 2003). Although the various methods have been
valuable tools in analyzing protein interactions, several intrinsic limitations apply (see (Ozawa
et al., 2001, and references within).
To  analyze  protein-protein  interactions  in  live  mammalian  cells,  we  applied  protein
translocation biosensors (PTBs) composed of glutathione S-transferase, mutants of GFP and
combinations  of  nuclear  import  and  export  signals  (Knauer  &  Stauber,  2005).  Nuclear
accumulation of the cytoplasmic biosensors served as the reliable indicator, which was
induced by the formation of protein complexes and could easily be detected by fluorescence
microscopy.  Efficacy  of  the  system  was  systematically  investigated  by  mapping  the
p53/Mdm2 protein interaction interface. Specificity and general applicability of the biosensors
were confirmed by studying not only protein interaction domains (IDs), which function as
heterodimers  (e.g.,  the  leucine-zipper  IDs  of  Jun/Fos)  but  also  of  IDs,  which  form
homodimers (e.g., the coiled-coil IDs of Bcr-Abl). Importantly, we found that, in comparison to
protein  complementation  assays  (e.g.,  BiFC),  our  system  proved  highly  efficient  and
reversible, and thus suited for the identification of molecular decoys to prevent specific
protein-protein interactions in living cells. Reversibility was demonstrated in competitionSUMMARY OF PUBLICATIONS
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experiments  by  overexpressing  the  specific  IDs  or  by  the  application  of  a  chemical
p53/Mdm2 protein interaction inhibitor.
Thus, in contrast to existing protein interaction assays, the presented strategy proved highly
efficient, flexible and reversible. Since the majority of GFP-prey fusions are not expected to
intrinsically localize to the nucleolus, our system is applicable to map the IDs of many
proteins. Moreover, the modular translocation system has great potential to be employed in
numerous  cell-based  assays  for  the  identification  of  small  molecule  protein  interaction
inhibitors as potential novel therapeutics.ACHIEVEMENTS OF THIS WORK AND OUTLOOK
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6  Achievements of this work and outlook
The thesis entitled "Investigations on the significance of nucleo-cytoplasmic transport for the
biological function of cellular proteins" aimed to unreveal molecular mechanism in order to
improve  our  understanding  of  the  impact  of  nucleo-cytoplasmic  transport  on  cellular
functions.
Within the scope of this work, it could be shown that regulated nucleo-cytoplasmic transport
of a subfamily of homeobox transcription factors also controls their intercellular transport,
thereby influencing their transcriptional activity (Knauer et al., 2005a). This study described a
novel regulatory mechanism, which could in general play an important role for the ordered
differentiation of complex organisms. Future work will focus on the analysis of the in vivo role
of PLC-HDPs’ nucleo-cytoplasmic shuttling for ordered development by the generation of
transgenic mouse knock-in models, in which the nuclear export/import signals of PLC-HDPs
are selectively abolished.
Besides cis-active transport signals, also post-translational modifications can influence the
localization and biological activity of proteins in trans. In addition to the known impact of
phosphorylation on the transport and activity of STAT1, experimental evidence was provided
demonstrating  that  acetylation  affected  the  interaction  of  STAT1  with  NF-κB  p65,  and
subsequently modulated the expression of apoptosis-inducing NF-κB target genes (Krämer
et al., 2005). Future work will be engaged in analyzing whether this mechanism is also
relevant for other members of the STAT family.
The impact of nucleo-cytoplasmic transport on the regulation of apoptosis was underlined by
showing that the evolutionary conservation of a NES within the anti-apoptotic protein survivin
plays an essential role for its dual function in the inhibition of apoptosis and ordered cell
division (Knauer et al., 2005b). Since survivin is considered a bona fide cancer therapy
target,  these  results  strongly  encourage  future  work  to  identify  molecular  decoys  that
specifically inhibit the nuclear export of survivin as novel therapeutics.
In  order  to  further  dissect  the  regulation  of  nuclear  transport  and  to  efficiently  identify
transport inhibitors, cell-based assays are urgently required. Therefore, the cellular assay
systems developed in this work (Knauer et al., 2005c) may not only serve to identify syntheticACHIEVEMENTS OF THIS WORK AND OUTLOOK
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nuclear export and import inhibitors, but may also be applied in systematic RNAi-screening
approaches  to  identify  novel  components  of  the  transport  machinery.  In  addition,  the
translocation based protease and protein interaction biosensors can be applied in various
biological systems, in particular to identify protein-protein interaction inhibitors of cancer
relevant proteins (Knauer et al., 2005c; Knauer & Stauber, 2005).
In summary, this work does not only underline the general significance of nucleo-cytoplasmic
transport on cell biology, but also demonstrates its potential for the development of novel
therapies against diseases like cancer and viral infections.   REFERENCES
58
7  References
Adam S. A. (1999). Transport pathways of macromolecules between the nucleus and the
cytoplasm. Curr Opin Cell Biol 11, 3, p. 402-6.
Affolter M., Marty T. & Vigano M. A. (1999). Balancing import and export in development.
Genes Dev 13, 8, p. 913-5.
Almholt D. L., Loechel F., Nielsen S. J., Krog-Jensen C., Terry R., Bjorn S. P., Pedersen
H. C., Praestegaard M., Moller S., Heide M., Pagliaro L., Mason A. J., Butcher S. &
Dahl  S.  W.  (2004). Nuclear export inhibitors and kinase inhibitors identified using a
MAPK-activated protein kinase 2 redistribution screen. Assay Drug Dev Technol 2, 1, p. 7-
20.
Alt J. R., Cleveland J. L., Hannink M. & Diehl J. A. (2000).  Phosphorylation-dependent
regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation.
Genes Dev 14, 24, p. 3102-14.
Alt  J.  R.,  Gladden  A.  B.  &  Diehl  J.  A.  (2002). p21(Cip1) Promotes cyclin D1 nuclear
accumulation via direct inhibition of nuclear export. J Biol Chem 277, 10, p. 8517-23.
Altieri D. C. (2003a). Blocking survivin to kill cancer cells. Methods Mol Biol 223, p. 533-42.
Altieri D. C. (2003b). Survivin and apoptosis control. Adv Cancer Res 88, p. 31-52.
Altieri D. C. (2003c). Survivin in apoptosis control and cell cycle regulation in cancer. Prog
Cell Cycle Res 5, p. 447-52.
Altieri D. C. (2003d). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3, 1,
p. 46-54.
Altieri D. C. (2004). Molecular circuits of apoptosis regulation and cell division control: The
survivin paradigm. J Cell Biochem 92, 4, p. 656-63.
Ambros V. (2001). microRNAs: tiny regulators with great potential. Cell 107, 7, p. 823-6.
Arkin M. R. & Wells J. A. (2004). Small-molecule inhibitors of protein-protein interactions:
progressing towards the dream. Nat Rev Drug Discov 3, 4, p. 301-17.
Arnaoutov A., Azuma Y., Ribbeck K., Joseph J., Boyarchuk Y., Karpova T., McNally J.
& Dasso M. (2005). Crm1 is a mitotic effector of Ran-GTP in somatic cells. Nat Cell Biol
7, 6, p. 626-32.
Arnaoutov A. & Dasso M. (2003). The Ran GTPase regulates kinetochore function. Dev
Cell 5, 1, p. 99-111.
Azuma Y. & Dasso M. (2000). The role of Ran in nuclear function. Curr Opin Cell Biol 12, 3,
p. 302-7.
Bednenko J., Cingolani G. & Gerace L. (2003). Nucleocytoplasmic transport: navigating
the channel. Traffic 4, 3, p. 127-35.
Ben-Efraim  I.  &  Gerace  L.  (2001).  Gradient  of  increasing  affinity  of  importin  beta  for
nucleoporins along the pathway of nuclear import. J Cell Biol 152, 2, p. 411-7.
Berg  T.  (2003). Modulation of protein-protein interactions with small organic molecules.
Angew Chem Int Ed Engl 42, 22, p. 2462-81.REFERENCES
59
Berg T., Cohen S. B., Desharnais J., Sonderegger C., Maslyar D. J., Goldberg J., Boger
D. L. & Vogt P. K. (2002). Small-molecule antagonists of Myc/Max dimerization inhibit
Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A 99,
6, p. 3830-5.
Briggs L. J., Stein D., Goltz J., Corrigan V. C., Efthymiadis A., Hubner S. & Jans D. A.
(1998).  The  cAMP-dependent  protein  kinase  site  (Ser312)  enhances  dorsal  nuclear
import through facilitating nuclear localization sequence/importin interaction. J Biol Chem
273, 35, p. 22745-52.
Brik A. & Wong C. H. (2003). HIV-1 protease: mechanism and drug discovery. Org Biomol
Chem 1, 1, p. 5-14.
Brooks C. L., Li M. & Gu W. (2004). Monoubiquitination: the signal for p53 nuclear export?
Cell Cycle 3, 4, p. 436-8.
Caldas H., Honsey L. E. & Altura R. A. (2005). Survivin 2alpha: a novel Survivin splice
variant expressed in human malignancies. Mol Cancer 4, 1, p. 11.
Cartwright P. & Helin K. (2000). Nucleocytoplasmic shuttling of transcription factors. Cell
Mol Life Sci 57, 8-9, p. 1193-206.
Clarke P. R. (2005). The Crm de la creme of mitosis. Nat Cell Biol 7, 6, p. 551-2.
Connor M. K., Kotchetkov R., Cariou S., Resch A., Lupetti R., Beniston R. G., Melchior
F.,  Hengst  L.  &  Slingerland  J.  M.  (2003).  CRM1/Ran-mediated  nuclear  export  of
p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol
Cell 14, 1, p. 201-13.
Cory S. & Adams J. M. (2002). The Bcl2 family: regulators of the cellular life-or-death
switch. Nat Rev Cancer 2, 9, p. 647-56.
Cullen B. R. (2003a). Nuclear mRNA export: insights from virology. Trends Biochem Sci 28,
8, p. 419-24.
Cullen B. R. (2003b). Nuclear RNA export. J Cell Sci 116, Pt 4, p. 587-97.
Dasso M. (2001). Running on Ran: nuclear transport and the mitotic spindle. Cell 104, 3, p.
321-4.
Dasso M. (2002). The Ran GTPase: theme and variations. Curr Biol 12, 14, p. R502-8.
Day  R.  N.  &  Schaufele  F.  (2005).  Imaging  molecular  interactions  in  living  cells. Mol
Endocrinol.
Denning D. P., Patel S. S., Uversky V., Fink A. L. & Rexach M. (2003). Disorder in the
nuclear pore complex: the FG repeat regions of nucleoporins are natively unfolded. Proc
Natl Acad Sci U S A 100, 5, p. 2450-5.
Deveraux Q. L. & Reed J. C. (1999). IAP family proteins--suppressors of apoptosis. Genes
Dev 13, 3, p. 239-52.
Doye V. & Hurt E. (1997). From nucleoporins to nuclear pore complexes. Curr. Opin. Cell
Biol. 9, p. 401-11.
Endter C., Kzhyshkowska J., Stauber R. & Dobner T. (2001).  SUMO-1  modification
required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein.
Proc Natl Acad Sci U S A 98, 20, p. 11312-7.
Englmeier L., Fornerod M., Bischoff F. R., Petosa C., Mattaj I. W. & Kutay U. (2001).
RanBP3 influences interactions between CRM1 and its nuclear protein export substrates.
EMBO Rep 2, 10, p. 926-32.REFERENCES
60
Englmeier L., Olivo J. C. & Mattaj I. W. (1999). Receptor-mediated substrate translocation
through the nuclear pore complex without nucleotide triphosphate hydrolysis. Curr Biol 9,
1, p. 30-41.
Fahrenkrog B. & Aebi U. (2003). The nuclear pore complex: nucleocytoplasmic transport
and beyond. Nat Rev Mol Cell Biol 4, 10, p. 757-66.
Fahrenkrog B., Aris J. P., Hurt E. C., Pante N. & Aebi U. (2000).  Comparative  spatial
localization of protein-A-tagged and authentic yeast nuclear pore complex proteins by
immunogold electron microscopy. J Struct Biol 129, 2-3, p. 295-305.
Fahrenkrog B., Koser J. & Aebi U. (2004). The nuclear pore complex: a jack of all trades?
Trends Biochem Sci 29, 4, p. 175-82.
Ferrando-May E. (2005). Nucleocytoplasmic transport in apoptosis. Cell Death Differ.
Fischer U., Huber J., Boelens W. C., Mattaj I. W. & Lührmann R. (1995). The HIV-1 Rev
activation domain is a nuclear export signal that accesses an export pathway used by
specific cellular RNAs. Cell 82, 3, p. 475-83.
Fornerod M. (1997). Chromosomal localization of genes encoding CAN/Nup214-interacting
proteins-human  CRM1  localizes  to  2p16,  whereas  Nup88  localizes  to  17p13  and  is
physically linked to SF2p32. Genomics 42, p. 538-40.
Fornerod  M.  &  Ohno  M.  (2002).  Exportin-mediated  nuclear  export  of  proteins  and
ribonucleoproteins. Results Probl Cell Differ 35, p. 67-91.
Forwood  J.  K.,  Lam  M.  H.  &  Jans  D.  A.  (2001).  Nuclear  import  of  creb  and  ap-1
transcription factors requires importin-beta1 and ran but is independent of importin-alpha.
Biochemistry 40, 17, p. 5208-17.
Fukuda M., Asano S., Nakamura T., Adachi M., Yoshida M., Yanagida M. & Nishida E.
(1997). CRM1 is responsible for intracellular transport mediated by the nuclear export
signal. Nature 390, 6657, p. 308-11.
Gadde S. & Heald R. (2004). Mechanisms and molecules of the mitotic spindle. Curr Biol 14,
18, p. R797-805.
Galliot B., de Vargas C. & Miller D. (1999). Evolution of homeobox genes: Q50 Paired-like
genes founded the Paired class. Dev Genes Evol 209, 3, p. 186-97.
Gerl R. & Vaux D. L. (2005).  Apoptosis  in  the  development  and  treatment  of  cancer.
Carcinogenesis 26, 2, p. 263-70.
Giuliano K. A., Chen Y. & Haskins J. R. (2003a). Fluorescent prorein biosensors - A new
screening tool moves drug targets out of the test tube and into the cell. Mod  Drug
Discovery 6, 8, p. 33-37.
Giuliano K. A., Haskins J. R. & Taylor D. L. (2003b). Advances in high content screening
for drug discovery. Assay Drug Dev Technol 1, 4, p. 565-77.
Goldberg M. (2004). Import and export at the nuclear envelope. Symp Soc Exp Biol, 56, p.
115-33.
Görlich D., Kostka S., Kraft R., Dingwall C., Laskey R. A., Hartmann E. & Prehn S.
(1995). Two different subunits of importin cooperate to recognize nuclear localization
signals and bind them to the nuclear envelope. Curr Biol 5, 4, p. 383-92.
Görlich D. & Kutay U. (1999). Transport between the cell nucleus and the cytoplasm. Annu.
Rev. Cell Dev. Biol. 15, p. 607-60.REFERENCES
61
Görlich D. & Mattaj I. W. (1996). Nucleocytoplasmic transport. Science 271, 5255, p. 1513-
8.
Grinberg A. V., Hu C. D. & Kerppola T. K. (2004). Visualization of Myc/Max/Mad family
dimers and the competition for dimerization in living cells. Mol Cell Biol 24, 10, p. 4294-
308.
Gu  J.,  Nie  L.,  Wiederschain  D.  &  Yuan  Z.  M.  (2001). Identification of p53 sequence
elements that are required for MDM2-mediated nuclear export. Mol Cell Biol  21, 24, p.
8533-46.
Hanahan D. & Weinberg R. A. (2000). The hallmarks of cancer. Cell 100, 1, p. 57-70.
Harel A. & Forbes D. J. (2004). Importin beta: conducting a much larger cellular symphony.
Mol Cell 16, 3, p. 319-30.
Harley  V.  R.,  Layfield  S.,  Mitchell  C.  L.,  Forwood  J.  K.,  John  A.  P.,  Briggs  L.  J.,
McDowall S. G. & Jans D. A. (2003). Defective importin beta recognition and nuclear
import of the sex-determining factor SRY are associated with XY sex-reversing mutations.
Proc Natl Acad Sci U S A 100, 12, p. 7045-50.
Harper J. V. & Brooks G. (2005). The mammalian cell cycle: an overview. Methods Mol Biol
296, p. 113-53.
Heger P., Lohmaier J., Schneider G., Schweimer K. & Stauber R. H. (2001). Qualitative
highly  divergent  nuclear  export  signals  can  regulate  export  by  the  competition  for
transport cofactors in vivo. Traffic 2, 8, p. 544-55.
Heger P., Rosorius O., Hauber J. & Stauber R. H. (1999). Titration of cellular export
factors, but not heteromultimerization,  is the molecular  mechanism  of trans-dominant
HTLV-1 Rex mutants. Oncogene 18, p. 4080-90.
Hemmila I. A. & Hurskainen P. (2002). Novel detection strategies for drug discovery. Drug
Discov Today 7, 18 Suppl, p. S150-6.
Hermeking H. (2003). The MYC oncogene as a cancer drug target. Curr  Cancer  Drug
Targets 3, 3, p. 163-75.
Hu C. D. & Kerppola T. K. (2003). Simultaneous visualization of multiple protein interactions
in living cells using multicolor fluorescence complementation analysis. Nat Biotechnol 21,
5, p. 539-45.
Hurlin P. J. & Dezfouli S. (2004). Functions of myc:max in the control of cell proliferation
and tumorigenesis. Int Rev Cytol 238, p. 183-226.
Igney F. H. & Krammer P. H. (2002). Death and anti-death: tumour resistance to apoptosis.
Nat Rev Cancer 2, 4, p. 277-88.
Izaurralde E. (2004). Directing mRNA export. Nat Struct Mol Biol 11, 3, p. 210-2.
Izaurralde E., Kutay U., von Kobbe C., Mattaj I. W. & Görlich D. (1997). The asymmetric
distribution of the constituents of the Ran system is essential for transport into and out of
the nucleus. Embo J 16, 21, p. 6535-47.
Jesenberger V. & Jentsch S. (2002). Deadly encounter: ubiquitin meets apoptosis. Nat Rev
Mol Cell Biol 3, 2, p. 112-21.
Kalderon D., Roberts B. L., Richardson W. D. & Smith A. E. (1984). A short amino acid
sequence able to specify nuclear location. Cell 39, p. 499-509.REFERENCES
62
Kau T. R., Schroeder F., Ramaswamy S., Wojciechowski C. L., Zhao J. J., Roberts T.
M., Clardy J., Sellers W. R. & Silver P. A. (2003). A chemical genetic screen identifies
inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient
tumor cells. Cancer Cell 4, 6, p. 463-76.
Kau T. R., Way J. C. & Silver P. A. (2004). Nuclear transport and cancer: from mechanism
to intervention. Nat Rev Cancer 4, 2, p. 106-17.
Kiernan R., Bres V., Ng R. W., Coudart M. P., El Messaoudi S., Sardet C., Jin D. Y.,
Emiliani S. & Benkirane M. (2003). Post-activation turn-off of NF-kappa B-dependent
transcription is regulated by acetylation of p65. J Biol Chem 278, 4, p. 2758-66.
Kim V. N. (2004). MicroRNA precursors in motion: exportin-5 mediates their nuclear export.
Trends Cell Biol 14, 4, p. 156-9.
Knauer S. K., Carra G. & Stauber R. H. (2005a). Nuclear export is evolutionarily conserved
in CVC paired-like homeobox proteins and influences protein stability, transcriptional
activation, and extracellular secretion. Mol Cell Biol 25, 7, p. 2573-82.
Knauer S. K., Krämer O. H., Knösel T., Engels K., Rödel F., Walendzik H., Kovács A. F.,
Habtemichael  N.,  Brieger  J.,  Mann  W.,  Heinzel  T.,  Petersen  I.  &  Stauber  R.  H.
(2005b). Nuclear export is essential for the biological activity of survivin - Novel aspects to
target the survivin pathway in cancer. Cancer Res, submitted.
Knauer S. K., Moodt S., Berg T., Liebel U., Pepperkok R. & Stauber R. H. (2005c).
Translocation  Biosensors  To  Study  Signal  Specific  Nucleo-Cytoplasmic  Transport,
Protease Activity & Protein Interactions. Traffic 6, p. 1-13.
Knauer S. K. & Stauber R. H. (2005). Development of an Autofluorescent Translocation
Biosensor System To Investigate Protein-Protein Interactions in Living Cells. Anal Chem,
published online.
Komiyama K., Okada K., Tomisaka S., Umezawa I., Hamamoto T. & Beppu T. (1985).
Antitumor activity of leptomycin B. J Antibiot (Tokyo) 38, 3, p. 427-9.
Kouzarides T. (1999). Histone acetylases and deacetylases in cell proliferation. Curr Opin
Genet Dev 9, 1, p. 40-8.
Krämer O. H., Baus D., Knauer S. K., Stein S., Jäger E., Stauber R. H., Grez M., Pfitzner
E. & Heinzel T. (2005). Acetylation of Stat1 modulates NF-kB signaling Genes Dev,
submitted.
Krammer P. H. (2000). CD95's deadly mission in the immune system. Nature 407, 6805, p.
789-95.
Krätzer F., Rosorius O., Heger P., Hirschmann N., Dobner T., Hauber J. & Stauber R. H.
(2000). The adenovirus type 5 E1B-55K oncoprotein is a highly active shuttle protein and
shuttling is independent of E4orf6, p53 and Mdm2. Oncogene 19, p. 850-57.
Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E. P., Wolff B., Yoshida M. &
Horinouchi  S.  (1999).  Leptomycin  B  inactivates  CRM1/exportin  1  by  covalent
modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S
A 96, 16, p. 9112-7.
Kuersten S., Ohno M. & Mattaj I. W. (2001). Nucleocytoplasmic transport: Ran, beta and
beyond. Trends Cell Biol 11, 12, p. 497-503.
Künzler M., Gerstberger T., Stutz F., Bischoff F. R. & Hurt E. (2000). Yeast Ran-binding
protein 1 (Yrb1) shuttles between the nucleus and cytoplasm and is exported from the
nucleus via a CRM1 (XPO1)-dependent pathway. Mol Cell Biol 20, 12, p. 4295-308.REFERENCES
63
Kutay U. & Guttinger S. (2005). Leucine-rich nuclear-export signals: born to be weak.
Trends Cell Biol 15, 3, p. 121-4.
La Cour T., Kiemer L., Molgaard A., Gupta R., Skriver K. & Brunak S. (2004). Analysis
and prediction of leucine-rich nuclear export signals. Protein Eng Des Sel 17, 6, p. 527-
36.
Laxman B., Hall D. E., Bhojani M. S., Hamstra D. A., Chenevert T. L., Ross B. D. &
Rehemtulla A. (2002). Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U
S A 99, 26, p. 16551-5.
Lens S. M., Wolthuis R. M., Klompmaker R., Kauw J., Agami R., Brummelkamp T.,
Kops G. & Medema R. H. (2003). Survivin is required for a sustained spindle checkpoint
arrest in response to lack of tension. Embo J 22, 12, p. 2934-47.
Levy D. E. & Darnell J. E., Jr. (2002). Stats: transcriptional control and biological impact.
Nat Rev Mol Cell Biol 3, 9, p. 651-62.
Li F. (2003). Survivin study: what is the next wave? J Cell Physiol 197, 1, p. 8-29.
Li F., Ackermann E. J., Bennett C. F., Rothermel A. L., Plescia J., Tognin S., Villa A.,
Marchisio P. C. & Altieri D. C. (1999). Pleiotropic cell-division defects and apoptosis
induced by interference with survivin function. Nat Cell Biol 1, 8, p. 461-6.
Li F., Ambrosini G., Chu E. Y., Plescia J., Tognin S., Marchisio P. C. & Altieri D. C.
(1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 6711,
p. 580-4.
Liebel U., Starkuviene V., Erfle H., Simpson J. C., Poustka A., Wiemann S. & Pepperkok
R.  (2003).  A  microscope-based  screening  platform  for  large-scale  functional  protein
analysis in intact cells. FEBS Lett 554, 3, p. 394-8.
Lindsay M. E., Holaska J. M., Welch K., Paschal B. M. & Macara I. G. (2001). Ran-binding
protein 3 is a cofactor for Crm1-mediated nuclear protein export. J Cell Biol 153, 7, p.
1391-402.
Lindsten K., Uhlikova T., Konvalinka J., Masucci M. G. & Dantuma N. P. (2001). Cell-
based fluorescence assay for human immunodeficiency virus type 1 protease activity.
Antimicrob Agents Chemother 45, 9, p. 2616-22.
Los M., Burek C. J., Stroh C., Benedyk K., Hug H. & Mackiewicz A. (2003). Anticancer
drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 8,
2, p. 67-77.
Maizel A., Tassetto M., Filhol O., Cochet C., Prochiantz A. & Joliot A. (2002). Engrailed
homeoprotein secretion is a regulated process. Development 129, 15, p. 3545-53.
McBride K. M. & Reich N. C. (2003). The ins and outs of STAT1 nuclear transport. Sci
STKE 2003, 195, p. RE13.
McManus M. T. (2003). MicroRNAs and cancer. Semin Cancer Biol 13, 4, p. 253-8.
Meier P., Finch A. & Evan G. (2000). Apoptosis in development. Nature 407, 6805, p. 796-
801.
Mendelsohn A. R. & Brent R. (1999). Protein interaction methods - toward an endgame.
Science 284, 5422, p. 1948-50.
Miele L. (2004). The biology of cyclins and cyclin-dependent protein kinases: an introduction.
Methods Mol Biol 285, p. 3-21.REFERENCES
64
Mingot J. M., Kostka S., Kraft R., Hartmann E. & Gorlich D. (2001). Importin 13: a novel
mediator of nuclear import and export. Embo J 20, 14, p. 3685-94.
Nachury M. V., Ryder U. W., Lamond A. I. & Weis K. (1998). Cloning and characterization
of hSRP1 gamma, a tissue-specific nuclear transport factor. Proc Natl Acad Sci U S A 95,
2, p. 582-7.
Nachury M. V. & Weis K. (1999). The direction of transport through the nuclear pore can be
inverted. Proc Natl Acad Sci U S A 96, 17, p. 9622-7.
O'Brate  A.  &  Giannakakou  P.  (2003).  The  importance  of  p53  location:  nuclear  or
cytoplasmic zip code? Drug Resist Updat 6, 6, p. 313-22.
Ohtoshi  A.,  Wang  S.  W.,  Maeda  H.,  Saszik  S.  M.,  Frishman  L.  J.,  Klein  W.  H.  &
Behringer R. R. (2004). Regulation of retinal cone bipolar cell differentiation and photopic
vision by the CVC homeobox gene Vsx1. Curr Biol 14, 6, p. 530-6.
Ozawa T., Kaihara A., Sato M., Tachihara K. & Umezawa Y. (2001). Split luciferase as an
optical  probe  for  detecting  protein-protein  interactions  in  mammalian  cells  based  on
protein splicing. Anal Chem 73, 11, p. 2516-21.
Pagliaro  L.,  Felding  J.,  Audouze  K.,  Nielsen  S.  J.,  Terry  R.  B.,  Krog-Jensen  C.  &
Butcher S. (2004). Emerging classes of protein-protein interaction inhibitors and new
tools for their development. Curr Opin Chem Biol 8, 4, p. 442-9.
Palacios I., Hetzer M., Adam S. A. & Mattaj I. W. (1997). Nuclear import of U snRNPs
requires importin beta. Embo J 16, 22, p. 6783-92.
Palmeri D. & Malim M. H. (1999). Importin beta can mediate the nuclear import of an
arginine-rich nuclear localization signal in the absence of importin alpha. Mol Cell Biol 19,
2, p. 1218-25.
Pante N. (2004). Nuclear pore complex structure: unplugged and dynamic pores. Dev Cell 7,
6, p. 780-1.
Pante N. & Kann M. (2002). Nuclear pore complex is able to transport macromolecules with
diameters of about 39 nm. Mol Biol Cell 13, 2, p. 425-34.
Paraskeva E., Izaurralde E., Bischoff F. R., Huber J., Kutay U., Hartmann E., Luhrmann
R. & Görlich D. (1999). CRM1-mediated recycling of snurportin 1 to the cytoplasm. J Cell
Biol 145, 2, p. 255-64.
Patel  D.,  Frelinger  J.,  Goudsmit  J.  &  Kim  B.  (2001).  In  vitro  assay  for  site-specific
proteases using bead-attached GFP substrate. Biotechniques 31, 5, p. 1194-98.
Paulmurugan R., Umezawa Y. & Gambhir S. S. (2002). Noninvasive imaging of protein-
protein  interactions  in  living  subjects  by  using  reporter  protein  complementation  and
reconstitution strategies. Proc Natl Acad Sci U S A 99, 24, p. 15608-13.
Pavlakis G. N. & Stauber R. H. (1998). Regulatory Proteins of HIV-1. In: N. Saksenas, N.
Saksenas.  Human  Immunodeficiency  Viruses:  Biology,  Immunology  and  Molecular
Biology.  Genova: Medical Systems SpA; p. 103-22.
Pemberton L. F. & Paschal B. M. (2005). Mechanisms of receptor-mediated nuclear import
and nuclear export. Traffic 6, 3, p. 187-98.
Perkins N. D. (2004). NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 14, 2, p.
64-9.
Phippard D. & Manning A. M. (2003). Screening for inhibitors of transcription factors using
luciferase reporter gene expression in transfected cells. Methods Mol Biol 225, p. 19-23.REFERENCES
65
Pollard V. W., Michael W. M., Nakielny S., Siomi M. C., Wang F. & Dreyfuss G. (1996). A
novel receptor-mediated nuclear protein import pathway. Cell 86, 6, p. 985-94.
Poon I. K. & Jans D. A. (2005). Regulation of nuclear transport: central role in development
and transformation? Traffic 6, 3, p. 173-86.
Porter L. A. & Donoghue D. J. (2003). Cyclin B1 and CDK1: nuclear localization and
upstream regulators. Prog Cell Cycle Res 5, p. 335-47.
Reichelt R., Holzenburg A., Buhle E. L., Jr., Jarnik M., Engel A. & Aebi U. (1990).
Correlation between structure and mass distribution of the nuclear pore complex and of
distinct pore complex components. J Cell Biol 110, 4, p. 883-94.
Ribbeck K. & Görlich D. (2001). Kinetic analysis of translocation through nuclear pore
complexes. Embo J 20, 6, p. 1320-30.
Ribbeck  K.  &  Görlich  D.  (2002).  The  permeability  barrier  of  nuclear  pore  complexes
appears to operate via hydrophobic exclusion. Embo J 21, 11, p. 2664-71.
Robbins J., Dilworth S. M., Laskey R. A. & Dingwall C. (1991). Two interdependent basic
domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite
nuclear targeting sequence. Cell 64, 3, p. 615-23.
Rosorius O., Fries B., Stauber R. H., Hirschmann N., Bevec D. & Hauber J. (2000).
Human ribosomal protein L5 contains defined nuclear localization and export signals. J
Biol Chem 275, 16, p. 12061-8.
Rosorius O., Heger P., Stelz G., Hirschmann N., Hauber J. & Stauber R. H. (1999). Direct
observation of nucleo-cytoplasmic transport by microinjection of GFP-tagged proteins in
living cells. BioTechniques 27, p. 350-55.
Rout M. P. & Aitchison J. D. (2001). The nuclear pore complex as a transport machine. J
Biol Chem 276, 20, p. 16593-6.
Rout M. P., Aitchison J. D., Suprapto A., Hjertaas K., Zhao Y. & Chait B. T. (2000). The
yeast nuclear pore complex: composition, architecture, and transport mechanism. J Cell
Biol 148, 4, p. 635-51.
Salvesen G. S. & Duckett C. S. (2002). IAP proteins: blocking the road to death's door. Nat
Rev Mol Cell Biol 3, 6, p. 401-10.
Schwoebel E. D., Talcott B., Cushman I. & Moore M. S. (1998). Ran-dependent signal-
mediated nuclear import does not require GTP hydrolysis by Ran. J Biol Chem 273, 52, p.
35170-5.
Sherr C. J. (2004). Principles of tumor suppression. Cell 116, 2, p. 235-46.
Sherr C. J. & Roberts J. M. (2004). Living with or without cyclins and cyclin-dependent
kinases. Genes Dev 18, 22, p. 2699-711.
Siomi H. & Dreyfuss G. (1995). A nuclear localization domain in the hnRNP A1 protein. J
Cell Biol 129, 3, p. 551-60.
Stauber R. H., Afonina E., Gulnik S., Erickson J. & Pavlakis G. N. (1998). Analysis of
intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells.
Virology 251, p. 38-48.
Stoffler D., Fahrenkrog B. & Aebi U. (1999). The nuclear pore complex: from molecular
architecture to functional dynamics. Curr Opin Cell Biol 11, 3, p. 391-401.
Strom A. C. & Weis K. (2001). Importin-beta-like nuclear transport receptors. Genome Biol
2, 6, p. REVIEWS3008.REFERENCES
66
Sun C., Nettesheim D., Liu Z. & Olejniczak E. T. (2005). Solution structure of human
survivin and its binding interface with smac/diablo. Biochemistry 44, 1, p. 11-7.
Suntharalingam M. & Wente S. R. (2003). Peering through the pore: nuclear pore complex
structure, assembly, and function. Dev Cell 4, 6, p. 775-89.
Tam W. F., Lee L. H., Davis L. & Sen R. (2000). Cytoplasmic sequestration of rel proteins
by IkappaBalpha requires CRM1-dependent nuclear export. Mol Cell Biol 20, 6, p. 2269-
84.
van Dam H. & Castellazzi M. (2001). Distinct roles of Jun : Fos and Jun : ATF dimers in
oncogenesis. Oncogene 20, 19, p. 2453-64.
Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N.,
Kammlott U., Lukacs C., Klein C., Fotouhi N. & Liu E. A. (2004). In vivo activation of
the p53 pathway by small-molecule antagonists of MDM2. Science 303, 5659, p. 844-8.
Vasu S. K. & Forbes D. J. (2001). Nuclear pores and nuclear assembly. Curr Opin Cell Biol
13, p. 363-75.
Vigneri P. & Wang J. Y. (2001). Induction of apoptosis in chronic myelogenous leukemia
cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7, 2, p. 228-34.
Vogelstein B. & Kinzler K. W. (2004). Cancer genes and the pathways they control. Nat
Med 10, 8, p. 789-99.
Vogelstein B., Lane D. & Levine A. J. (2000). Surfing the p53 network. Nature 408, 6810,
p. 307-10.
Vogt P. K. (2002). Fortuitous convergences: the beginnings of JUN. Nat Rev Cancer 2, 6, p.
465-9.
Vousden K. H. & Prives C. (2005). P53 and prognosis: new insights and further complexity.
Cell 120, 1, p. 7-10.
Wehrman T., Kleaveland B., Her J. H., Balint R. F. & Blau H. M. (2002). Protein-protein
interactions  monitored  in  mammalian  cells  via  complementation  of  beta  -lactamase
enzyme fragments. Proc Natl Acad Sci U S A 99, 6, p. 3469-74.
Weis K. (2003). Regulating access to the genome: nucleocytoplasmic transport throughout
the cell cycle. Cell 112, 4, p. 441-51.
Wolff B., Sanglier J. J. & Wang Y. (1997). Leptomycin B is an inhibitor of nuclear export:
inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1
(HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 4, 2, p. 139-47.
Xu L. & Massague J. (2004). Nucleocytoplasmic shuttling of signal transducers. Nat Rev
Mol Cell Biol 5, 3, p. 209-19.
Yu H., West M., Keon B. H., Bilter G. K., Owens S., Lamerdin J. & Westwick J. K. (2003).
Measuring drug action in the cellular context using protein-fragment complementation
assays. Assay Drug Dev Technol 1, 6, p. 811-22.
Yuan Z. L., Guan Y. J., Chatterjee D. & Chin Y. E. (2005). Stat3 dimerization regulated by
reversible acetylation of a single lysine residue. Science 307, 5707, p. 269-73.
Zhao Y. & Westphal H. (2002). Homeobox genes and human genetic disorders. Curr Mol
Med 2, 1, p. 13-23.
Zhong H., May M. J., Jimi E. & Ghosh S. (2002). The phosphorylation status of nuclear NF-
kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9, 3, p. 625-36.APPENDIX
67
8  Appendix
8.1  List of figures and tables
Figure 3.1.1.  Structure of the nuclear pore complex...................................................................10
Figure 3.1.2.  NUP Subcomplexes in Vertebrate NPCs................................................................12
Figure 3.2.  The Ran-GTP/GDP cycle...........................................................................................13
Figure 3.5.  Different NPC translocation models.......................................................................18
Figure 3.5.1.  Schematic representation of the transport cycles of importin-α and -β...........19
Figure 3.5.2.1.  Michael-type addition of LMB with the Cys528 of CRM1.....................................22
Figure 3.5.2.2.  Schematic representation of the transport cycles of CRM1...............................22
Figure 3.6.  Mechanisms of nuclear transport regulation ........................................................25
Figure 3.7.1.  Karyopherin-mediated nuclear RNA export pathways.........................................29
Figure 3.7.4.1.  The mammalian cell cycle........................................................................................36
Figure 3.7.4.2.  Regulation of multiprotein complexes by Ran-GTP during mitosis..................38
Figure 5.1.  (A) Organization of evolutionary conserved domains in PLC-HD proteins
regulating cellular transport.
(B) Model linking nucleo-cytoplasmic transport with PLC-HDP activity...........47
Figure 5.2.  Model for acetylation-dependent STAT1-NF-κB crosstalk..................................48
Figure 5.4.   Nuclear translocation of the biosensors as the principle for cell-based
screening applications..............................................................................................53
Table 3.1.  NPC Components in Vertebrates. ...........................................................................11
Table 3.3.  Members of the human karyopherin-β family........................................................15
Table 3.5.2.  Examples of viral and vertebrate leucine-rich NESs............................................21APPENDIX
68
8.2  Abbreviations and units
Abbreviations
40S small ribosomal subunit
60S large ribosomal subunit
aa amino acids
Abl Abelson murine leukemia
AIF apoptosis inducing factor
Apaf apoptotic protease activating factor
APRIL A proliferation-inducing ligand
ATP adenosine triphosphate
Bcl B-cell lymphoma
Bcr breakpoint cluster region
BFP blue fluorescent protein
bHLH basic helix-loop-helix
bHLH-ZIP basic helix-loop-helix-leucine-zipper
BiFc bimolecular fluorescence complementation
bZIP basic leucine zipper
bzw. beziehungsweise
Ca calcium
CAS cellular apoptosis susceptibility
caspase cysteine aspartate-specific protease
CBA cell-based assay
CBC cap-binding complex
CBP cap-binding protein
CBP/p300 CREB-binding protein and its homologue p300
CDK cyclin dependent kinase
CDKI CDK inhibitor
Chx10  Ceh-10 homologous homeobox
CRM chromosome region maintenance
CTEM conventional transmission electron microscopy
DNA deoxyribonucleic acid
e.g. for example
EM electron microscopy
FADD Fas-associated via death domain
FG repeats phenylalanine-glycine repeats
FRET fluorescence resonance energy transfer
G gap phase
GAP GTPase activating protein
GAS IFN-gamma activated sequence
GDP guanosine diphosphate
GEF guanine nucleotide exchange factorAPPENDIX
69
GFP green fluorescent protein
GR glucocorticoid receptor
GST glutathione-S-transferase
GTP guanosine triphosphate
GTPase guanosine-5'-triphosphatase
HAT histone acetyl transferase
HC high-content
HCS high-content screening
HD homeodomain
HDAC histone deacetylase
HDACi HDAC inhibitor
HDP homeodomain protein
HIV human immunodeficiency virus
HMWC high molecular weight complexes
hnRNP heterogenous nuclear ribonucleoprotein particle
HOX homeobox protein
Hsp heat shock protein
HTLV human T-cell leukemia virus
IAP inhibitors of apoptosis
IBB domain importin-β binding domain
ID interaction domain
i.e. lat., id est
I-κB inhibitor of NF-κB
Imp importin
Jak Janus kinase
LMB leptomycin B
M M-phase, mitosis
m7G 7-methylguanosine
MAPKK Map kinase
Mdm2 Double minute 2 protein
MMP matrix metalloproteinase
mRNA messenger RNA
mRNP mRNA containing ribonucleoprotein
NES nuclear export signal (Kernexportsignal)
NF-κB nuclear factor κB
NLS nuclear localization signal (Kernimportsignal)
NPC  nuclear pore complex (Kernporenkomplex)
NTF nuclear transport factor
NUP nucleoporin
NXT NTF2-related export protein
ORF open reading frame
p55 55kDa NF-κB subunit
p65 65kDa NF-κB subunitAPPENDIX
70
PARC p53-associated Parkin-like cytoplasmic protein
PARP poly-(ADP-Ribose) polymerase
PHAX phosphorylated adapter for RNA export
PI3K phosphoinositide-3 kinase
PKI protein kinase inhibitor
PLC-HDP paired-like CVC homeodomain protein
PPI protein-protein interaction
pre precursor
PSA prostate specific antigen
PTB protein translocation biosensor
PTD protein transduction domain
PTEN phosphatase and tensin homologue
Ran Ras-related nuclear protein
RanBP Ran binding protein
RCC Regulator of chromosome condensation
Rev regulator of expression of virion proteins
RNA ribonucleic acid
RNP ribonucleoprotein
RRE Rev response element
rRNA ribosomal RNA
S S-phase, synthesis phase
SAF spindle assembly factor
SH2 src homology 2
snRNA small nuclear RNA
snRNP small nuclear RNP
SV40 Simian Virus 40
SRY sex determing factor
STAT signal transducer and activator of transcription
TAD transactivation domain
T-Ag T-antigen
TAP tip associating protein
TFIIIA transcription factor IIIA
TRADD TNF receptor-associated via death domain
tRNA transfer RNA
UsnRNA uridine-rich small nuclear RNA
UsnRNP  uridine-rich small nuclear RNP
Vsx visual system homeobox
XPO-t exportin-t
YTH yeast two-hybrid
z.B.  zum BeispielAPPENDIX
71
Units and measures
Da Dalton
m meter
M Mega (10
6)
k kilo (10
3)
n  nano (10
-9)
Amino acids
A Ala alanine
C Cys cysteine
D Asp aspartic acid
E Glu glutamic acid
F Phe phenylalanine
G Gly glycine
H His histidine
I Ile isoleucine
K Lys lysine
L Leu leucine
M Met methionine
N Asn asparagine
P Pro proline
Q Gln glutamine
R Arg arginine
S Ser serine
T Thr threonine
V Val valine
W Trp tryptophan
Y Tyr tyrosinePUBLICATIONS
72
9  Publications
1.  Knauer, S.K., Carra, G. and Stauber, R.H. (2005) Nuclear export is evolutionary
conserved in CVC paired-like homeobox proteins and influences protein stability,
transcriptional activation and extracellular secretion. Mol Cell Biol, 25: 2573–2582.
2.  Krämer, O., Baus, D., Knauer, S.K., Stein, S., Jäger, D., Stauber, R.H., Grez, M.,
Pfitzner, E. and Heinzel, T. (2005) Acetylation of STAT1 modulates NF-κB signaling.
Genes Dev, submitted.
3.  Knauer, S.K., Krämer, O., Knösel, T., Engels, K., Rödel, F., Walendzik, H., Kovács,
A.F., Habtemichael, N., Brieger, J., Mann, W., Heinzel, T., Petersen, I. and Stauber,
R.H. (2005) Nuclear export is essential for the biological activity of survivin - Novel
aspects to target the survivin pathway in cancer. Cancer Res, submitted.
4.  Knauer,  S.K., Moodt, S., Berg, T., Liebel, U., Pepperkok, R. and Stauber, R.H.
(2005) Translocation biosensors to study signal specific nucleo-cytoplasmic transport,
protease activity & protein interactions. Traffic, 6: 594-606.
5.  Knauer, S.K. and Stauber R.H. (2005) Application of Autofluorescent Translocation
Biosensors to Investigate Protein-Protein Interactions in Living Cells. Anal Chem,
DOI 10.1021/ac050413o.PUBLICATIONS
73
1PUBLICATIONS
74MOLECULAR AND CELLULAR BIOLOGY, Apr. 2005, p. 2573–2582 Vol. 25, No. 7
0270-7306/05/$08.000 doi:10.1128/MCB.25.7.2573–2582.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
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Homeodomain transcription factors control a variety of essential cell fate decisions during development. To
understand the developmental regulation by these transcription factors, we describe here the molecular
analysis of paired-like CVC homeodomain protein (PLC-HDP) trafﬁcking. Complementary experimental
approaches demonstrated that PLC-HDP family members are exported by the Crm1 pathway and contain an
evolutionary conserved leucine-rich nuclear export signal. Importantly, inactivation of the nuclear export
signal enhanced protein stability, resulting in increased transactivation of transfected reporters and decreased
extracellular secretion. In addition, PLC-HDPs harbor a conserved active nuclear import signal that could also
function as a protein transduction domain. In our study, we characterized PLC-HDPs as mobile nucleocyto-
plasmic shuttle proteins with the potential for unconventional secretion and intercellular transfer. Nucleocy-
toplasmic transport may thus represent a conserved control mechanism to ﬁne-tune the transcriptional activity
of PLC-HDPs prerequisite for regulating and maintaining the complex expression pattern during development.
Ordered development depends on the activity of transcrip-
tion factors in a controlled manner. One deﬁning feature of
eukaryotic cells is their spatial and functional division into the
nucleus and the cytoplasm by the nuclear envelope. Thus,
among other mechanisms, regulated subcellular localization
provides an attractive way to control the activity of transcrip-
tion factors which has been demonstrated for several key play-
ers of signal transduction cascades (reference 6 and references
therein). This type of regulation requires a speciﬁc and selec-
tive transport machinery for the controlled transport of mac-
romolecules between both compartments. Nucleocytoplasmic
transport takes place through the nuclear pore (29) and is
regulated by speciﬁc signals and transport receptors. In gen-
eral, active nuclear import requires energy and is mediated by
short stretches of basic amino acids, termed nuclear localiza-
tion signals (NLS), which interact with speciﬁc import recep-
tors (reviewed in references 3 and 13). In contrast, signal-
mediated nuclear export pathways (31) are less understood.
The best-characterized nuclear export signals (NES) consist of
a short leucine-rich stretch of amino acids, interact with the
export receptor Crm1 (references 3 and 13 and references
therein), and depend on the RanGTP/GDP axis. Leucine-rich
NES have been identiﬁed in an increasing number of cellular
and viral proteins executing heterogeneous biological func-
tions. These include transcription control (6, 35), cell cycle
control (43), and RNA transport (8). Proteins containing both
NLS and NES have the capacity for continuous shuttling be-
tween the cytoplasm and the nucleus.
Homeodomain proteins (HDPs) have been shown to exert
key developmental functions throughout the metazoa since
defects in the evolutionary conserved homeobox genes were
shown to cause many human disorders and aberrant animal
phenotypes (reference 57 and references therein). Homeobox-
containing genes encode transcription factors and are charac-
terized by the homeodomain (HD), a motif that directs speciﬁc
DNA binding to regulate the expression of target genes. Ho-
meobox genes are grouped into several subclasses according to
the primary structure of their homeodomain and its ﬂanking
sequences (reference 12 and references therein). Among the
paired-like subclass, the paired-like CVC (PLC)-HDPs are
characterized by a conserved CVC domain and can be grouped
into the Vsx-1 and Vsx-2 family (32, 40), containing orthologs
from several species. PLC-HDPs appear to play a particular
role in ocular development (references 7, 21, 38, and 41 and
references therein) and execute their functions by binding to
the conserved locus control region (LCR), located upstream of
the transcription initiation site of the red opsin gene, and thus
specify the development and differentiation of cone photore-
ceptors and a subset of retinal inner nuclear layer bipolar cells
(references 16 and 49 and references therein). The observation
that null mutations in Chx10 cause congenital microphthalmia,
including small eyes, cataracts, iris coloboma, and blindness in
humans (42), mice (5), and zebra ﬁsh (2), underscores the
importance of the PLC-HDP gene family for retinogenesis.
Thus, a precise control of PLC-HDP functions is clearly critical
for ordered development and homeostasis.
In concordance with their role as transcriptional regulators,
homeoproteins localize predominantly to the nucleus, al-
though several reports characterize them also as nucleocyto-
plasmic shuttle proteins, e.g., Extradenticle (1), Otx1 (56), and
Engrailed (34). Since regulated subcellular localization has
been reported for several transcription factors (e.g., p53,
STATs, NF-B, etc.) (6), we investigated the intracellular traf-
* Corresponding author. Mailing address: Georg-Speyer-Haus, In-
stitute for Biomedical Research, Paul-Ehrlich-Str. 42-44, D-60596
Frankfurt, Germany. Phone: (49) 69-63395-222. Fax: (49) 69-63395-
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2573ﬁcking of PLC-HDPs and analyzed its consequences for PLC-
HDP function as transcriptional regulators. As representatives
of the Vsx-1 and Vsx-2 group, we studied the zebra ﬁsh Vsx1
and the murine Chx10 protein in detail. Nucleocytoplasmic
transport was investigated by interspecies heterokaryon assays,
microinjection of recombinant transport substrates, and the
use of chemical transport inhibitors. We could demonstrate
that PLC-HDPs contain a Crm1-dependent NES, previously
described as the “octapeptide.” Nuclear export inﬂuenced
PLC-HDP transcriptional activation by enhancing proteasomal
protein degradation and by facilitating extracellular secretion.
The predominant nuclear steady-state localization of PLC-
HDPs is mediated by the presence of an active nuclear import
signal. This NLS can function also as a protein transduction
domain (PTD), explaining the evolutionary conservation of
this signal. The integrity of both NES and NLS/PTD appears to
be prerequisite for PLC-HDPs to function as mobile nucleo-
cytoplasmic shuttle proteins with the potential for intercellular
transfer.
MATERIALS AND METHODS
Plasmids. Plasmids pc3-DrVsx1-green ﬂuorescent protein (GFP) and pc3-
MmChx10-GFP encode a zebra ﬁsh Vsx1-GFP or a mouse Chx10-GFP fusion
protein, respectively. The coding regions of the genes were ampliﬁed by PCR
with pSTT91zVsx-1 (27) and pT7tagNChx10 (42) as templates and appropriate
primers containing BamHI and NheI restriction sites. The PCR products were
subsequently cloned into the vector pc3-GFP as described previously (25). Like-
wise, truncated forms of various GFP fusion proteins were constructed by the
same cloning strategy. To generate NES-deﬁcient GFP fusion proteins critical
residues were changed into alanines by mutagenesis as described previously (25).
The MmChx10-responsive luciferase reporter pLCR-R-luc was constructed by
PCR ampliﬁcation of the luciferase gene with pHH-luc as the template (23), and
appropriate primers containing SpeI/NotI-restriction sites and subsequent clon-
ing into pcDNA3 (Invitrogen). Subsequently, the LCR, together with the red
pigment promoter (48), was inserted into this construct by PCR ampliﬁcation
and subsequent cloning by SpeI restriction digest, thereby replacing the cyto-
megalovirus promoter. Potential nuclear export or import signals were cloned
into the bacterial expression vector pGEX-GFP as described previously (45).
pGEX-MmChx10 encodes a glutathione S-transferase (GST)–mouse Chx10 fu-
sion protein. Plasmid p3-Crm1-HA, pGEX-RanQ69L, and pSV40-Gal were al-
ready described (18, 23).
Cells, transfection, microscopy, and microinjection. Vero cells, the microglia
cell line CRL-2540, 293 cells, NIH 3T3 cells, and HeLa cells were maintained
under conditions recommended by the American Type Culture Collection and
were prepared for microinjection or transfected as described previously (18).
Microinjection, observation, and image analysis in living or ﬁxed cells were
performed as described previously (18). Cells were observed and analyzed by
using the appropriate ﬂuorescence ﬁlters as described previously (19), and 12-bit
black and white images were captured by using a digital Axiocam CCD camera
(Zeiss). Quantitation, image analysis, and presentation was performed by using
IPLab Spectrum (Scanalytics) and Axiovision software (Zeiss). The total cellular
GFP signal was measured by calculating the integrated pixel intensity in the
imaged cell multiplied by the area of the cell. The nuclear signal was similarly
obtained by measuring the pixel intensity in the nucleus. The cytoplasmic signal
was calculated by subtracting the nuclear signal from the total cellular signal. All
pixel values were measured below the saturation limits, and the background
signal in an area with no cells was subtracted from all values. To determine the
average intracellular localizations of the respective proteins, at least 200 ﬂuo-
rescent cells in three independent experiments were examined, and the standard
deviations were determined.
Transactivation assays. For transactivation assays, HeLa cells were trans-
fected with 0.5 g of the pLCR-R-luc reporter plasmid and the indicated
amounts of the MmChx10 expression constructs, together with 0.1 g of pSV40-
Gal, and the cells were assayed for luciferase and -galactosidase (-Gal) activity
as described previously (23). To analyze intercellular transactivation, 5  10
5 293
cells were transfected with either 3 g of the indicated MmChx10 expression
construct or with 1 g of pLCR-R-luc and 0.1 g of pSV40-Gal. At 12 h later
MmChx10 transfected and pLCR-R-luciferase transfected cells were mixed at a
ratio of 2:1 and assayed for luciferase and -Gal activity 36 h later. Luciferase
activity was normalized to -Gal expression, and all measurements were con-
ducted in duplicates in three independent experiments.
Puriﬁcation of recombinant GST fusion proteins. GST-GFP hybrid proteins
were expressed and puriﬁed as described previously (45). Removal of GST by
proteolytic cleavage using factor Xa protease (Roche) was performed according
to the manufacturer’s recommendations.
Immunoblotting, immunoﬂuorescence, and antibodies. Immunoblotting and
immunoﬂuorescence were carried out according to standard procedures, as pre-
viously described (18). Puriﬁed mouse Chx10 fused to GST was used for immu-
nization of rabbits by using standard protocols (10). The immunoglobulin G
fraction was puriﬁed by protein A chromatography and used at a 1:500 dilution
for immunoﬂuorescence.
Protein transduction assay. Exponentially growing Vero cells were incubated
with 1 M concentrations of the corresponding recombinant GFP fusion pro-
teins in phosphate-buffered saline (PBS) for 2 h. Subsequently, cells were exten-
sively washed with PBS before incubation with trypsin (1 mg/ml) for 2 min to
remove unspeciﬁcally bound protein from the cell surface. After removal of
trypsin cells were cultured in medium for 3 h, washed with PBS, ﬁxed with
ice-cold methanol for 15 min and rehydrated in PBS prior to analysis by ﬂuo-
rescence microscopy.
Heterokaryon assay. HeLa cells were transfected with the indicated plasmids
and 12 h later seeded with untransfected mouse NIH 3T3 cells at a ratio of 1:3.
Cells were cultured and fused 8 h later by using polyethylene glycol (Gibco) in
the presence of cycloheximide as described previously (50). To discriminate
between human donor and mouse acceptor nuclei, staining with Hoechst 33258
was performed as described previously (50). A total of 50 heterokaryons were
chosen at random, and the percentage of fusion events positive for internuclear
transfer was calculated in three independent experiments, and the standard
deviations were determined.
Treatment with chemical export inhibitors. Cells transfected with the indi-
cated plasmids were treated with 10 nM leptomycin B (LMB; Sigma-Aldrich) or
5 nM Ratjadone A (Alexis Biochemicals) as described previously (25).
Crm1 pull-down assays and in vitro translation. Coupled transcription-trans-
lation was performed by using the TNT reticulocyte lysate system (Promega)
supplemented with [
35S]methionine (Amersham) and the plasmid p3-Crm1-HA
as a template. Crm1 pull-down assays with the speciﬁc recombinant GST-GFP
substrates, Ran-GTP and nuclear extracts were performed as described previ-
ously (18). Care was taken to ensure equal input levels of labeled Crm1 protein
into the binding reactions.
Secretion assay. A total of 2  10
6 293 cells were transfected with the indi-
cated plasmids and incubated for 8 h. Subsequently, cells were cultured in
methionine-free medium supplemented with [
35S] methionine (50 Ci) for ad-
ditional 12 h. To block classical protein secretion, brefeldin A (BFA; Sigma-
Aldrich) at 10 g/ml was added to the cultures. Culture supernatants were
collected and cleared by centrifugation (10,000  g, 1 h, 4°C). Analysis of
whole-cell lysates and immunoprecipitation of GFP fusion proteins from culture
supernatants and cellular lysates by using a polyclonal anti-GFP antibody (BD
Biosciences), as well as analysis of the complexes by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography, were
performed as described previously (18, 28).
Pulse-chase experiments. A total of 5  10
5 HeLa cells were transfected with
pc3DrVsx1-GFP or pc3DrVsx1_NESmut-GFP, followed by incubation for 16 h.
Subsequently, cells were incubated for2hi nDulbecco’s modiﬁed Eagle medium
lacking methionine and pulse-labeled with 50 Ci of [
35S]methionine (Amer-
sham) for 2 h. Unlabeled methionine was then added to a ﬁnal concentration of
100 mM. At the indicated time points, cells were washed with cold PBS, and
whole-cell lysates were prepared as described previously (28). To prevent pro-
teasomal degradation, cells were treated with the proteasome inhibitors MG-132
and hemin (Sigma-Aldrich; 50 M ﬁnal concentration). The total radioactivity in
each sample was determined by trichloroacetic acid precipitation, and sample
volumes were adjusted to represent equal amounts of radioactivity. Immunopre-
cipitation was done by using a polyclonal anti-GFP antibody (Clontech), and the
complexes were resolved by SDS-PAGE as described previously (18). Band
intensities were quantiﬁed by using a phosphorimager (Bio-Rad).
RESULTS
PLC-HDPs are active shuttle proteins and nuclear export is
mediated by the Crm1 pathway. To study PLC-HDPs localiza-
tion and trafﬁcking in live cells, we expressed the complete
zebra ﬁsh (Dr) Vsx1 (amino acids [aa] 1 to 344) and murine
2574 KNAUER ET AL. MOL.C ELL.B IOL.(Mm) Chx10 (aa 1 to 380) as GFP fusion proteins. Fluores-
cence microscopy revealed that DrVsx1-GFP and MmChx10-
GFP were predominantly nuclear. However, a signiﬁcant
amount of the respective protein was detectable also in the
cytoplasm following transient expression in human (HeLa and
293) and rodent (NIH 3T3) cell lines (Fig. 1A and E and data
not shown), indicating their potential for nucleocytoplasmic
transport. Indirect immunoﬂuorescence revealed a similar in-
tracellular localization for the endogenous MmChx10 in the
microglia cell line CRL-2540 (Fig. 1D) thereby excluding the
possibility that the observed localization was due to the ectopic
expression of GFP-tagged fusion proteins. Antiserum speciﬁc-
ity was conﬁrmed by staining MmChx10-GFP expressing HeLa
cells (data not shown).
To examine whether nuclear export was mediated via the
Crm1 pathway, we used the export inhibitors LMB and Rat-
jadone A. These substances bind to Crm1, thereby preventing
the interaction with leucine-rich NES (24, 55). LMB or Ratja-
done A treatment not only resulted in exclusive nuclear accu-
mulation of DrVsx1- and MmChx10-GFP in transfected HeLa
and 293 cells but also blocked export of the endogenous
MmChx10 protein (Fig. 1A/D/E and data not shown).
To further address whether DrVsx1-GFP and MmChx10-
GFP were capable of nucleocytoplasmic trafﬁcking, we per-
formed heterokaryon assays in the presence of cycloheximide
to prevent de novo protein synthesis. Upon fusion of DrVsx1-
GFP and MmChx10-GFP expressing HeLa donor cells with
untransfected NIH 3T3 acceptor cells, both PLC-HDPs were
exported from the donor and imported into the mouse accep-
tor nuclei 60 min after fusion (Fig. 1F and G). As a control,
incubation of the fused cells at 4°C (data not shown) or in the
presence of LMB did not result in detectable accumulation of
GFP fusion proteins in the acceptor nuclei, indicative for active
transport (Fig. 1G). Since the cytoplasm of donor and acceptor
FIG. 1. PLC-HD proteins are nucleocytoplasmic shuttle proteins. (A) HeLa cells were transfected with the indicated plasmids and analyzed by
ﬂuorescence microscopy. In living cells, DrVsx1-GFP and MmChx10-GFP localized predominantly to the nucleus. Signiﬁcant amounts of the
proteins were also detectable in the cytoplasm and accumulated completely in the nucleus after LMB treatment. (B) DrVsx1_1-147-GFP still
responded to LMB treatment, whereas the construct lacking the ﬁrst 47 aa (DrVsx1_47-344-GFP) displayed an exclusively nuclear localization.
(C) Inactivation of the NES by mutating critical residues into alanines (DrVsx1_NESmut-GFP, aa
37FAITDLLGL
45 3
37AAITDLAGA
45;
MmChx10_NESmut-GFP, aa
32FGIQEILGL
40 3
32AGIQEIAGA
40) resulted in complete nuclear localization. (D) Endogenous MmChx10 protein
in the microglia cell line CRL-2540 displayed a similar intracellular localization and LMB responsiveness as observed for the MmChx10-GFP
protein. MmChx10 was visualized by indirect immunoﬂuorescence with a polyclonal anti-MmChx10 antiserum. (E) To determine the average
intracellular localizations of the respective proteins, at least 200 ﬂuorescent cells in three independent experiments were examined, and the
standard deviations were determined. (F) DrVsx1- and MmChx10-GFP are capable of nucleocytoplasmic trafﬁcking in a heterokaryon assay. Upon
polyethylene glycol fusion of DrVsx1-GFP- and MmChx10-GFP-expressing HeLa donor cells with untransfected NIH 3T3 acceptor cells,
DrVsx1-GFP and MmChx10-GFP were exported from the donor (marked by asterisks) and imported into the mouse acceptor nuclei (marked by
arrows) 60 min after fusion. In contrast, NES-deﬁcient mutants (DrVsx1_NESmut-GFP and MmChx10_NESmut-GFP) were not exported. (G) To
quantify the number of transfer events, 50 heterokaryons were chosen at random, and the percentage of fusion events positive for internuclear
transfer was calculated in three independent experiments with standard deviations. Scale bars: 10 m (A, B, C, and F) and 100 m (D).
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cytoplasmic DrVsx1-GFP or MmChx10-GFP protein, respec-
tively, initially present in the donor cells was diluted and not
detectable postfusion. Of note, the level of nuclear ﬂuores-
cence in the acceptor nuclei increased, and the ﬂuorescence
signal in the donor nuclei decreased over time, excluding the
formal possibility that the observed nuclear transfer events
resulted from the import of the cytoplasmic GFP fusion pro-
teins present prior to fusion.
PLC-HDPs contain a highly conserved NES previously de-
scribed as the “octapeptide.” To identify domains directing
nuclear export, we ﬁrst expressed N- and C-terminal deletion
mutants of DrVsx1 and MmChx10 as GFP hybrids. As indi-
cated in Fig. 1B, only fusion proteins containing the ﬁrst 47 aa
responded to LMB treatment, indicating the presence of an
active NES. Database searches identiﬁed potential NES in the
PLC-HDPs, matching the still loosely deﬁned consensus se-
quence for leucine-rich NES (18, 20). Because predicted sig-
nals need to be veriﬁed experimentally, we tested the activity of
the potential NES in a highly stringent system that allows the
observation and quantiﬁcation of nuclear export in living cells,
independent of drug treatment, nuclear import, and passive
diffusion (45). Signals (Fig. 2A) were expressed as fusions with
GST and GFP (GST-NES-GFP) and tested by microinjection.
Due to the size of the fusion proteins (54 kDa, as a monomer)
the localization of the microinjected autoﬂuorescent transport
substrate is not ﬂawed by passive diffusion, and the protein
remains at the site of injection for up to 24 h (45). We observed
that only substrates containing active PLC-HDP NES were
quantitatively exported into the cytoplasm within 16 h after
microinjection into the nucleus of Vero (Fig. 2B) and microglia
CRL-2540 cells (data not shown). As a stringent control, a
signal in which essential residues were replaced by alanines was
inactive under identical experimental conditions (Fig. 2A and
B). Likewise, treatment with LMB completely prevented ex-
port (data not shown). Interestingly, analysis of NES represen-
tative for all known PLC-HDP family members revealed that
these NES mediated export with comparable kinetics (Fig. 2A
and B). Approximately 100 cells were injected and analyzed,
and representative examples are shown. These results were
conﬁrmed in two independent experiments (data not shown).
The evolutionary conservation of the NES strongly argues that
nuclear export is critical for the biological function of PLC-
HDPs. Since nuclear export had been proposed also for other
members of the homeoprotein family (34), we included the
proposed NES of the Engrailed homeoprotein (Fig. 2A;
GgEn2 NES) in our study. In contrast to the PLC-HDP NES,
the GgEn2 NES was not active in our assay (data not shown).
NES inactivation prevents export of PLC-HDPs. To verify
the functionality of the export signals also in the context of the
full-length proteins in vivo, we mutated critical residues of the
NES into alanines (DrVsx1_NESmut-GFP, aa
37FAITDL
LGL
45 3
37AAITDLAGA
45; MmChx10_NESmut-GFP, aa
32
FGIQEILGL
40 3
32AGIQEIAGA
40). In contrast to the wild-
type proteins DrVsx1_NESmut-GFP and MmChx10_NESmut-
GFP displayed a complete nuclear localization after transient
transfection (Fig. 1C). Likewise, the NES-deﬁcient mutants
were not exported in the heterokaryon assays (Fig. 1F and G),
excluding the presence of additional NES or the possibility that
export was mediated by shuttling interaction partners in trans.
PLC-HDP export signals interact with Crm1 in vitro. If the
deﬁned PLC-HDPs are exported via the Crm1 pathway, these
FIG. 2. PLC-HDPs contain evolutionarily conserved active NES and interact with Crm1 in vitro. (A) Alignment of the tested PLC-HDPs export
signals from different species with the NES consensus motif (18) and the inactive Engrailed “NES.” (B) Indicated GST-NES-GFP substrates were
microinjected into the nuclei of Vero cells, and nuclear export was recorded in living cells by ﬂuorescence microscopy after various time points.
Approximately 100 cells were injected and representative examples are shown. Panels: left, t  0 min; middle, t  8 h; right, t  16 h. Nuclear export
was completed after 16 h. Inactivation of the NES by mutating critical residues into alanines (DrVsx1_NESmut) completely blocked export.
(C) MmChx10 interacts with Crm1 in a GST pull-down assay. In vitro-translated
35S-labeled Crm1 protein was incubated with equal amounts of
immobilized full-length GST-MmChx10-GFP, GST-MmChx10_NESmut-GFP, or GST-GFP in the presence of GST-RanQ69L and nuclear
extracts. The speciﬁc binding of Crm1 to GST-MmChx10-GFP (lane 1) was abolished by mutating the NES (lane 2). GST-GFP served to control
for unspeciﬁc binding (lane 3). Homo sapiens (Hs), Mus musculus (Mm), Bos taurus (Bt), Danio rerio (Dr), Carassius auratus (Ca), Oryzias latipes
(Ol), Gallus gallus (Gg), Caenorhabditis elegans (Ce), Drosophila melanogaster (Dm). Scale bar, 10 m.
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cell-free system. We therefore performed in vitro interaction
assays to biochemically verify the Crm1 interaction. Figure 2C
demonstrates that recombinant GST-MmChx10-GFP signiﬁ-
cantly bound to Crm1 in the presence of Ran-GTP and nuclear
extracts in contrast to inactive GST-MmChx10_NESmut-GFP
or GST-GFP alone. Similar results were obtained for GST-
DrVsx1-GFP or the other GST-NES-GFP fusion proteins, re-
spectively (data not shown).
Nuclear export facilitates intracellular degradation of
DrVsx1-GFP. Kurtzman et al. (26) reported the polyubiquiti-
nation and degradation of DrVsx1 by the ubiquitin/proteasome
pathway. Because the proteasome degradative pathway
appears to operate predominantly in the cytoplasm (51), we
investigated whether nuclear export inﬂuences indirectly the
intracellular stability of DrVsx1. HeLa cells transiently ex-
pressing DrVsx1-GFP or DrVsx1_NESmut-GFP, respectively,
were metabolically pulse-labeled, followed by a chase with cold
methionine for 0, 30, 60, and 120 min. Subsequently, GFP
fusion proteins were immunoprecipitated with anti-GFP anti-
serum and resolved by SDS-PAGE (Fig. 3A). Band intensities
from two independent experiments were quantiﬁed by using a
phosphorimager; this showed that both DrVsx1-GFP and
DrVsx1_NESmut-GFP were degraded over time and that deg-
radation could be reduced by treatment with proteasomal in-
hibitors. Interestingly, preventing nuclear export resulted in a
signiﬁcantly increased half-live for DrVsx1_NESmut-GFP
(Fig. 3A and B), suggesting that nuclear export is continuously
supplying substrate for the proteasomal degradation machin-
ery. Similar results were obtained for MmChx10 (data not
shown).
Nuclear export inﬂuences MmChx10-mediated transactiva-
tion. To investigate the effect of export-enhanced degradation
on the transcriptional activity of MmChx10, we tested the
ability of the export-defective MmChx10 to transactivate a
MmChx10-responsive luciferase reporter plasmid in transient
transfections. These experiments revealed a good correlation
between dose-dependent MmChx10 mediated transactivation
and protein stability since expression of MmChx10_NESmut
resulted in increased stimulation of gene expression (Fig. 3C).
Nuclear export facilitates unconventional secretion of
PLC-HD proteins. Having demonstrated that PLC-HDPs are
nucleocytoplasmic shuttle proteins, we investigated their po-
tential for intercellular trafﬁcking. In general, intercellular
transfer requires both internalization and secretion. To analyze
secretion of DrVsx1-GFP and to investigate the inﬂuence of
nuclear export on secretion, we attempted to recover metabol-
ically labeled DrVsx1-GFP or DrVsx1_NESmut-GFP protein,
respectively, from the culture supernatant of transfected 293
cells. Figure 4A illustrates that DrVsx1-GFP, but not
DrVsx1_NESmut-GFP could be immunoprecipitated by anti-
GFP antibodies from the supernatant. Transfected cells were
controlled by microscopic observation for cytotoxic effects
caused by the expression of the respective GFP fusion proteins
prior to lysate preparation to minimize unspeciﬁc protein re-
lease due to cell death. To also exclude the possibility that the
observed result reﬂects differences in protein expression, equal
expression levels of the GFP fusion proteins were veriﬁed by
Western blot analysis of cellular extracts (Fig. 4B). Similar
results were obtained for the MmChx10-GFP or MmChx10_
NESmut-GFP protein, respectively (data not shown). Of note,
we could not recover a NES-GFP fusion protein (DrVsx1
NES-GFP) from the supernatant of transfected 293 cells (data
not shown). Thus, the continuous supply of cytoplasmic
DrVsx1 from the nuclear pool by active nuclear export appears
to facilitate secretion, but the NES itself does not represent an
unconventional secretion signal. To determine whether protein
secretion was mediated via the classical endoplasmic reticu-
lum/Golgi-dependent pathway or by unconventional secretion,
we attempted to inhibit secretion by treatment of the trans-
FIG. 3. Nuclear export affects PLC-HD protein stability and transcriptional activation. (A) Preventing nuclear export increases the intracellular
stability of DrVsx1-GFP. HeLa cells were transiently transfected with expression plasmids encoding DrVsx1-GFP (2 g) or DrVsx1-NESmut-GFP
(2 g). After 16 h, methionine-starved cells were pulsed with [
35S]methionine for 2 h and chased with excess methionine for the indicated times.
Proteins were immunoprecipitated with anti-GFP antibody, resolved by SDS-PAGE and detected by ﬂuorography. Whereas DrVsx1-GFP and
DrVsx1-NESmut-GFP were degraded over time, inactivation of the NES resulted in a signiﬁcantly increased half live of DrVsx1-NESmut-GFP.
(B) Band intensities from two independent experiments (including the gel in panel A) were quantiﬁed by using a phosphorimager and graphed
with standard errors for DrVsx1-GFP (■ ), DrVsx1-GFP  proteasomal inhibitors (PI) (F), DrVsx-1_NESmut-GFP (), and DrVsx-1_NESmut-
GFP  PI (E). (C) Luciferase assays after cotransfection of HeLa cells with pSV40-Gal, an MmChx10-responsive luciferase reporter and different
amounts of expression plasmids for GFP, MmChx10-GFP, and MmChx10_NESmut. Expression of wild-type MmChx10-GFP resulted in higher
transcriptional activation compared to the export-deﬁcient mutant. Luciferase activity was normalized to -Gal expression. Error bars indicate the
standard deviations.
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fere with MmChx10-GFP release in support of secretion by the
unconventional pathway, as also reported for several other
proteins (39; data not shown).
PLC-HDPs contain a highly conserved active nuclear im-
port signal which can function as a PTD. For continuous
signal-mediated shuttling between the cytoplasm and the nu-
cleus proteins require both NES and NLS. Thus, we next
sought to determine whether the predominant nuclear steady-
state localization of PLC-HDPs is the result of active nuclear
import or is mediated by nuclear retention. The database com-
parisons revealed that the motif KRKKRRHR located at the
beginning of the homeodomain is 100% conserved in all known
PLC-HDPs (Fig. 5A). In contrast to GFP alone, a KRKK
RRHR-GFP fusion protein localized to the nucleus (data not
shown). However, because even a GFP-GFP fusion protein (54
kDa) can enter the nucleus by passive diffusion (45), we inves-
tigated whether this motif can function not only as nuclear
retention but also as an active nuclear import signal. Microin-
jection experiments with recombinant GST-GFP fusion pro-
teins (Fig. 5B) demonstrated that the tested signal mediated
nuclear import and can therefore be considered as a bona ﬁde
nuclear import signal for PLC-HDs (PLC_NLS). Import activ-
ity was lost by replacing two conserved arginines by alanines
(Fig. 5A and B, PLC_NLSmut). Approximately 100 cells were
injected and analyzed, and representative examples are shown.
These results were conﬁrmed in two independent experiments
(data not shown). Our observations are supported by the re-
port of Kurtzman and Schechter (27), who demonstrated that
a DrVsx1 mutant lacking the sequence QKRKKRR no longer
accumulated in the nucleus. Of note, GST-QKRKKRR-GFP
(Vsx1_short) was less active in mediating import (Fig. 5B).
Interestingly, the KRKKRRHR motif displayed a high ho-
mology to the widely used PTD KRKKRRQRRR of the hu-
man immunodeﬁciency virus type 1 (HIV-1) Tat protein (Fig.
5A) (52). To test the potential of the PLC-HD_NLS to also
traverse intact cellular membranes, human cells were incu-
bated with recombinant GFP fusion proteins, followed by
treatment with trypsin to remove unspeciﬁcally bound protein.
Fluorescence microscopy revealed that PLC-HD_NLS-GFP
displayed a similar protein transduction activity as the positive
control, HIV1Tat_PTD-GFP, and localized to the cytoplasm
and nucleus of the treated cells (Fig. 6A). In contrast, GFP
fusion proteins containing the QKRKKRR motif (Vsx1-short-
GFP), the mutated NLS, or GFP alone could not mediate
protein transduction under identical experimental conditions,
arguing against PTD-independent cellular entry (Fig. 6A).
These results provide a rational for the evolutionary conserva-
tion of the bifunctional KRKKRRHR motif. Importantly, re-
combinant full-length DrVsx1-GFP protein was also able to
enter cells, although less efﬁciently, most likely due to its larger
size since GST-HIV1Tat_PTD-GFP or GST-PLC-HD_NLS-
GFP, respectively, also displayed a diminished transduction
activity (data not shown).
PLC-HD proteins have the potential for intercellular trans-
port. Having demonstrated that PLC-HDPs are nucleocyto-
plasmic shuttle proteins, can be secreted, and contain a PTD,
we investigated their potential for intercellular trafﬁcking. Al-
though described for the Engrailed protein (22), we could not
visually detect the spread of DrVsx1-GFP or MmChx10-GFP
FIG. 4. Nuclear export affects DrVsx1-GFP protein secretion.
(A) 293 cells were transfected with the indicated plasmids (4 g) and
cultured in methionine-free medium supplemented with [
35S]methi-
onine. GFP fusion proteins were immunoprecipitated from the culture
supernatants and from whole-cell lysates with an anti-GFP antibody.
Although DrVsx1_NESmut-GFP and DrVsx1-GFP could be immuno-
precipitated equally from cellular lysates (lanes 1 and 2), only DrVsx1-
GFP could be recovered from the supernatants (lanes 3 and 4).
(B) Equal expression levels of the GFP fusion proteins were veriﬁed by
Western blot analysis of cellular lysates using a polyclonal anti-GFP
antiserum.
FIG. 5. PLC-HD proteins contain a highly conserved active nuclear
import signal. (A) Sequence alignment of the NLS conserved in all
PLC-HDP members, the inactive NLS mutant, Vsx1_short, and the
HIV1Tat_PTD. (B) GST-NLS-GFP fusion protein were microinjected
into the cytoplasm of Vero cells, and nuclear import was observed
directly by ﬂuorescence microscopy. Approximately 100 cells were
injected, and representative examples are shown. Nuclear import of
GST-PLC_NLS-GFP was completed after 10 h (upper panel). Import
activity was lost by replacing two conserved arginines by alanines
(GST-PLC_NLSmut-GFP, middle panel). In contrast, Vsx1_short was
less active in mediating import (GST-Vsx1_NLSshort-GFP, lower
panel). Scale bars, 10 m.
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microscopy upon cocultivation for up to 72 h (data not shown).
This might be due to the low amount of secreted and internal-
ized protein which could be below the detection level. How-
ever, since even low concentrations of transcription factors are
sufﬁcient to trigger biological relevant responses in vivo, we
used an intercellular transactivation assay to investigate inter-
cellular trafﬁcking. 293 cells transfected with MmChx10-GFP,
MmChx10_NESmut-GFP, or GFP alone were cocultivated
with 293 cells transfected with the MmChx10 responsive
pLCR-R-luc reporter plasmid. Intercellular transport of
MmChx10 should result in enhanced luciferase activity that
should be abolished by NES inactivation. Figure 6B indicates
that the wild-type but not the export-deﬁcient MmChx10 pro-
tein was able to activate reporter gene expression, supporting
the potential of CVC-HDPs for intercellular trafﬁcking.
DISCUSSION
Transcriptional networks ensure the ordered development
of complex multifunctional organs as exempliﬁed by the spinal
cord (17) or the retina (9). In particular, homeodomain pro-
teins represent transcription factors exerting key developmen-
tal functions. The paired-like CVC-HDPs play an essential role
in ocular development and, therefore, a precise control of
PLC-HDPs functions is critical for ordered development and
homeostasis. In eukaryotic cells, the nuclear envelope gener-
ates two distinct cellular compartments that separate transcrip-
tion and DNA replication from protein biosynthesis. Among
other mechanisms, regulated subcellular localization provides
an attractive way to control the activity of PLC-HDPs. We
demonstrated for two representatives of the PLC-HDP family
that endogenous MmChx10, as well as ectopically expressed
MmChx10-GFP and DrVsx1-GFP proteins, did not exclusively
localize to the nucleus. A similar, nonexclusive nuclear local-
ization was recently reported for the MmChx10 protein (46).
This could either be due to the retention of newly synthesized
protein in the cytoplasm or to its continuous nucleocytoplasmic
transport. We showed that PLC-HDs can shuttle between the
nucleus and the cytoplasm by using the heterokaryon assay.
Furthermore, we characterized the previously described “oc-
tapeptide” as part of an evolutionary conserved active leucine-
rich NES present in all members of the PLC-HDP family.
Nuclear export of PLC-HDPs was mediated by the Crm1 path-
way, as supported by several lines of evidence. First, Crm1
antagonists caused nuclear accumulation of DrVsx1 and
MmChx10, were able to block nuclear export in the hetero-
karyon assay, and prevented export of recombinant PLC-HDP-
NES transport substrates. Second, DrVsx1-GFP, MmChx10-
GFP, and PLC-HDP-NES bound to Crm1 in vitro, and these
interactions could be prevented by mutating critical residues in
the NES which also blocked export of the full-length proteins
in vivo. The NES of PLC-HDPs ﬁt the still loosely deﬁned
consensus sequence for leucine-rich export signals and are
evolutionary conserved in all known PLC-HDPs from human,
mouse, rat, chicken, and zebra ﬁsh (see Fig. 3A). Interestingly,
the tested PLC-HDP NES were equally active in microinjec-
tion experiments and displayed a similar activity, as observed
for the NES from other transcriptional regulators such as p53
or Mdm2 (19). As demonstrated in our previous work (18) and
by others (20), it appears that the distance between the critical
LxL motif and the next hydrophobic residue should not exceed
3 aa in the proposed NES consensus sequence (see Fig. 3). We
are not aware of any functional NES breaking this rule. The
4-aa spacer in the suggested Engrailed export signal (34) marks
this sequence as nonfunctional explaining the lack of activity
observed in our study. To date, nuclear export has been pro-
posed for a growing list of proteins, including also several
homeodomain proteins, e.g., Extradenticle (1), Otx1 (56), and
Engrailed (34). However, the numerous reports on nuclear
export sometimes lead to conﬂicting results. To standardize
the deﬁnition for active, Crm1-mediated nuclear export medi-
ated by a “classical” leucine-rich NES, we propose the follow-
ing quality criteria. (i) Nuclear export of a protein, as assayed
by transfection and heterokaryon assay, should be blocked by
Crm1 inhibitors. (ii) The export signal should be active also in
the context of a heterologous system in trans and should inter-
act with Crm1 in vitro. (iii) Mutation of critical residues in the
NES should inactivate its export activity also in the context of
the full-length protein. According to our knowledge, the
FIG. 6. PLC-HDPs have the capacity for intercellular transport. (A) The PLC-HD NLS can function as a PTD. Vero cells were incubated with
1 M concentrations of the indicated GFP fusion proteins for 2 h and treated as described in Materials and Methods. Fluorescence microscopy
indicated that DrVsx1_NLS-GFP, HIV1Tat_PTD-GFP and, to a lesser extent, DrVsx1-GFP were able to enter the cells. In contrast,
DrVsx1_NLSmut-GFP, DrVsx1_short-GFP or GFP could not mediate cellular entry. Scale bars, 10 m. (B) Inhibition of nuclear export interferes
with intercellular transactivation. Luciferase assays after cocultivation of 293 cells expressing MmChx10-GFP, MmChx10_NESmut-GFP, or GFP,
together with 293 cells transfected with the MmChx10-responsive luciferase reporter and pSV40-Gal. Luciferase activity was normalized to -Gal
expression. Error bars indicate the standard deviations.
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homeodomain proteins fulﬁlling all of these criteria.
As transcription factors, PLC-HDPs have to access the nu-
cleus to execute their function. Theoretically, the size of ca. 34
kDa allows PLC-HDPs to enter the nucleus also by passive
diffusion. However, even smaller proteins are transported by
active, signal-mediated mechanisms, most likely because active
transport is more efﬁcient and amendable to speciﬁc control
mechanisms (3, 13). The transfection and/or microinjection
experiments indicated that the conserved KRKKRRHR motif
can not only function as a nuclear retention signal but also
represents a bona ﬁde monopartite nuclear import signal for
PLC-HDPs in which the underlined arginines are critical for
function and efﬁciency. Although Ubc9 has been suggested to
mediate the nuclear localization of Vsx1 (27), we are currently
investigating in detail whether Vsx1 is directly imported via the
transportin 13/Ubc9 axis (37) or can also use alternative import
pathways. Although the PLC-HDPs NLS is less active com-
pared to the classical SV40 NLS (45), the rate of import still
exceeds the rate of export, resulting in the observed dynamic
but predominantly nuclear steady-state localization of PLC-
HDPs.
The activity of transcriptional regulators can be modulated
at various levels. As shown for other transcription factors (6,
44), these include posttranscriptional modiﬁcations in the nu-
cleus or the cytoplasm, e.g., phosphorylation (35), sumoylation
(10), and interactions with other proteins (14). The detailed
molecular pathways regulating the activity of PLC-HDPs are
currently under intense investigation. Here, we provided evi-
dence that PLC-HDPs are dynamic transcription factors that
have the capability to shuttle between the nucleus and the
cytoplasm. Consequently, PLC-HDPs might be subjected to
regulatory control mechanism homing in these speciﬁc com-
partments. Degradation by the ubiquitin/proteasome pathway
is crucial to control protein homeostasis and was described for
several transcription factors, including the DrVsx1 protein
(26). In the present study, we found that inactivation of the
nuclear export activity of DrVsx1 and MmChx10 resulted in
increased protein stability and thus in increased transcriptional
activation. Since the ubiquitin/proteasome pathway appears to
act predominantly in the cytoplasm (47), our transactivation
result indicate that regulating nucleocytoplasmic transport can
indirectly inﬂuence the intracellular protein levels and the bi-
ological activity of PLC-HDPs by the proteasome pathway. A
similar model was proposed for the IB/NF-B axis in which
the nuclear export activity of IB regulates the intracellular
localization, degradation, and transcriptional activity of NF-B
(see references 30 and 33 and references therein). In contrast,
Rehberg et al. reported that the inactivation of the NES in the
Sox10 protein resulted in decreased transactivation by an un-
known mechanism (44). Although it is less likely, we cannot
formally rule out the possibility that the mutations introduced
to generate the export deﬁcient DrVsx1 protein directly re-
sulted in enhanced degradation resistance. The increased sta-
bility observed would thus be due to conformational changes
and not caused by blocking export.
We found that the continuous supply of cytoplasmic DrVsx1
or MmChx10 from the nuclear pool by active export facilitated
also extracellular release of the proteins. PLC-HDPs in general
lack a canonical secretion signal and appear not to be targeted
into the endoplasmic reticulum by a cotranslational mecha-
nism. In addition, secretion could not be inhibited by treatment
with BFA, an inhibitor of the classical endoplasmic reticulum/
Golgi-dependent secretion pathway. Thus, extracellular re-
lease appears to be mediated by the unconventional secretion
pathway reported also for several viral and cellular proteins
(see reference 39 and references therein). In this context,
Julian Huxley’s term “growth gradient” may be relevant for the
biological function of PLC-HDPs. In the morphogen gradient
model, the local concentration of a diffusible molecule can
determine cells’ rates of proliferation and differentiation as a
continuous function of concentration (4, 11, 36). This model is
made particularly attractive by our ﬁnding that PLC-HDPs
also harbor a highly conserved PTD with a similar activity as
the widely used HIV-1 Tat PTD (52). The mechanism of trans-
duction has been studied extensively for a variety of proteins,
including the Antennapedia and PDX-1 homeodomain tran-
scription factors (15). Recent evidence suggests that transduc-
tion occurs via a multistep mechanism involving endocytosis
and macropinocytosis (54). Although we could not visually
monitor the spread of DrVsx1-GFP or MmChx10-GFP from
expressing donor to untransfected acceptor cells as described
for the Engrailed protein (22), the results of our intercellular
transactivation assays support the intercellular trafﬁcking of
PLC-HDPs, as demonstrated for other PTD-containing tran-
scription factors (53). However, to fully understand the biolog-
ical relevance of transduction in vivo, the activity of PTD-
deﬁcient PLC-HDP mutants has to be investigated in adequate
animal models.
In summary, our report provides novel insights into the
functional domain organization of PLC-HDPs (Fig. 7A).
Based on our ﬁndings, we propose a model in which the con-
tinuous nucleocytoplasmic shuttling of PLC-HDPs contributes
to the optimal and ﬂexible execution of their transcriptional
FIG. 7. (A) Organization of evolutionary conserved domains in
PLC-HD proteins regulating cellular transport. (B) Model linking nu-
cleocytoplasmic transport with PLC-HDP activity. The predominantly
nuclear localization of PLC-HD proteins is the net result of import
exceeding the rate of export due to the different activities of NES and
NLS. Nuclear export allows PLC-HD protein levels to be regulated by
the proteasomal degradation pathway and continuously supplies cargo
for extracellular unconventional secretion. Intercellular transport and
transactivation could be mediated by the protein transduction domain/
NLS.
2580 KNAUER ET AL. MOL.C ELL.B IOL.activities (Fig. 7B). The evolutionarily conserved combination
of a PTD, together with active nuclear export and import
signals, may allow the ﬁne-tuning of intracellular protein levels
by the proteasome pathway and, in addition, also permits in-
tercellular transfer. The overlapping complex patterns of ho-
meobox gene expression in the embryonic retina requires a
complex regulatory network of transcription factors that spec-
iﬁes differentiation of competent retinal progenitors. Although
transcriptional regulation of PLC-HDPs is an important con-
trol mechanism, PLC-HDPs may have additional unexpected
paracrine activity, thereby inﬂuencing and maintaining the
complex expression pattern during development. To ultimately
gain profound insight into the detailed role of PLC-HDPs’
nucleocytoplasmic shuttling for ordered development has to
await transgenic mouse knock-in models in which nucleocyto-
plasmic transport of Chx10 is selectively abolished. Currently,
we are pursuing this strategy in our laboratory.
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Summary 
The modulation of signaling events by histone deacetylase inhibitors has been shown to lead to 
the induction of apoptosis or differentiation of carcinoma cells. Nevertheless, the molecular 
mechanisms underlying these processes are still under intense investigation. Our study shows 
that Stat1 and NF-κB, two key regulators of signal transduction, gene expression and apoptosis 
are linked via acetylation of Stat1 lysine residues. Stat1 expression levels correlate with 
sensitivity of cells to HDAC inhibitors and introduction of Stat1 into resistant cells permits 
induction of apoptosis. Although acetylation of Stat1 does not change its transcriptional activity, 
it is a prerequisite for the interaction with NF-κB p65. As a consequence, p65 DNA-binding, 
nuclear localization and expression of anti-apoptotic NF-κB target genes decrease. The analysis 
of Stat1 mutants revealed lysines 410 and 413 as acetylation sites. Mutations of these residues 
mimicking either constitutively acetylated or non-acetylated states demonstrate that the 
crosstalk between Stat1 and NF-κB signaling pathways is modulated by changes in the 
acetylation status of Stat1. Krämer et al. 
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Introduction 
Many signal transduction pathways ultimately result in the posttranslational modification of 
histones, which determines the expression of genes important for cell growth, differentiation and 
apoptosis (Wolffe and Hayes 1999; Schreiber and Bernstein 2002). Acetylation of the N-
terminal tails of histones correlates with gene activation, whilst histone deacetylation mediates 
transcriptional repression (Strahl and Allis 2000). It has also become clear that regulated 
acetylation of non-histone proteins determines cellular fate and survival (Blobel 2000; 
Kouzarides 2000; Cohen et al. 2004). The fine-tuned equilibrium of protein acetylation and 
deacetylation is maintained by histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) (Kouzarides 1999). HDAC-inhibitors (HDACi) have been shown to change the 
expression pattern of genes involved in differentiation, cell cycle arrest and apoptosis. 
Intriguingly, repression of gene expression after HDAC-inhibition has been demonstrated (Van 
Lint et al. 1996; Nusinzon and Horvath 2003; Mitsiades et al. 2004) and HDACi were also 
shown to affect several signal transduction pathways (Blaheta and Cinatl 2002; Gurvich et al. 
2004). 
Despite the fact that HDACi are considered as candidate drugs for cancer therapy (Krämer et 
al. 2001; Kelly et al. 2002; Melnick and Licht 2002), it often remains to be elucidated why they 
may induce either apoptosis, necrosis, differentiation or have no effect in different cell types. 
Consequently, the molecular mechanisms underlying cell-specific modulation of signaling 
pathways by HDACi and factors determining sensitivity towards these compounds are still 
subject to intense investigation (Mayo et al. 2003). Several recent reports suggest that HDACi-
induced apoptosis depends on the expression of Jun, Bcl-2-proteins, p21
WAF/CIP1, p53, NF-κB 
and Akt (Vrana et al. 1999; Henderson et al. 2003; Mayo et al. 2003). For some of these 
proteins association with HDACs and/or acetylation of lysine residues has been shown 
(Kouzarides 2000; Chen and Greene 2003; Kiernan et al. 2003; Weiss et al. 2003). Krämer et al. 
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In the case of NF-κB, which contributes significantly to anti-apoptotic signaling (Perkins 2004), 
HDACi were shown to up-regulate NF-κB transcriptional activity in certain cell lines (Mayo et al. 
2003). On the other hand, there is strong evidence that NF-κB signaling and expression of 
several NF-κB target genes are repressed by compounds inhibiting HDACs (Huang et al. 1997; 
Inan et al. 2000; Krämer et al. 2001). Given the critical role of NF-κB in tumorigenesis, several 
studies were undertaken to identify factors influencing this tumor promoter (Perkins 2004). It 
became clear that NF-κB signaling is controlled at several levels by regulatory proteins, such as 
the I-κB protein family. Besides the I-κBs, Stat1 has been suggested to repress signaling 
mediated by NF-κB (Wang et al. 2000; Suk et al. 2001; Shen and Lentsch 2004). Moreover, 
several stimuli induce apoptosis to a significantly greater extent in a Stat1-positive cellular 
background (Kumar et al. 1997; Meyer et al. 2002). Similar to NF-κB, Stat1 associates with 
histone acetyltransferases (HATs) and HDACs (Korzus et al. 1998; Nusinzon and Horvath 
2003). Stat1 regulates the expression of gene products mediating apoptosis, growth and other 
cellular processes constitutively or inducibly in a phosphorylation-dependent manner 
(Chatterjee-Kishore et al. 2000; Ihle 2001). Remarkably, tyrosine phosphorylation and 
transcriptional activity of Stat1 appear dispensable for the inhibition of NF-κB and apoptosis 
induction in response to certain stimuli (Wang et al. 2000; Meyer et al. 2002). However, it is still 
unclear which other posttranslational modifications are involved in this process and whether 
conditions exist in which Stat1 and NF-κB can interact with each other. 
We investigated the molecular mechanisms underlying the induction of apoptosis and the 
modulation of signaling pathways by HDACi in human melanoma cells. Our results show that in 
sensitive cells HDACi increase expression and induce acetylation of Stat1. Experiments 
conducted in both, HDACi-sensitive and -resistant cell lines, indicate that acetylated Stat1 
interacts with NF-κB and reduces NF-κB signaling. These molecular changes are critical for the 
induction of cell death by these substances. Krämer et al. 
  5
Results 
Response of human melanoma cells to HDAC-inhibitors 
HDAC-inhibitors (HDACi) can induce growth arrest and apoptosis in tumor cells of different 
origin (Krämer et al. 2001; Kelly et al. 2002). We found significant differences in the sensitivity of 
various melanoma cell lines towards these compounds. SK-37 cells show strong growth 
reduction in the MTT-assay upon HDACi-treatment, whereas NW-1539 cells are not affected 
significantly (Figure 1A). These cell lines are prototypical examples and have characteristics 
similar to other melanoma cell lines which are either HDACi-sensitve (e. g. MZ-19) or -resistant 
(e. g. NW-450). 
In order to investigate the molecular mechanisms underlying this differential response, we first 
had to evaluate whether the reduced proliferation due to HDACi relies on pro-apoptotic 
properties and effects on caspases (Thornberry and Lazebnik 1998). In the HDACi-sensitive 
SK-37 cell line, we detected activation of the initiator caspases 8 and 9 after treatment (Figure 
1B). Furthermore, we measured Caspase 3 activity in extracts from these cells by colorimetric 
assay. Conversion of the proenzyme form of the excutioner Caspase 3 (p32) to the catalytically 
active proteases p17 and p19 was detectable in SK-37 but not in HDACi-resistant NW-450 cells 
(Figure 1B). 
Activation of Caspase 3 during HDACi-mediated apoptosis of SK-37 cells was also verified by 
examining the cleavage of PARP (116 kDa) into 85-kDa and 28-kDa fragments (Thornberry and 
Lazebnik 1998) (Figure 1C). The pan-caspase-inhibitor Z-VAD-FMK inhibits PARP cleavage as 
well as occurence of a hypodiploid (sub G1) fraction resulting from DNA fragmentation in SK-37 
cells (Figure 1C). Analysis of nuclei stained with Hoechst 33258 gave similar results (data not 
shown). These results confirm that HDACi trigger apoptotic, caspase-dependent pathways in 
SK-37 melanoma cells (Figure 1C). Furthermore, no signs of nonspecific cell permeabilization 
and necrotic cell death were found in a PI/Hoechst staining assay (data not shown). Krämer et al. 
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Alteration of Stat1 gene expression after HDAC-inhibition 
We employed microarray and Western blot analyses to define alterations in gene expression 
patterns after incubation with HDACi. These assays revealed a time- and dose-dependent 
increase in Stat1 expression at the mRNA and protein level in SK-37 (Figure 2A) and several 
other HDACi-sensitive cell lines (data not shown). Treatment of SK-37 cells with HDACi and 
cycloheximide showed that the HDACi-induced increase in Stat1 expression depends on de 
novo protein synthesis (data not shown). Hence, an increase in Stat1 stability due to reduced 
HDAC-activity cannot account for higher Stat1 expression levels. Intriguingly, HDACi-resistant 
cell lines, such as NW-450 and NW-1539 do not undergo HDACi-induced Caspase 3 cleavage 
and apoptosis (Figures 1A, B) and express very low levels of Stat1, which are not induced by 
HDACi (Figure 2B, C). Since no significant difference in HDACi-induced histone 
hyperacetylation was detected between NW-1539 and SK-37 cells, HDACi were equally 
effective in blocking HDAC activity in both cell lines (Figure 2C). This result shows that not only 
inhibition of HDACs but also the presence of Stat1 appears to be crucial for HDACi-mediated 
apoptosis in melanoma cells. Consistent with previous reports (Wong et al. 2002), we detected 
a strong increase in Stat1 expression in the Stat1-positive SK-37 cell line, but not in NW-1539 
cells treated with interferon α. Moreover, co-treatment with HDACi further increased Stat1 
expression in SK-37 cells. (data not shown). This correlates with enhanced induction of 
apoptosis as assessed by MTT and FACS analysis (Figure 2D). 
These results prompted us to investigate whether Stat1α is required for HDACi-induced 
apoptosis in NW-1539 cells. We transduced these cells with a lentiviral vector expressing 
Stat1α. Indeed, sensitivity towards VPA was confered to Stat1α-transduced NW-1539 cells but 
not to cells which received only the vector encoding GFP (Figures 3A, B). Hence, Stat1 
expression levels appear to determine the response of this cell line to HDACi. Furthermore, 
introduction of Stat1α renders these cells susceptible to enhanced apoptosis induction by VPA 
and interferon α (Figure 3B), whereas interferon α alone did not induce apoptosis (data not Krämer et al. 
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shown). Similar results were obtained with the Stat1-negative cell line U3A (Müller et al. 1993) 
reconstituted with Stat1α, albeit with less pronounced apoptosis induction (data not shown). 
Our results clearly show that HDACi induce Stat1 in a cell-type specific manner. However, 
microarray analyses gave no evidence for increased expression of Stat1 target genes as a 
result of HDAC inhibition in SK-37 cells. Therefore, the activity of Stat1 in HDACi-induced 
apoptosis is likely to involve non-genomic effects of Stat1, such as cross-talk with other 
signaling pathways. 
HDACi modulate NF-κB activity 
In order to identify such signaling pathways, gene expression analyses can provide valuable 
information. Since a critical role of NF-κB for HDACi-induced apoptosis has been described, we 
analyzed the expression of NF-κB-dependent genes in the HDACi-sensitive cell line SK-37. Our 
data indicate HDACi-dependent repression of NF-κB target genes such as bcl-XL, survivin and 
Stat5 (Figure 4A, left). These results confirm several reports describing effects of HDACi on 
these genes (Krämer et al. 2001; Hinz et al. 2002; De Schepper et al. 2003). On the other hand, 
expression of NF-κB-regulated genes remained unaltered in HDACi-resistant NW-1539 cells, 
which express hardly any Stat1 (Figure 4A, right). 
Data shown in Figure 4A indicate that Stat1α expression inversely correlates with the activity of 
NF-κB after HDACi-treatment. Therefore, we investigated whether DNA binding of NF-κB might 
be affected. EMSAs displayed functional impairment of NF-κB p65/p50 heterodimer binding to 
its cognate DNA-sequence in extracts from HDACi-treated SK-37 cells (Figure 4B, compare 
lanes 1 and 4). The same observation was made with Stat1α-transduced NW-1539 cells, but 
not in parental or vector-transduced NW-1539 cells (Figure 4B, compare lanes 13 and 16 with 
lanes 5 and 8, 9 and 12). Hence, DNA-binding of NF-κB after treatment with HDACi is only 
reduced if Stat1α is expressed, suggesting a link of both signaling pathways. Krämer et al. 
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The localization of nuclear p65 is modulated by Stat1 and HDACi 
Immunoblotting and fluorescence microscopy were employed to gain further insights into the 
mechanism underlying inhibition of NF-κB in HDACi-treated SK-37 cells. In situ 
immunofluorescence analysis shows a shift of NF-κB p65 from the nucleus to the cytosol and 
increased co-localization with Stat1α. Treatment of cells with the nuclear export inhibitor LMB 
prevents basal and HDACi-induced export of NF-κB p65 and causes nuclear accumulation of 
Stat1α and p65. Again, co-localization of these proteins was enhanced if HDACs were inhibited 
by VPA (Figure 5A). The analysis of cytosolic and nuclear fractions of SK-37 cells indicates that 
Stat1 expression increases both, in the cytosol and in the nucleus (Figure 5B). For NF-κB p65 a 
clear reduction in the nuclear compartment is evident after treatment with HDACi, which 
confirms our microscopy results. These data suggest that removal of p65 from the nucleus and 
interaction with Stat1 might be a key step in HDACi-induced repression of NF-κB target genes 
and apoptosis induction. Another possible explanation, changes in NF-κB p65 expression, can 
be ruled out, since p65 levels are not altered significantly (Figure 5B). Western blot analysis of 
2fTGH cells and their derived Stat1-negative cell line U3A confirmed dependence on Stat1 for 
nuclear export of p65 upon HDAC-inhibition (Figure 5C). Hence, it appears plausible that 
HDACi inhibit nuclear localization of p65 only in cells expressing Stat1. 
HDACi induce the interaction of Stat1α and NF-κB 
Having established a role of Stat1α in NF-κB signaling, we investigated whether these 
transcription factors could interact physically. First, we tested if this interaction is mediated by 
TRADD, which was shown to associate with Stat1α under certain conditions (Wang et al. 2000). 
However, in several immunoprecipitation experiments, we could not detect an HDACi-
dependent interaction of Stat1α with TRADD in SK-37 cells (data not shown). On the other 
hand, precipitation of Stat1α or NF-κB p65 with monoclonal antibodies revealed robust 
association of these proteins under conditions in which HDACs were inhibited (Figure 5D). Krämer et al. 
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Next, we analyzed Stat1 complexes by Superose 6 column fractionation of SK-37 cell extracts 
and found that in high molecular weight complexes the amount of Stat1 increases together with 
NF-κB p65 after VPA treatment (Figure 5E). Notably, this complex accumulates in a time-
dependent manner and parallels apoptosis induction after HDAC-inhibition. Immunoprecipitation 
of Stat1α out of these fractions followed by Western blotting against p65 showed that a weak 
basal interaction of these proteins is increased upon HDAC-inhibition (Figure 5E). 
We also analyzed the composition of the Stat1 complex before and after HDAC-inhibition by 
specific immunoprecipitation and Western blot. Addition of HDACi to SK-37 cells leads to 
reduced association of Stat1 with HDACs 1 and 3 (Figure 5F). However, no binding of Stat1 to 
other class I HDACs (2 and 8) was observed (data not shown). Superose 6 fractionation 
substantiates these results and revealed decreased co-migration of Stat1α complexes with the 
corepressor mSin3 (Figure 5E). Our observations not only confirm that Stat1 can interact with 
negative cofactors but also indicate that HDACs dissociate upon HDACi treatment. 
Acetylation of Stat1 
Stat1 can undergo multiple posttranslational modifications (Darnell 1997). Since recent 
publications show that acetylation of proteins mediates multiple cellular processes (Kouzarides 
2000; Cohen et al. 2004), we tested whether Stat1 undergoes acetylation. Stat1α was 
immunoprecipitated from SK-37 whole cell extracts with a monoclonal antibody under stringent 
lysis conditions in RIPA-buffer. A pan-acetyl-lysine antibody recognized a band corresponding 
to the molecular weight of Stat1α (Figure 6A). Reprobing with the monoclonal Stat1α antibody 
confirmed the acetylation signal as Stat1α. As expected, the basal acetylation level of 
endogenous Stat1α is increased after HDAC-inhibition (Figure 6A). To obtain further evidence 
for acetylation of Stat1, an anti-acetyl-lysine antibody was used for immunoprecipitation and 
Western blots were probed with an antibody against Stat1. In this direction, the pan-acetyl-
lysine antibody precipitated Stat1. Again, the acetylation level of Stat1 increased after HDAC-
inhibition and allowed recovery of increasing amounts of Stat1 from treated cells (Figure 6A, Krämer et al. 
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right panel). These findings indicate that endogenous Stat1 is acetylated in vivo and that this 
modification can be increased by HDACi (Figure 6A) and/or decreased association with 
corepressors and HDACs (Figure 5E). No acetylation of endogenous NF-κB p65 was detectable 
under these conditions. Furthermore, p65 could not be precipitated with the pan-acetyl-lysine 
antibody (Figure 6A). This is consistent with reports stating the need for overexpression of a 
histone acetyltransferase (HAT) to detect NF-κB acetylation (Chen and Greene 2003). 
Transfection experiments with 293T cells revealed that increased expression of CBP enhances 
Stat1 acetylation (Figure 6B). Moreover, we were able to acetylate Stat1α   in vitro using 
immunoprecipitated CBP (Figure 6B, right panel). Ectopically expressed Stat1 was also found to 
be acetylated upon co-transfection of CBP (Figure 6C). Presumably, CBP levels became 
limiting under conditions of Stat1 overexpression. A deletion mutant of Stat1 (∆XbaΙ) lacking the 
Ser
727 phosphorylation site retained acetylation, as indicated by a corresponding smaller band 
detected with an anti-acetyl-lysine antibody (Figure 6C). Hence, stress-induced serine 
phosphorylation of Stat1 (Ihle 2001), which has been described as a response to VPA treatment 
(Gurvich et al. 2004), should not be critical for Stat1 acetylation. Considering that the Stat1 
∆XbaΙ mutant resembles Stat1β, it is likely that this Stat1 splice variant can also be acetylated. 
To identify lysine residues in Stat1α that are subject to acetylation, several Stat1 lysine mutants 
(Horvath et al. 1996; Yang et al. 1999; Meyer et al. 2002; Yang et al. 2002) were overexpressed 
in 293T cells and immunoprecipitated. Western blot analysis with an antibody against acetylated 
lysine showed that only the Stat1 410,413
K→E mutant (Meyer et al. 2002) was not acetylated 
under conditions in which wild-type Stat1 became strongly acetylated (Figure 6D). Since this 
was not due to decreased interaction of this mutant with CBP (data not shown), our 
experimental data suggest that lysines located in the Stat1 DNA-binding domain (DBD) are the 
major sites of acetylation. Krämer et al. 
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Acetylation of Stat1α mediates p65-binding and confers susceptibility to apoptosis 
Given that the acetylation of Stat1 correlates with the induction of apoptosis, interaction with 
p65 and repression of NF-κB signaling, we tested whether p65-associated Stat1α is acetylated 
in vivo. Indeed, an acetylated protein corresponding in size to Stat1α co-precipitated with NF-κB 
p65 from 2fTGH cell lysates after VPA treatment (Figure 6E). We confirmed that this acetylated 
protein is indeed Stat1 by reprobing the membrane with Stat1 antibody. Additionally, both, the 
acetylation signal and the signal for Stat1 were not detectable in the Stat1-negative U3A cell 
line. Thus, we conclude that at least a fraction of p65-associated Stat1α  is acetylated in vivo. 
We hypothesized that acetylation of Stat1α might render cells sensitive to HDACi-induced 
apoptosis. Therefore, we tested whether induction of apoptosis is specifically due to the 
acetylation of lysines within the DBD of Stat1α.  Lysines K410 and K413 were replaced either 
with glutamine (K→Q) or arginine (K→R) resembling constitutively acetylated or non-acetylated 
states, respectively (Figure 6F). NW-1539 cells transfected with wild-type and corresponding 
mutant Stat1α expression vectors were either incubated with VPA or left untreated. Proliferation 
and apoptosis were scored by MTT and FACS analysis (Figure 7A). Equal expression was 
verified by Western blot (Figure 7B). Consistent with Figure 3A, overexpression of Stat1 
together with VPA treatment led to reduced proliferation and apoptosis induction (Figure 6A). 
Transfection of the Stat1 mutant, in which K410 and K413 were replaced by glutamine 
(410,413
K→Q) even enhanced the ability of Stat1α to confer HDACi sensitivity to NW-1539 cells 
and reduced proliferation. In contrast, substitution of K410 and K413 with arginine (410,413
K→R) 
could not render cells sensitive to HDACi as measured by the ability of VPA to induce apoptosis 
(Figure 7A). In order to test whether these results are due to differential interactions of Stat1α 
mutants and NF-κB p65, we examined the association of endogenous p65 with ectopically 
expressed wild-type and mutant Stat1 proteins in U3A cells. Immunoprecipitates of p65 were 
analyzed for the presence of Stat1 by Western blotting. Results shown in Figure 7B confirm that 
treatment with VPA significantly enhances the association of wild-type Stat1α and p65. Krämer et al. 
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Furthermore, the pseudo-acetylated Stat1α mutant 410,413
K→Q constitutively bound p65 in vivo, 
whereas Stat1α 410,413
K→R did not associate with p65 even after treatment with VPA (Figure 
7B). We found that Stat1α 410,413
K→Q significantly reduced expression of the NF-κB target 
gene survivin independent of HDAC-inhibition. In contrast, Stat1α 410,413
K→R failed to reduce 
Survivin expression under identical conditions (Figure 7C). Furthermore, immunofluorescence 
analysis showed that nuclear p65 is reduced in NW-1539 cells only if wild-type Stat1 is 
expressed ectopically and cells are treated with HDACi. Stat1α 410,413
K→Q mimicked these 
effects, whereas expression of Stat1α 410,413
K→R did not increase cytoplasmic localization of 
p65 (Figure 7D; compare transfected and untransfected cells within each field). Moreover, 
expression of Stat1α 410,413
K→Q in NW-1539 cells reduced DNA-binding of NF-κB similar to 
overexpressed wild-type Stat1 in cells treated with VPA, whereas expression of Stat1α 
410,413
K→R did not (Figure 7E). Based on these results, we propose a model in which 
acetylated Stat1α binds and sequesters NF-κB p65 in the cytoplasm, which interferes with NF-
κB function (Figure 7F). As a consequence, cells become susceptible to apoptosis induction. Krämer et al. 
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Discussion 
A number of recent publications have shown that HDAC inhibitors (HDACi) can induce 
apoptosis in many tumor cell lines (Krämer et al. 2001; Kelly et al. 2002). However, the 
molecular mechanisms determining whether a particular cell line responds to HDACi treatment 
are not well understood. In this study we show that in melanoma cell lines resistance towards 
HDACi inversely correlates with Stat1 expression levels. HDACi-induced acetylation of lysines 
410 and 413 within the DNA-binding domain of Stat1 promotes strong interaction with NF-κB 
p65. As a consequence, the level of nuclear p65 decreases significantly and DNA-binding of 
NF-κB is inhibited. This leads to the down-regulation of anti-apoptotic NF-κB target genes, thus 
shifting the balance towards cell death. This mechanism of altered cross-talk of signal 
transduction pathways provides an explanation how HDACi could down-regulate target gene 
expression. 
HDACi-resistant and -sensitive melanoma cell lines 
When we started to study the effects of HDACi on melanoma cell lines, we realized that they 
can be divided into resistant and sensitive sub-classes. This allowed us to investigate the 
underlying molecular mechanisms in a set of cell lines derived from the same type of tumor. Our 
data indicate that sensitive cell lines (e. g. SK-37) undergo programmed cell death via both, the 
extrinsic and the intrinsic apoptotic pathways (Figure 1). In sensitive cell lines HDACi treatment 
significantly decreases the expression of anti-apoptotic genes such as bcl-XL, survivin and Stat5 
which are bona fide target genes of NF-κB (Krämer et al. 2001; Hinz et al. 2002; De Schepper 
et al. 2003). In resistant cell lines, on the other hand, neither changes in expression levels of 
these genes nor apoptosis induction are detectable, although hyperacetylation of histones is 
readily apparent (Figures 2C and 4A). 
A microarray analysis revealed that Stat1 is among those genes which are significantly up-
regulated in sensitive melanoma cell lines in response to the HDACi VPA and TSA. These Krämer et al. 
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findings were confirmed at the protein level (Figure 2A, B). Interestingly, Stat1 expression was 
very low (close to the detection limit) and not inducible in the HDACi-resistant cell lines NW-450 
and NW-1539. Furthermore these cell lines, in contrast to HDACi-sensitive cells, did not 
respond to interferon α, which induces Stat1 signaling (Darnell 1997; Ihle 2001). In order to 
investigate whether these findings are merely correlative or whether Stat1 plays indeed a 
causative role in the induction of apoptosis in response to HDACi we introduced Stat1α into 
NW-1539 cells by lentiviral transduction. Our results show that expression of Stat1 in NW-1539 
restored sensitivity of this cell line towards HDACi and interferon α (Figure 3A, B). The 
introduction of wild-type and mutant Stat1 into melanoma cells which initially had very low 
expression levels of Stat1 (Figures 3, 7) indicates that Stat1 is required but not sufficient to 
enter apoptosis. Additional actions of HDACi such as modulation of other signaling pathways 
and altered cell cycle regulation appear to be necessary. 
The HDACi-resistant cell lines were originally established from patients who had undergone 
immunotherapy including interferon α treatment. We speculate that during this process 
interferon  α resistant cells with defects in Stat1 signaling were selected. In principle both, 
mutations within the Stat1 gene as well as epigenetic silencing could shut down Stat1 
expression. Our observation that the resistant cell lines NW-450 and NW-1539 re-express Stat1 
when treated with 5-aza-cytidine highlights the relevance of DNA methylation in this context 
(O.H.K. and T.H. unpublished results). HDACi are being considered as candidate drugs for 
cancer therapy (Krämer et al. 2001; Kelly et al. 2002). According to our data, the combination of 
HDACi and interferon α or demethylating agents could be particularly effective in the treatment 
of melanomas. If this would turn out to be the case, Stat1 expression might serve as a useful 
marker for the prediction of clinical response. 
Stat1 - NF-κB cross-talk 
The finding that the expression of a subset of NF-κB target genes inversely correlates with Stat1 
expression levels prompted us to analyze the DNA-binding activity of NF-κB using lysates from Krämer et al. 
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cells with different Stat1 expression levels. A reduction of NF-κB DNA binding was only 
observed with VPA-treated Stat1-positive but not with Stat1-negative cell extracts (Figure 4). 
Remarkably, the amount of p65 in the nucleus drops significantly in response to HDACi 
treatment, and this effect can be inhibited by the nuclear export inhibitor LMB (Figure 5A). Since 
these results could be due to an interaction of both proteins we performed co-IP experiments. 
Indeed, we detected formation of a Stat1 - NF-κB complex upon HDACi treatment. Gel filtration 
experiments indicate that the molecular weight of this complex is in the mega-dalton range. 
Therefore, several additional proteins have to be involved (Figure 5). Although a potential cross-
talk of Stat1 and NF-κB signaling pathways has been discussed in several reports (Chatterjee-
Kishore et al. 2000; Suk et al. 2001; Shen and Lentsch 2004; Sizemore et al. 2004), 
unequivocal evidence for the physical association of these factors has not been published. This 
is most likely due to the fact that we observed a robust interaction only upon treatment of cells 
with HDACi. Additional experiments are required to establish whether the Stat1-dependent 
mechanism determining resistance or sensitivity towards HDACi represents a general principle 
relevant to many different types of tumor cells. 
Acetylated Stat1 mediates suppression of anti-apoptotic NF-κB target genes 
Acetylation is considered as a covalent modification which could, similar to phosphorylation 
affect the activity of a wide range of proteins by altering intermolecular interactions. However, a 
relatively limited number of acetylated regulatory proteins including p53, Ku70, NF-κB p65 and 
Stat3 is known (Kouzarides 2000; Chan et al. 2001; Chen and Greene 2003; Kiernan et al. 
2003; Cohen et al. 2004; Yuan et al. 2005). In this report, we show that CBP can serve as an 
acetyltransferase for Stat1 and that acetylation of Stat1 lysine residues 410 and 413 regulates 
the interaction with NF-κB p65. Inhibition of HDAC-activity exerts negative effects on Stat1 
signal transduction (Nusinzon and Horvath 2003). This finding provides a possible explanation 
why the transcriptional activity of Stat1 is reduced after HDAC-inhibition (Nusinzon and Horvath 
2003; Sakamoto et al. 2004). In contrast to Stat1, Stat3 acetylation occurs on a C-terminal Krämer et al. 
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residue and exerts positive effects on Stat3 signal transduction (Wang et al. 2005; Yuan et al. 
2005). Based on interactions of endogenous proteins in Co-IP experiments, HDACs 1 and 3, 
but not HDACs 2 and 8, are likely candidates for enzymes which could deacetylate Stat1. It is 
conceivable that cell type-specific differences in expression or activity of HATs and HDACs 
could alter Stat1 acetylation levels and thereby modulate NF-κB signaling. Consistent with this 
hypothesis, HDACi can shift the dynamic equilibrium of Stat1 acetylation towards the fully 
acetylated state which in turn promotes complex formation with p65. The resulting down-
regulation of anti-apoptotic NF-κB target genes could be a prototypical example for the HDACi-
mediated inhibition of gene expression. 
Interestingly, microarray experiments revealed that in cells exposed to HDACi about one third of 
significant changes in gene expression reflect repression instead of activation events (Van Lint 
et al. 1996; Mitsiades et al. 2004). This initially unexpected observation could be due to the 
induction of transcriptional repressors that do not require HDAC activity to function. Such an 
indirect mechanism would be rather slow as it requires de novo protein synthesis. On the other 
hand, the modulation of cross-talk between Stat1 and NF-κB signaling pathways we discovered 
is independent of protein synthesis and provides a plausible explanation for the rapid 
suppression of genes upon inhibition of HDAC activity. Krämer et al. 
  17
Materials and methods 
Drugs and Chemicals 
Valproic acid, trichostatin A, prodidium iodide, LMB, Hoechst 33258, trypan blue and 4,5 
dimethyl-2-yl 2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma. Interferon-α  
was from Roche and Z-VAD-FMK and Ac-DEVD-pNA were supplied by Alexis. 
Cell Lines, transfections and microscopy 
SK-Mel-37, Mz-Mel-19, NW-Mel-1539, NW-Mel-450 (Jäger et al. 2002) (abbreviated as SK-37, 
Mz-19, NW-1539 or NW-450), Mz-Mel-5, Mz-Mel-7, NW-Mel-726, NW-Mel-745, 293T, 2fTGH 
and U3A cells were maintained in DMEM (Invitrogen) supplemented with 10% FCS 
(Gibco/Sigma), 1% penicillin/streptomycin and 5% L-glutamine (BioWhittaker) at 37 °C in a 5% 
CO2 atmosphere. SK-Mel-28 and Malme-3-M cell lines were grown in RPMI containing the 
same additives. Cells were transfected using PEI (Sigma) for 293T or Lipofectamine 
(Invitrogen). Preparation and image analysis of cells were performed as described (Heger et al. 
2001). 
Preparation of cell lysates and immunoblotting 
Lysate preparation and Western blot procedures were carried out as described (Standke et al. 
1994; Krämer et al. 2003). Antibodies were obtained from Santa Cruz Biotechnology (Stat1, 
sc346/sc417; p65, sc8008; p50, sc7178; HDAC1, sc6298; HDAC3, sc8138/sc11417; Survivin, 
sc17779; Caspase 3, sc7272/sc7148; Tradd, sc1163; TBP, sc204; HA, sc7392/805; GFP, 
sc9996; mSin3, sc994), Sigma (Actin, A2066), Pharmingen (Bcl-XL, 66461A; PARP, 556362), 
Transduction labs (Stat5, S21520) and NEB (Caspase 8, 9746; Caspase 9, 9501S; AcK, 
9441/9681). The AcH4 antibody has been described (Göttlicher et al. 2001). Western blots were 
probed for Actin to ensure equal sample loading. Co-immunoprecipitation experiments were 
performed as described (Heinzel et al. 1997). For direct immunoprecipitations of Stat1α and NF-
κB cells were lysed in RIPA-buffer. To detect interactions NETN buffer containing 0.1% NP-40 
was used. TSA (1 µM) was added to preserve acetylation. Krämer et al. 
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Measurement of proliferation and apoptosis 
MTT assays were performed as described (Denizot and Lang 1986). The cellular DNA content 
was determined by PI flow cytometry (Göttlicher et al. 2001). Cell viability was also determined 
by trypan blue exclusion and a PI/Hoechst staining assay (Suk et al. 2001). Caspase 3 assays 
were performed with 200 µl of caspase 3 cleavage buffer (100 mM Tris pH 8.0, 10% sucrose, 
150 mM NaCl, 0.1% CHAPS, 10 mM DTT), 2.5 µl of 2 mM Ac-DEVD-pNA and 50 µg protein. 
Production of lentiviral particles 
HA-Stat1α was cloned into the SacII site of the pHR’cPPT SIEW Sin vector (kindly provided by 
M. Scherr, Hannover) to yield pS-Stat1α-IEW. Lentiviral vector stocks were produced from 293T 
cells cotransfected with the pCMV∆R9.81 packaging construct (Zufferey et al. 1997) and the 
pMD.G envelope construct (Naldini et al. 1996). Effective transduction was confirmed by 
fluorescence microscopy, FACS and Western blot. 
EMSA (gel retardation assay) 
Radioactive DNA-binding assays were performed as described (Garcia et al. 1997). The NF-κB 
oligonucleotide (sc-2505) and supershift antibodies were purchased from Santa Cruz. 
Plasmids 
Untagged Stat1α was mutagenized by overlap extension PCR (Ho et al. 1989) using HA-Stat1 
as template. The primers (Thermo Electron) used are: 
KK: 5'AAAAGATCTATGTCTCAGTGGTACGAACTTCAGCAGC  3';   
 5'AAAGAATTCGTACTGTGTTCATCATACTGTCGAACTCTAC  3' 
QQ:  5'GCAATTGCAAGAACAGCAAAATGCTGG 3';  
5'CCAGCATTTTGCTGTTCTTGCAATTGC 3' 
RR:   5'GCAATTGCGAGAACAGCGAAATGCTGG 3';  
 5'CCAGCATTTCGCTGTTCTCGCAATTGC  3'. 
PCR products were cloned into pc3.1 TOPO (Invitrogen). Krämer et al. 
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Legends 
Figure 1. HDACi induce apoptosis in SK-37 cells. 
(A) The proliferation of SK-37 and NW-1539 melanoma cells was determined by MTT test after 
exposure to VPA (0.5 - 5 mM) or TSA (100 nM) for 48 h (SK-37) or 72 h (NW-1539); 0, 
untreated cells. 
(B) Induction of activated Caspase 9 (Casp 9, activation denoted by an asterisk) and cleavage 
of Caspase 8 (Casp 8 fl) into the active subunits p43/41/18 were detected by Western blot after 
treatment of SK-37 cells with VPA (V, 1.5 mM) or TSA (T, 100 nM) for 48 h. Caspase 3 activity 
was measured by conversion of Ac-DEVD-pNA to pNA, which has an absorption peak at 405 
nm. This increase is given relative to the activity of lysates from untreated cells (Ctl). HDACi-
induced conversion of Caspase 3 (Casp 3 fl) to the active p17/19 subunits was analyzed in SK-
37 and NW-450 cells. 
(C) Proteolytic cleavage of PARP and apoptotic chromatin fragmentation induced by VPA (1.5 
mM) or TSA (100 nM) after 48 h were detected by Western blot and PI FACS analysis. Co-
treatment of SK-37 cells with Z-VAD-FMK (Z, 100 µM) blocks HDACi-induced apoptosis. 
 
Figure 2. Correlation of Stat1 expression and apoptosis induction. 
(A) The time- and dose-dependent increase of Stat1 expression was investigated by Western 
blot. SK-37 cells were exposed to 1.5 mM VPA or 100 nM TSA for the indicated periods of time. 
Alternatively, cells were treated for 24 h with different concentrations of VPA (0.1-1.5 mM) or 
TSA (10-300 nM) as indicated or left untreated (0). 
(B) Expression of Stat1α in SK-37 and NW-450 melanoma cells treated with 1.5 mM VPA (V), 
100 nM TSA (T) or left untreated (C) or for 24 h was analyzed by Western blot. 
(C) Expression of Stat1 and accumulation of hyperacetylated histone H4 (AcH4) in SK-37 and 
NW-1539 cells after 24 h were analyzed by Western blot. Cells were treated with VPA (V, 1.5 
mM), TSA (T, 30 nM) or left untreated (C) Krämer et al. 
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(D) Sensitivity of melanoma cell lines to VPA (V, 1.5 mM) and interferon α (α, 10
3 U/ml) was 
determined by MTT assay. Enhanced induction of apoptosis after treatment of SK-37 cells with 
VPA and interferon α (α/V) was detected by PI FACS analysis. 
 
Figure 3. Stat1 sensitizes resistant melanoma cells to HDACi-induced apoptosis. 
(A) Western blot analysis was employed to detect Stat1 expression and induction of apoptosis 
in NW-1539 cells transduced with SIEW (vector) or S-Stat1α-IEW (Stat1) and treated with VPA 
(1.5 mM) for 48 h. Asterisks denote activated forms of Caspase 3 or Caspase 8. 
(B) DNA fragmentation was analyzed by PI FACS analysis after treatment with VPA (1.5 mM) or 
VPA and IFN-α (10
3 U/ml) for 60 h; Ctl, untreated cells. 
 
Figure 4. Expression of Stat1 interferes with NF-κB DNA-binding in cells exposed to HDACi. 
(A) Expression of NF-κB target genes after HDAC-inhibition was investigated by Western blot 
analysis of SK-37 and NW-1539 cell lysates. Cells were incubated with 1.5 mM VPA (V), 30 nM 
TSA (T) or left untreated (C) for 24 h. 
(B) NF-κB was analyzed by EMSA of lysates from SK-37, NW-1539 and transduced NW-
1539 cells (vector or Stat1), which were either untreated or treated with VPA (1.5 mM) for 48 h. 
Identity of the NF-κB-DNA complex was verified by p65 and p50 antibody supershifts (SS-AB). 
 
Figure 5. HDCAi-induced complex formation of Stat1α and NF-κB p65. 
(A) Interaction and co-localization of Stat1α and NF-κB p65 in SK-37 cells treated with VPA (1.5 
mM, 24 h) and/or LMB (10 nM) were analyzed by immunofluorescence microscopy (Ctl, 
untreated). Cy3- and FITC-labeled secondary antibodies were used for detection of Stat1 and 
NF-κB . 
(B) Exclusion of p65 from the nuclear compartment after treatment of SK-37 cells with VPA (1.5 
mM) or TSA (100 nM) for 24 h was confirmed by cellular fractionation and p65 Western blot. 
Reprobing was done with antibodies against Stat1. The affinity of the Stat1α antibody is not Krämer et al. 
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sufficient to detect nuclear Stat1. All other proteins detected serve as loading and fractionation 
controls. 
(C) U3A and 2fTGH cells were analyzed for cytoplasmic retention of p65 after incubation with 
1.5 mM VPA (V) for 24 h by Western blot of cytosolic and nuclear fractions. 
(D) Interaction of Stat1α and NF-κB p65 in SK-37 cell lysates was investigated by Western blot 
of specific immunoprecipitations (IP; Ctl, untreated; V, 1.5 mM VPA, 24 h; Pre, pre-immune 
serum). Input lanes and IP-efficiencies are shown to allow comparison of protein amounts used. 
(E) The composition of Stat1 complexes in SK-37 cells after treatment with VPA (1.5 mM, 48 h) 
was investigated by Western blot analysis of Superose 6 column fractions. IP was used to verify 
the interaction of Stat1α with NF-κB. 
(F) HDAC1 and HDAC3 were precipitated from whole cell extracts (IP). Western blot analysis 
was performed with an antibody against Stat1α/β. 
 
Figure 6. Acetylation of Stat1. 
(A) SK-37 cells were either treated with VPA (1.5 mM) or left untreated for 24 h. Endogenous 
Stat1α or NF-κB p65 were immunoprecipitated from RIPA lysates and analyzed by Western blot 
with an antibody recognizing acetylated lysines (anti-AcLys, left). Reprobing of the same 
membrane confirms that the acetylation signal corresponds to Stat1α and shows efficiency and 
specificity of the immunoprecipitation (IP). Anti-AcLys immunoprecipitates from RIPA lysates 
were probed with antibodies recognizing Stat1α/β or NF-κB p65. Pre-immune serum was used 
as a control. Input lanes show 2% of the extract used for IP. 
(B) Increasing amounts of a CBP expression vector (1; 5; 10 µg) were transfected into 293T 
cells. Stat1α was precipitated from RIPA lysates and probed with anti-AcLys. IPs with pre-
immune serum and IPs from cells transfected with the empty vector pc3.1 (10 µg) are controls. 
TNT-translated HA-Stat1 was acetylated in vitro as described (Gu and Roeder 1997) using 
immunoprecipitated CBP. Krämer et al. 
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(C) Acetylation levels of HA-Stat1∆XbaΙ compared to full-length HA-Stat1α were determined by 
IP from 293T cell lysates as described in (A). Cells were transfected with recombinant Stat1 and 
CBP vectors at a ratio of 5:1. 
(D) The experiment was performed as in (C), except that HA-Stat1α or GFP-Stat1 410,413
K→E 
were transfected. 
(E) NF-κB p65 was immunoprecipitated from 2fTGH or U3A cell extracts. Presence and 
acetylation of Stat1α were detected by Western blot as described in (A). Cells were treated with 
1.5 mM VPA for 24 h or left untreated. 
(F) Schematic representation of Stat1α showing positions of acetylated lysines and mutants 
generated. NTD, N-terminal domain; CC, coiled coil, DBD, DNA-binding domain; LD, linker 
domain; TAD, transcriptional activation domain. Mutants are designated QQ (mutation of both, 
K410 and K413 to Q) and RR (mutation of both, K410 and K413 to R). 
 
Figure 7. Identification of Stat1α acetylation as critical regulator of HDACi-induced apoptosis. 
(A) NW-1539 cells were transfected with Stat1α (WT), lysine mutants or equal amounts of 
empty vector (pc3.1). Proliferation and apoptosis were scored 72 h later by MTT and PI FACS-
analysis, respectively. WT, wild type; QQ, 410,413
K→Q; RR, 410,413
K→R; -, untreated; V, 1.5 mM 
VPA. 
(B) Interaction of overexpressed WT and mutant Stat1α (QQ, RR) with NF-κB p65 in U3A cells 
was analyzed by immunoprecipitation and Western blot. Cells were incubated with 1.5 mM VPA 
for 48 h or left untreated. Input lanes are 2% of the lysate used for IP and are shown at 
expositons allowing signal comparison. 
(C) U3A cells were transfected and treated as described in (B). Survivin expression was 
analyzed by Western blot. Detection of Actin and AcH4 serve as loading and treatment controls, 
respectively. Krämer et al. 
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(D) p65 localization was analyzed by immunofluorescence microscopy of NW-1539 cells 
transfected and treated as described in (B). Note: Compare transfected and non-transfected 
cells within each field. 
(E)  DNA-binding of NF−κB was investigated by EMSA with cell lysates of NW-1539 cells 
transfected and treated as described in (B). 
(F) Model for acetylation-dependent Stat1 - NF-κB cross-talk. 
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Abstract
Survivin  functions  as  an  apoptosis  inhibitor  and  a  regulator  of  cell  division  during
development and tumorigenesis, and is thus regarded an attractive target for tumor therapy.
We found survivin overexpressed in head and neck as well as in colorectal cancers and 5
identified an evolutionary conserved Crm1 dependent nuclear export signal (NES) in survivin,
present also in the splice variants 2B and 3B, but absent in the splice variants ∆Exon3 and
2α. Although, survivin was detectable in both, the cytoplasm and the nucleus in tumors,
survivin does not contain an active nuclear import signal and appears to enter the nucleus by
passive diffusion. Importantly, nuclear export was required for survivin mediated protection 10
against  chemo-  and  radiotherapy-induced  apoptosis  and  also  for  its  function  as  a
chromosomal passenger. In dividing cells, the NES mediated tethering of survivin to the
mitotic  machinery  and  thus,  was  required  for  proper  execution  of  cytokinesis.  Export
mediated  cytoplasmic  localization  in  interphase  cells  secured  efficient  direct  or  indirect
interference with caspases. The clinical relevance of our finding was supported by showing 15
that  preferential  nuclear  localization  of  survivin  correlated  with  enhanced  survival  in
colorectal cancer patients. Cell culture experiments suggested interference with the nuclear
export  machinery  as  one  mechanism  to  promote  survivin’s  nuclear  accumulation.  In
conclusion, nuclear export is essential for the pivotal biological activity of survivin, and thus,
interfering specifically with survivin’s nuclear export will be a promising strategy for anti- 20
cancer therapies.Knauer et al.
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Introduction
Evasion  from  apoptosis  as  well  as  enhanced  proliferation  are  invariant  molecular
characteristics of human cancer (1), which facilitate the acquisition of additional cancer traits
promoting resistance to therapy and disseminated disease. Among various mechanisms,
escape  from  apoptosis  can  be  the  result  of  deregulated  overexpression  of  apoptosis 5
inhibitors (2, 3). A major therapeutic and prognostic interest is focused on survivin (3, 4),
which at 16.5 kDa, is the smallest mammalian member of the inhibitor of apoptosis (IAP)
gene  family (5). Survivin contains a single Baculovirus IAP Repeat (BIR) and exists as a
stable homodimer in solution (6). A single-copy survivin gene located on chromosome 17q25
gives rise also to the four alternatively spliced survivin transcripts survivin-2B, -3B, -∆Ex-3 10
and -2α (7-9) and references within). Survivin is largely undetectable in differentiated tissues,
but is expressed in most human tumors and correlates with reduced tumor cell apoptosis,
abbreviated patient survival, accelerated rates of recurrences, and increased resistance to
chemo- and radiotherapy (see 3, 10, 11, and references within). The molecular mechanisms,
by which survivin and in particular survivin splice variants counteract apoptosis and facilitate 15
cell division, have been extensively explored, but are not yet understood. The large amount
of data reported so far provide considerable evidence that survivin acts as a link between the
apoptotic process and the checkpoints that control mitotic progression (see 12, 13). This
assumption is also supported by the dynamic intracellular localizations of survivin reported,
which range from predominantly cytoplasmic, nuclear, mitochondrial, to components of the 20
mitotic apparatus (reviewed in 8, 13, 14).
Although,  the  low  molecular  weight  would  allow  survivin  to  access  intracellular
compartments by passive diffusion, regulated subcellular localization in general provides an
attractive way to control the activity of proteins (15), which has been proposed also for key
players  of  apoptosis  (referenced  in  (16).  Nucleocytoplasmic  transport  for  instance  is 25
regulated by specific signals and transport receptors, and takes place through the nuclear
pore complex (17). Active nuclear import requires energy and is mediated by short stretches
of basic amino acids, termed nuclear localization signals (NLS), which interact with import
receptors (reviewed in 15). The best characterized nuclear export signals (NESs) consist of a
short leucine-rich stretch of amino acids, interact with the export receptor Crm1 and depend 30
on the RanGTP/GDP axis (18 and references therein). Active transport signals have been
identified  in  an  increasing  number  of  cellular  proteins  executing  crucial  heterogeneous
biological functions (15), and have been suggested also for survivin (reviewed in 12).
Interfering specifically with regulated nucleocytoplasmic transport of proteins as a novel
therapeutic  principle  has  recently  attracted  major  interest  by  academia  and  industry 35
(reviewed in 19). Consequently, to conclusively credential the survivin pathway for novel
cancer  therapeutics  we  thoroughly  characterized  the  molecular  regulation  of  survivin’sKnauer et al.
4
dynamic localization and analyzed its consequences for the tumor promoting functions of
survivin.
Complementary  experimental  approaches  demonstrated  that  all  mammalian  survivin
homologs are actively exported via the Crm1 pathway and contain a conserved leucine-rich
nuclear export signal. Importantly, active nuclear export of survivin was essential for its 5
protection against apoptosis and for tethering survivin to the mitotic machinery. Our data
provide a molecular rational why cancer patients displaying predominantly nuclear survivin
showed improved survival. In addition, our study suggests that targeting survivin’s nuclear
export but not import pathway by molecular decoys may represent a novel therapeutic
strategy. 10Knauer et al.
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Materials and Methods
Patient  Characteristics  and  Biopsy  Samples.  Tissue  samples  were  obtained  from
patients undergoing surgical resection between 1998 and 2004 at the Charité University
Medical Center Berlin, the Department of Radiation Oncology of the University Erlangen-
Nuremberg, the Department of Otolaryngology of the University Mainz, and the Department 5
of  Maxillofacial  Plastic  Surgery  of  the  University  Frankfurt.  The  study  protocols  were
approved by the local ethics committee after obtaining the patients’ informed consent to
participate  in  the  study  and  processed  anonymously.  All  cases  were  diagnosed
histopathologically as colorectal carcinoma (CRC) or head and neck squamous carcinoma
(HNSCC),  respectively,  and  staged  according  to  the  TNM  classification.  The  biopsy  of 10
macroscopically normal mucosa (NOM) was taken at a distance of >3 cm surrounding the
tumor  location.  Tissue  specimens  were  flash  frozen  in  liquid  nitrogen  and  stored  until
extraction of mRNA.
RNA extraction, reverse transcription and quantitative real-time PCR analysis (RT- 15
qPCR).  Total  RNA  was  purified  from  patient  material  or  cells  using  TRIzol
®  reagent
(Invitrogen Life Technologies, Karlsruhe, Germany) and quality controlled as described (20).
Changes in mRNA levels were compared by reverse transcription (RT) and subsequent
quantitative  real-time  PCR  analysis  as  described  (20).  To  define  the  relative  gene
expression, the PCR product from each tumor sample was compared with NOM from the 20
same patient. The relative expression ratio (R) of target gene was calculated using the
equation:
( )
( )
sample) (control ref
sample) (control target
ref
target
−
−
Δ
Δ
= CP
CP
E
E
R , based on its real-time PCR efficiencies E, the crossing point
(CP) difference of the tumor sample versus NOM in comparison to the expression of the
reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (20). Primers were: 25
Hu  survivin  WT,  5’-ATGGCCGAGGCTGGCTTCATC-3’  (sense)  and  5’-
GCGCAACCGGACGAATGCT-3’  (antisense);  Hu  survivin∆Exon3,  5’-
ATGGCCGAGGCTGGCTTCATC-3’  (sense)  and  5’-GCACTTTCTCCGCAGTTTCCTC-3’
(antisense).
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Statistical analysis. Survival analysis was applied to all patients and was performed with
SPSS software  (SPSS,  Munich,  Germany)  as  described  (21).  The  differences  of the
Kaplan-Meier survival curves were tested for statistical significance with the log-rank test,
and the 95 percent confidence intervals were calculated. Differences were considered to be
significant for p<0.05. No multivariate analysis was conducted. 35Knauer et al.
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Irradiation procedure. Cells were irradiated at room temperature from a cesium 137 (
137
Cs) source using a CIS IBL437 irradiation device (CIS, France) at a dose rate of 5,2 Gy/min
with a single dose of 8 Gy. Sham-irradiated cultures were kept at room temperature in the X-
ray control room while the other samples were irradiated. After irradiation, the cells were kept 5
in culture medium up to 48 h.
Plasmids. Eukaryotic and bacterial expression constructs for GFP-tagged and untagged
versions of survivin wild type (WT), splice forms and deletion mutants were constructed by
PCR amplification using appropriate primers containing BamHI/NheI-restriction sites and 10
cloned into the vector pc3-GFP or pGEX-GFP, respectively, as described (22). To generate
NES deficient survivin mutants, critical aa were changed by mutagenesis (
89VKKQFEELTL
98
→ 
89VKKQPEEATA
98,  essential  residues  underlined)  as  described  (22).  siRNA-resistant
human survivin mutants were generated by introducing silent mutations at positions essential
for siRNA-binding (nucleotides 
1229C→T  and 
1235A→C) by mutagenesis as described (22). 15
Plasmids p3-Crm1-HA, pc3-PKI-BFP, encoding a PKI-BFP fusion, p3CANc/VSV-G, encoding
the  carboxy  terminus  of  CAN/Nup214,  and  pDS-RED-N1,  encoding  the  red-fluorescent
protein (RFP) were already described (23).
Cells,  transfection,  microscopy  and  microinjection.  The CRC cell line RKO, the 20
HNSCC  cell  line  1624,  HeLa,  Vero  and  293  cells  were  maintained  under  conditions
recommended by the American Type Culture Collection and were prepared for microinjection
or transfected as described (22). Microinjection, observation and image analysis in living or
fixed cells were performed as described in detail (24). Briefly, to determine the average
intracellular protein localization at least 200 fluorescent cells from three separate images 25
were examined. The number of cells exhibiting cytoplasmic (C; cytoplasmic signal > 70% of
the total cellular signal), cytoplasmic and nuclear (C/N), or nuclear (N; nuclear signal > 70%
of the total cellular signal) fluorescence was counted, and the percentages of C, N/C and N
cells  were  calculated.  DNA/cell  nuclei  were  visualized  by  staining  with  Hoechst  33258
(Sigma Aldrich, Munich, Germany) as described (22). Cell lines stable expressing survivin- 30
GFP fusion proteins were selected with G418 as described (24).
Immunoprecipitation,  immunoblotting,  immunofluorescence  and  immuno-
histochemistry.  Immunoblotting and immunofluorescence were carried out according to
standard  procedures  as  described  (22).  Immunoprecipitation  of  survivin-GFP/survivin- 35
complexes  from  co-transfected  cell  lysates  using  polyclonal  anti-GFP  antibodies  (BD
Biosciences, San Jose, CA, USA) as well as analysis of the complexes by immunoblottingKnauer et al.
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using polyclonal anti-survivin antibodies was performed according to standard procedures
(22).
Immunohistochemical  staining  of  survivin  was  performed  according  to  standard
procedures  using  the  polyclonal  anti-survivin  antibodies  (1:2000)  and  the  FastRed
Chromogen® detection system (Immunotech, Hamburg, Germany) as described (21). The 5
slides were finally counterstained with 50% hematoxylin and examined by light microscopy
on a Leica microscope at 100x magnification. The overall intracellular localization of survivin
in the tumors was evaluated independently by two pathologists and scored semiquantitatively
as: •, negative; +C, predominantly cytoplasmic (>70% of tumor cells display cytoplasmic
staining); +N, predominantly nuclear (>70% of tumor cells display nuclear staining). 10
The following antibodies were used in the study: polyclonal anti-survivin (Novus NB 500-
201; Novus Biologicals, Littleton, CO, USA), anti-ß-actin (A2066; polyclonal antibody; Sigma-
Aldrich, St. Louis, MO, USA), anti-α-tubulin (T5168; monoclonal antibody; Sigma-Aldrich, St.
Louis, MO, USA), anti-CRM1 (goat polyclonal antibody, Santa Cruz), anti-caspase-3 (C8487;
polyclonal  antibody;  Sigma-Aldrich,  St.  Louis,  MO,  USA),  and  anti-caspase-9  (C7729; 15
polyclonal antibody; Sigma-Aldrich, St. Louis, MO, USA).
Drug treatment. Cells were treated with the export inhibitor leptomycin B (LMB) (Sigma
Aldrich, Munich, Germany) (10 nM) as described (22). Treatment with 1.5 mM valproic acid,
1.5 mM sodium butyrate or 3 mM cisplatin (Sigma Aldrich, Munich, Germany) was performed 20
as described (25).
Purification  of  recombinant  GST-fusion  proteins. GST-GFP  hybrid  proteins  were
expressed and purified as described (22).
25
Crm1 pull-down assays and in vitro translation. Coupled transcription/translation was
performed using the plasmid p3-Crm1-HA as the template, the specific recombinant GST-
GFP substrates, Ran-GTP and nuclear extracts as described (22).
RNAi. The sequence and activity of the survivin double-stranded siRNA (Eurogenetec, 30
Searing, Belgium) (sense: 5´-CUGGACAGAGAAAGAGCCATT-3´, residues mutated in the
siRNA-resistant  survivin  mutants  are  underlined;  antisense:  5´-UGG-
CUCUUUCUCUGUCCAGTT-3´) has been described (26). Cells were treated in parallel with
a scrambled siRNA duplex (sense: 5´-GGUGUGCUGUUUGGAGGUCTT-3´, antisense: 5´-
GAACUCCAAACAGCACACCTT-3´) as a non-specific control. The siRNA duplexes (each 50 35
nM)  were  transfected  together  with  0.5  µg  of  the  RFP  expression  plasmid  using  theKnauer et al.
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Lipofectamine2000
®  reagent  (Invitrogen,  Carlsbad,  CA,  USA)  according  to  the
manufacturer’s recommendations.
Quantification of apoptosis. Apoptosis was assessed by labeling free 3’OH ends in
genomic DNA with rhodamine-dUTP (TUNEL-staining) using the in situ cell death detection 5
kit (Roche Diagnostics) as described (24). Briefly, 200 GFP-positive cells from three separate
images  were  inspected,  the  number  of  TUNEL-positive  cells  was  counted,  and  the
percentages were calculated.
Cell  extracts  were  assayed  for  caspase-3-dependent  hydrolysis  of  the  fluorogenic
substrate  N-acetyl-Asp-Glu-Val-Asp-p-nitroanilide  (Axxora,  Grunberg,  Germany)  and 10
enzyme-catalyzed release of p-nitroanilide was monitored at 405nm as described (27).Knauer et al.
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Results
Survivin is overexpressed in colorectal and head and neck cancer, and localized to
the nucleus and the cytoplasm of tumor cells. We examined the levels of survivin gene
expression  in  colorectal  (CC)  as  well  as  in  head  and  neck  squamous  cell  carcinomas
(HNSCC) and in the corresponding normal mucosa (NOM) of the same patient by RT-qPCR 5
analysis. As summarized in Figure 1A, survivin was found to be overexpressed in the tumors
of  almost  all  patients  examined  (see  Supplementary  Table  S1  and  S2  for  patient
characteristics and for values of the RT-qPCR analysis). Gene expression data could be
confirmed on the protein level by IHC (Fig. 1B). Whereas survivin expression was almost
absent in NOM, we observed tumors, in which survivin was predominantly cytoplasmic (Fig. 10
1B, left panel), but also tumors showing predominantly nuclear survivin staining (Fig. 1B,
right panel).
Survivin contains an evolutionary conserved leucine-rich nuclear export signal. The
results of the IHC analysis as well as the pivotal role of survivin as an apoptosis inhibitor and 15
a regulator of cell division were indicative for a regulated nucleocytoplasmic localization of
survivin. To systematically investigate the nucleocytoplasmic transport of survivin in live cells,
we expressed human survivin, all known splice variants as well as the rat (Rn) survivin as C-
terminal  GFP  fusion  proteins  (see  Supplementary Table S3). Fluorescence microscopy
revealed that survivin-GFP and Rn_survivin-GFP were predominantly cytoplasmic following 20
transient or stable expression in several cell lines including the HNSCC cell line 1624, the
human CRC cell line RKO, and HeLa cells (Fig. 2A, upper panel, and data not shown).
Treatment with the nuclear export inhibitor LMB resulted in enhanced nuclear localization
(Fig.  2A,  lower  panel).  Indirect  immunofluorescence  revealed  a  similar  intracellular
localization and LMB sensitivity for the endogenous survivin in 1624, RKO and HeLa cells 25
(Fig.  2B,  and  data  not  shown).  Survivin  splice  variants  2B-  and  3B-GFP  fusions  also
localized to the cytoplasm (Fig. 2C), and were sensitive to LMB treatment. In contrast,
survivin∆Ex3-GFP  was  predominantly  nuclear  and  survivin2α-GFP  distributed  equally
between the nucleus and the cytoplasm, and both did not respond to LMB as analyzed in
several cell lines (Fig. 2C, and data not shown). To further map the nuclear export signal 30
(NES), we expressed survivin deletion mutants aa1-119 and aa1-88 as GFP-fusions and
tested their localization and LMB-sensitivity. These results located the NES between aa 88 to
119 (Fig. 2D; and Supplementary Table S3).
We  next  examined  the  nucleocytoplasmic  transport  of  survivin  in  a  highly  stringent
system that allows the observation and quantification of transport in living cells (22). Survivin 35
was expressed as a fusion with glutathione S-transferase (GST) and GFP (GST-survivin-
GFP), and tested by microinjection. Due to the size of the GST-GFP fusion protein (54 kDa),Knauer et al.
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the localization of the recombinant autofluorescent transport substrate is not flawed by
passive diffusion, and the protein remains at the site of injection (22). Following nuclear
injection in 1624, Vero and RKO cells, GST-survivin-GFP was quantitatively exported into
the cytoplasm (Fig. 3A/B, upper panel; Supplementary Fig. S1, and data not shown). Export
was abrogated by treatment with LMB (data not shown). In contrast, no nuclear import was 5
observed upon cytoplasmic injection, even in the presence of LMB, arguing against the
presence of an active nuclear import signal (Fig. 3A/B). Similar results were observed for
GST-Rn_survivin-GFP (data not shown).
Database searches identified motifs within aa 88 to 119 of survivin, matching the loosely
defined consensus sequence for leucine-rich NESs (28). To verify the predicted signals, we 10
tested  the  activity  of  the  potential  NESs  by  microinjection.  Microinjection  experiments
revealed that only a recombinant GST-GFP protein containing the survivin aa 89-99 was
quantitatively exported (Fig. 3B and Supplementary Fig. S1). As a stringent control, a signal
in  which  essential  residues  were  mutated  (NESmut)  was  inactive  under  identical
experimental  conditions  (Fig.  3B/D  and  Supplementary  Fig.  S1).  The  evolutionary 15
conservation of the NES (Fig. 3D) was verified by the analysis of the respective survivin
NESs from several species (data not shown). To confirm the functionality of the export signal
also in the context of the full-length protein in vivo, we mutated critical residues of the NES
(Fig. 3D). In contrast to the wild type protein, survivin∆NES-GFP was equally distributed
between the nucleus and the cytoplasm, and did not respond to LMB treatment (Fig. 3E, and 20
data not shown). In addition, recombinant GST-survivin∆NES-GFP was neither exported nor
imported in microinjection experiments (Fig. 3A, lower panel). These data exclude additional
NESs as well as an active nuclear import signal in survivin.
Survivin interacts with Crm1. Inhibition of export by treatment with LMB indicated that 25
survivin  was  exported  via  the  Crm1  pathway.  This  assumption  was  supported  by
demonstrating that overexpression of Crm1 resulted in colocalization with survivin-GFP at
the nuclear membrane in contrast to survivin∆NES-GFP (Fig. 3E). The direct Crm1-survivin
interaction  was  biochemically  verified  in  a  cell  free  system.  Figure  3C  illustrates  that
recombinant GST-survivin-GFP bound to Crm1 in contrast to inactive GST-survivin∆NES- 30
GFP or GST-GFP alone. Similar results were obtained for GST-survivinNES-GFP and GST-
survivinNESmut-GFP fusion proteins, respectively (Fig. 3C).
Nuclear  export  of  survivin  is  required  for  proper  cytokinesis. Various reports
demonstrated defects in cell cycle progression following downregulation of survivin levels 35
resulting in mitotic arrest and polyploidy. To investigate the role of nuclear export for proper
cytokinesis, we analyzed whether survivin∆NES-GFP was able to counteract the formation ofKnauer et al.
11
multinucleated cells upon ablation of endogenous survivin by RNAi. Transfection of HeLa
cells  stably  expressing  GFP  with  survivin  siRNA  resulted  in  an  increased  number  of
multinuclear cells, which was significantly reduced in survivin-GFP but not in survivin∆NES-
GFP  expressing  cell  lines  (Fig.  4A/B).  Since  RNAi  affected  endogenous  as  well  as
ectopically  expressed  survivin,  we  generated  HeLa  cell  lines  stably  expressing  siRNA 5
resistant survivin-GFP fusion proteins (survivin_sim-GFP and survivin∆NES_sim-GFP), by
introducing two silent mutations within the survivin siRNA target sequence. Upon RNAi-
mediated transient ablation of endogenous survivin, the inability of export deficient survivin to
rescue cytokinesis became more prominent (Fig. 4A/B; right panel, and Supplementary Fig.
S2). Of note, prolonged treatment with LMB also resulted in multinuclear cells (data not 10
shown).
The integrity of the NES is required for tethering survivin to the mitotic machinery.
To provide a molecular rationale why NES-deficient survivin-GFP was unable to promote
proper cytokinesis, we examined the localization of survivin-GFP and survivin∆NES-GFP in 15
stable  cell  lines.  In  contrast  to  wild  type  survivin-GFP,  which  localized  correctly  to  the
metaphase plate, the kinetochores and the midbody during cytokinesis, survivin∆NES-GFP
failed to associate with the mitotic machinery (Fig. 4C, and data not shown). Similar results
were observed in the RKO cell line, for untagged survivin and survivin∆NES, respectively, as
well as for the rat survivin (data not shown). Thus, the integrity of the NES is required for 20
survivin to function as a chromosomal passenger and explains, why the survivin NES is
evolutionary conserved and required for proper cytokinesis.
Survivin mediated protection against chemo- or radiotherapy-induced apoptosis
depends on active nuclear export. Survivin expression in tumors has been correlated with 25
resistance against and chemo- and radiotherapy induced apoptosis. To investigate whether
nuclear export was required for the clinical relevant protective activity of survivin, HeLa and
RKO cells stably expressing survivin-GFP or survivin∆NES-GFP, respectively, were treated
with  apoptosis  inducing  chemotherapeutic  compounds  or  irradiated.  Figure  5A/B
demonstrates that WT survivin-GFP could counteract induction of apoptosis by treatment 30
with butyrate, VPA and cisplatin, whereas treatment of survivin∆NES-GFP expressing cells
resulted  in  an  increased  apoptotic  rate  as  analyzed  by  TUNEL  staining  (Fig.  5A,  and
Supplementary Fig. S3; and data not shown) and measurement of caspase-3 activity (Fig.
5B). Importantly,  export  deficient  survivin-GFP  also  displayed  a  significantly  reduced
protective activity against irradiation-induced apoptosis (Fig. 5A/B). Of note, blocking the 35
nuclear export of survivin by treatment with LMB for 24 h enhanced irradiation induced
apoptosis analyzed by measurement of caspase-3 activity. Similar expression levels ofKnauer et al.
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survivin-GFP  and  survivin∆NES-GFP  were  controlled  by  immunoblot  analysis  (data  not
shown).
The activity of IAPs is assumed to be mediated predominantly in the cytoplasm. Although
for  survivin  the  types  of  caspases  and  exact  molecular  mechanisms  involved  are  still
disputed. Our co-localization studies demonstrate that the amount of cytoplasmic survivin, 5
capable to directly or indirectly inhibit cytoplasmic localized pro-caspase-3 and -9, was
significantly higher for survivin-GFP compared to survivin∆NES-GFP (Fig. 5C/D, and data
not shown). These results provide an explanation for the observed reduced anti-apoptotic
effect of the NES-mutant and nuclear export appears not only to be required for proper
cytokinesis but also plays a role in protection against cancer therapy induced apoptosis. 10
To exclude the formal possibility that the observed inhibition of the biological activity of
survivin was not primarily mediated by blocking nuclear export but by affecting survivin
dimerization  due  to  the  introduced  NES-inactivating  mutations,  we  performed
immunoprecipitation experiments. Survivin could be immunoprecipitated as a complex with
survivin-GFP  as  well  as  with  survivin∆NES-GFP  from  the  lysates  of  HeLa  cells  co- 15
transfected  with  the  respective  expression  constructs  with  equal  efficiencies  (data  not
shown).
Preferential nuclear localization of survivin correlated with enhanced survival. Our
results  argued  that  nuclear  export  is  important  for  the  biological  activity  of  survivin. 20
Consequently, interference with the nuclear export of survivin should result in increased
nuclear survivin in tumor cells, and thereby impair the tumor promoting activity of survivin.
Thus, we would expect that patients with predominantly nuclear survivin in their tumors
should show increased overall survival. To test this hypothesis, the intracellular localization
of survivin was analyzed by immunohistologic staining (IHC) in colorectal cancer specimens 25
(for patients characteristics see Supplementary Table S4). Predominantly nuclear survivin
staining of tumor cells (Fig. 1B shows an example in a representative tumor) was evident in
24 out of 263 cases (9,2%), and Kaplan-Meier curves of overall and recurrence-free survival
showed a statistically significant association (p=0.005) with improved survival as calculated
by the log-rank test (Fig. 6A). 30
The possibility that the detected nuclear survivin represented the survivin∆Exon3 splice
variant  instead  of WT survivin  was excluded  by analyzing  the expression  levels  of the
respective proteins in several tumors with enhanced nuclear survivin staining by RT-qPCR.
In contrast to WT survivin, survivin∆Exon3 levels were almost undetectable (data not shown),
consistent with previous reports (referenced in 9). 35
Nuclear localization of survivin can be induced by interference with nuclear export.Knauer et al.
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To provide a molecular mechanism causing enhanced nuclear localization of survivin as also
observed in the patient specimens, we investigated whether nuclear accumulation of survivin
could be induced by overexpressing proteins competing for export factors or interfering with
the  nuclear  transport  machinery.  Figure  6B  shows  that  co-expression  of  survivin-GFP
together with PKI-BFP or together with the FG-repeat containing C-terminal part of Nup214 5
affected nuclear export and caused nuclear accumulation of survivin-GFP. Similar results
were obtained for endogenous survivin (data not shown).Knauer et al.
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Discussion
We have identified the evolutionary conserved Crm1 mediated nuclear export signal in
survivin. The integrity of the NES was not only important for the anti-apoptotic activity of
survivin  but  also  for  its  function  as  a  chromosomal  passenger.  Thereby,  we  annotated 5
survivin as another essential regulatory protein the activity of which is regulated by active
nucleocytoplasmic transport.
We demonstrated that endogenous as well as ectopically expressed survivin localized
predominantly to the cytoplasm during interphase. This could either be due to the retention of
newly synthesized protein in the cytoplasm or to its continuous nuclear export. Rodriguez et 10
al. (29) assigned the export activity of survivin to its carboxy-terminal domain, but could not
map the NES, and proposed that export is mediated in trans by a NES-containing protein
binding  to  the  carboxy-terminal  domain.  In  contrast,  we  identified  the  NES,  which  was
present in WT survivin, the splice variants 2B and 3B, but absent in the splice variants
∆Exon3 and 2α. Absence or presence of the NES also correlated with the cytoplasmic 15
localization of the splice variants (Supplementary Fig. S4A). Nuclear export of survivin was
mediated by the Crm1 pathway as supported by several lines of evidence presented in our
report. For one, Crm1 antagonists caused nuclear accumulation of survivin and prevented
export  of  recombinant  full-length  survivin  as  well  as  survivinNES  transport  substrates.
Secondly, survivin-GFP and survivinNES-GFP bound to Crm1 in vitro and in vivo, and these 20
interactions could be prevented by mutating critical residues in the NES, which also blocked
export of the full length protein in vivo. The NES of survivin is evolutionary conserved in all
known mammalian survivin proteins (VxxxF/M/VxxLxL/V) and fits the consensus sequence
for leucine-rich export signals (28). Although suggested in previous reports (referenced in
14), our data do not support the presence of an active nuclear import signal. First, Crm1 25
antagonists  did  not  result  in  complete  nuclear  accumulation  of  survivin.  Secondly,
recombinant  full-length  GST-survivin-GFP  as  well  as  GST-survivin∆NES-GFP  were  not
imported into the nucleus upon microinjection into the cytoplasm. Thus, the low molecular
weight of survivin even as a dimer, allows survivin to enter the nucleus by passive diffusion,
and if active nuclear export is inhibited may attach to nuclear binding sites in interphase cells. 30
This assumption is supported in dividing cells, where we and others found survivin attached
to  components  of  the  mitotic  machinery  and  to  localize  to  the  metaphase  plate,  the
kinetochores and the midbodies (30,  31).  It  is  tempting  to  speculate  that  among  other
components of the chromosomal passenger complex (CPC) like Aurora B and INCENP,
Crm1 is critically involved in tethering survivin to the mitotic machinery. First, Crm1 has 35
clearly been identified as an essential Ran-GTP effector for mitotic spindle assembly and
function in yeast and mammalian cells (32 and references therein), besides its function as aKnauer et al.
15
nuclear export receptor. Secondly, survivin but not NES-deficient survivin interacts with Crm1
in vitro and in  vivo, which correlates with its localization to the mitotic machinery and its
activity to promote proper cytokinesis. As reported by Yang et al. (13), survivin is essential
for  cellular  proliferation  by  ensuring  accurate  sister  chromatid  segregation  and
assembly/stabilization of microtubules in late mitosis. 5
Although the notion that survivin inhibits apoptosis is established, the mechanis by which
this occurs has not been conclusively determined (2, 3). Several reports suggest that survivin
directly interacts with Smac/DIABLO (6, 33), can form complexes with other IAP members
(34)  or  binds  to  pro-caspase-3 (35)  and  -9  (36). Clearly, a predominantly cytoplasmic
localization of survivin mediated by active nuclear export would enable survivin to function 10
effectively an inhibitor of apoptosis. This molecular mechanism could be supported by our
findings that survivin but not export deficient survivin was able to counteract chemo- and
radiotherapy induced apoptosis.
As survivin appears to play a dual role as an apoptosis inhibitor and a regulator of cell
division, it is intriguing how the concept of active nuclear export is exploited to efficiently 15
function in both pathways. First, during cell division, the NES is used to target survivin to the
chromosomal passenger complex in order to promote proper cytokinesis. During interphase,
nuclear export serves to ensure a high cytoplasmic concentration of survivin to counteract
pro-apoptotic signals. Since survivin is not only expressed in somatic cancer cells but also in
stem  cells  (37),  the  same  molecular  mechanism  may  control  stem  cell  survival  and 20
proliferation, and might also be important for the development and maintenance of cancer
stem cells (38).
Thus, besides other mechanism like phosphorylation or interaction with other proteins,
nuclear export is clearly important not only for the biological function of survivin in normal
cells, but also for its cancer promoting activity. Is this finding also of clinical relevance? 25
Others and we could show that preferential nuclear localization of survivin in tumors was
linked with a favorable prognosis in colorectal cancer patients (this study), breast cancers
(39), non-small-cell lung cancers (40), gastric cancers (41), ovary tumors (42, 43), pancreatic
cancer  patients  (44)  and  osteosarcomas  (45).  Some  reports  however  consider  nuclear
survivin to be associated with poor survival (46-48). This discrepancy may be due to different 30
IHC staining protocols, the tumor entity examined or caused by additional unknown factors
(14).  Applying  defined  standardized  procedures  for  analyzing  nuclear/cytoplasmic
localization of survivin by IHC is clearly required to clarify the predictive value of nuclear
survivin.
The molecular reasons why survivin accumulated in some tumors in contrast to others is 35
not known. Our previous studies (23, 49) and the cell culture experiments in this report
indicate that nuclear localization of shuttle proteins can be induced by competing for exportKnauer et al.
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factors or by interfering with the nuclear transport machinery. Although this mechanism
needs to be verified in tumors, it is known that shuttling proteins like cyclin D1, p21, p27, p53,
mdm2,  STATs  are  overexpressed  in  various  types  of  cancers  (19)  and  can  influence
nucleocytoplasmic transport of other proteins (50). Likewise, overexpression of full length or
truncated FG-repeat containing proteins has been described (19, 51). 5
Recently, interfering specifically with regulated nucleocytoplasmic transport of proteins as
a novel therapeutic principle has attracted major interest by academia and industry (reviewed
in 19). Although our data indicate that the inhibition of the nuclear export of survivin by LMB
increased  irradiation  induced  apoptosis,  Crm1-directed  inhibitors  will  not  be  used  in
therapeutic applications due to their toxic side effects by blocking all cellular Crm1-mediated 10
transport pathways. Therefore, protein specific transport inhibitors are urgently needed.
Since NESs can be grouped into specific categories according to their activity in vivo (23),
these differences represent an attractive opportunity to selectively interfere with export and
the biological functions of proteins by the generation of NES-specific inhibitors. The NMR
structure of survivin (6) indicates that the hydrophobic NES is exposed at the surface of the 15
survivin dimer (Supplementary Fig. S4B). This knowledge may now allow to in silico design
molecules specifically binding to the NES. Application of our recently developed cell based
translocation assays (24) will allow the systematic identification and validation of NES-
specific  inhibitors.  Thus,  besides  known molecular antagonists of the survivin pathway,
including siRNAs or dominant negative mutants, survivin-specific nuclear export inhibitors will 20
be promising candidates for a novel class of cancer therapeutics.Knauer et al.
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Figure legends
Figure 1. Survivin is overexpressed in CRC and HNSCC, and could be detected in the
cytoplasm and the nucleus. A, quantitative RT-PCR indicating the fold change in expression
of survivin mRNA in tumor versus NOM. Bar, median. B, examples of nuclear (upper panel) 5
and cytoplasmic staining of survivin in tumor sections. Scale bar, 20µm.
Figure 2. Localization and LMB sensitivity of survivin and survivin splice variants. Cells
were transfected with the indicated plasmids and analyzed by fluorescence microscopy or
indirect immunofluorescence using a polyclonal anti-survivin antiserum. A, human and rat 10
(rat) survivin-GFP localized predominantly to the cytoplasm in RKO, 1624 or HeLa cells
(upper panel). Significant amounts of the proteins accumulated in the nucleus following LMB-
treatment (lower panel). B, endogenous survivin in RKO or 1624 cells also displayed a
predominantly  cytoplasmic  localization  and  accumulated  in  the  nucleus  following  LMB-
treatment (lower panel). C, survivin splice variants 2B- and 3B-GFP fusions also localized to 15
the cytoplasm and were sensitive to LMB treatment. In contrast, survivin∆Ex3-GFP was
predominantly nuclear and survivin2α-GFP distributed equally between the nucleus and the
cytoplasm and both, did not respond to LMB. D, survivin aa1-119- but not aa1-88-GFP was
cytoplasmic and LMB sensitive. Representative images are shown. Scale bars, 10 µm.
20
Figure 3. The survivin NES is evolutionary conserved and interacts with Crm1. Indicated
GST-survivin-GFP substrates were microinjected into the nucleus or cytoplasm of 1624 cells,
and transport was recorded in living cells by fluorescence microscopy after the indicated time
points. Approximately 100 cells were injected, and representative examples are shown.
Scale  bars,  10  µm.  A, GST-survivin-GFP was injected into the nuclei of 1624 cells and 25
nuclear export was completed after 3 h (upper panel). In the multinucleated cell, no import
activity into the non-injected nucleus (marked by the asterisk) was observed. In contrast,
export deficient survivin∆NES was neither exported after nuclear injection nor imported after
cytoplasmic injection (lower panel). B, nuclear injected GST-survivin aa89-99-GFP (NES)
was efficiently exported (upper panel), whereas inactivation of the NES blocked export (lower 30
panel). C, survivin interacts with Crm1 in GST-pulldown-assays. In vitro translated  [
35S]-
labeled Crm1 protein was incubated with equal amounts of immobilized GST-survivin-GFP,
GST-survivin∆NES-GFP, GST-survivinNES-GFP, GST-survivinNESmut-GFP or GST-GFP in
the presence of GST-RanQ69L and nuclear extracts. Binding of Crm1 to the NES containing
substrates (lanes 1/3) was abolished by mutating the NES (lanes 2/4). GST-GFP served to 35
control for unspecific binding (lane 5). D, inter-species alignment of the tested survivin export
signals from different species and the inactive mutated NES. Homo sapiens (Hs), Bos taurusKnauer et al.
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(Bt), Canis familiarias (Cf), Felis canis (Fc), Pan trophogloydes (Pt), Sus scrofa (Ss), Mus
musculus  (Mm),  Rattus  norvegicus  (Rn). E, survivin  interacts  with  Crm1  in  vivo.
Overexpression  of  Crm1  resulted  in  colocalization  with  survivin-GFP  at  the  nuclear
membrane in contrast to survivin∆NES-GFP. HeLa cells were transfected with the indicated
plasmids  and  Crm1  expression  was  visualized  by  indirect  immunofluorescence  using  a 5
monoclonal anti-Crm1 antibody. Scale bars, 10 µm.
Figure 4. Nuclear export of survivin is required for proper cytokinesis. Hela cells stably
expressing GFP, survivin-GFP, survivin∆NES-GFP or the siRNA resistant survivin mutants
(survivin_sim-GFP and survivin∆NES_sim-GFP), were transfected with survivin siRNA or a 10
control siRNA together with an RFP expression plasmid as the transfection control. A, siRNA
mediated silencing, and similar expression levels of the survivin-GFP fusion proteins were
verified by Western-blot analysis of cellular lysates using a polyclonal anti-survivin antiserum
(upper panel). Actin was used as a control. Exposition times were 30s for survivin-GFP and
actin and 90s for endogenous survivin. B, in parallel cultures, the number of multinucleated 15
cells was examined in 200 cells from three separate images and the percentages of GFP-
and  RFP-double-positive  cells,  in  which  two  ore  more  nuclei  could  be  detected,  were
determined.  Columns, mean; bars, ±  SD  from  two  independent  experiments.  siRNA-
mediated silencing of survivin resulted in an increased number of multinuclear cells (left
panel),  which  could  be  partially  rescued  by  coexpressing  survivin-GFP,  but  not  by 20
survivin∆NES-GFP (middle panel). Since RNAi affected endogenous as well as ectopically
expressed survivin, rescue by survivin-GFP but not by survivin∆NES-GFP became more
prominent in the siRNA–resistant cell lines (right panel). C, the NES tethers survivin to the
mitotic machinery. Cell-cycle distribution of survivin-GFP and survivin∆NES-GFP (green).
DNA was marked by Hoechst dye (blue), and microtubules by a monoclonal anti-α-tubulin 25
antibody (red). Whereas wild type survivin-GFP correctly localized to the metaphase plate
(M) and the midbody during cytokinesis (left panel), survivin∆NES-GFP failed to associate
with the mitotic machinery (right panel). Representative images are shown. Scale bars, 10
µm.
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Figure 5. Nuclear export is required for survivin mediated protection against chemo- and
radiotherapy induced apoptosis. HeLa cells stably expressing the indicated proteins were
treated with valproic acid (VPA), butyrate, cisplatin (CPL) or irradiated (8 Gy). 48 h later,
apoptosis was assessed by TUNEL staining A, or by measuring caspase-3 activity B (see
material  and  methods  for  details).  Columns, mean; bars,  ±  SD  from  two  independent 35
experiments. In contrast to WT survivin-GFP, overexpression of survivin∆NES-GFP could not
counteract induction of apoptosis by drug treatment or irradiation. Survivin∆NES-GFP orKnauer et al.
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GFP expressing cells showed similar levels of apoptosis, whereas survivin-GFP displayed
significantly  reduced  rate  of  apoptotic  cells. Blocking  the  nuclear  export  of  survivin  by
treatment with LMB for 24 h enhanced irradiation induced apoptosis. C, nuclear export of
survivin ensures efficient co-localization with pro-caspase-3. HeLa cells were transfected
with the indicated plasmids, fixed and stained with an anti-caspase-3 antibody. The amount 5
of survivin protein that co-localized with pro-caspase-3 in the cytoplasm (left panel) was
significantly reduced for the NES mutant (right panel). Scale bar, 10µm. D, to quantify the
degree of co-localization the percentage of total cellular survivin-GFP that co-localized with
caspase-3 was quantitated in 100 cells. Columns, mean; bars, ± SD from two independent
experiments. 10
Figure 7. Preferential nuclear localization of survivin is associated with enhanced survival
of colorectal cancer patients, and can be induced by interference with nuclear export. A,
Kaplan-Meier  survival  curves  for  positive  (n=24)  and  negative  (n=239)  cases  of  CRC
regarding nuclear survivin localization. The intracellular localization of survivin was analyzed 15
by IHC staining. Predominantly nuclear survivin staining of tumors was evident in 24 cases
(9,2%) and showed a statistically significantly association (p=0.005) with improved survival
as calculated by the log-rank test. B, HeLa cells expressing survivin-GFP were transfected
with the PKI-BFP or the CanC expression plasmids (3 µg each) together with 0.3 µg of the
RFP expression plasmid and analyzed by fluorescence microscopy. Overexpression of PKI- 20
BFP or CanC inhibited nuclear export and resulted in the nuclear accumulation of survivin-
GFP in contrast to non-transfected cells (marked by the asterisk). Scale bar, 10 µm.
Supplementary Figure S1. The survivin NES is active also in Vero cells. Indicated GST-
survivin-GFP substrates were microinjected into the nucleus or cytoplasm of Vero cells, and 25
transport was recorded in living cells by fluorescence microscopy after the indicated time
points. Approximately 100 cells were injected, and representative examples are shown.
Whereas A, GST-survivin-GFP or B, GST-survivinNES-GFP was completed exported (upper
panel),  inactivation  of  the  NES  by  mutating  critical  residues  into  alanines
(aa
89VKKQFEELTL
98  → 
89VKKQPEEATA
98)  completely  blocked  export  (lower  panel). In 30
contrast, no import was observed after cytoplasmic injection (A, lower panel). Scale bars, 10
µm.
Supplementary Figure S2. NES deficient survivin cannot support proper cytokinesis.
Representative image of siRNA/RFP-transfected Hela cells expressing survivin∆NES_sim- 35
GFP.  Survivin  silencing  resulted  in  multinuclear  RFP  positive  cells  in  contrast  to
untransfected control cells. Scale bar, 10 µm.Knauer et al.
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Supplementary Figure S3. The integrity of the nuclear export signal is crucial for the
cytoprotective activity of survivin against apoptosis. Hela cells stably expressing the indicated
proteins were treated with valproic acid (VPA) (middle panel) or cisplatin (CPL) (lower panel)
to induce apoptosis. The amount of TUNEL-positive apoptotic cells (shown in red) was 5
significantly reduced in cells expressing survivin-GFP (middle panel) compared to cells
expressing GFP (left panel) or export deficient survivin (right panel). Scale bars, 100µm.
Supplementary Figure S4. A, domain organization of survivin and its alternatively spliced
variants. The first two exons (aa1-73) are common to all splice forms. Survivin-2B, (165aa) 10
contains an insertion of exon 2B (23 aa) between exon 2 and 3, disrupting the BIR domain.
The survivin-DeltaEx3 variant (137aa) encodes a truncated BIR domain and a frameshift
from  exon  4  generates  a  novel  C-terminal  protein  sequence  with  64  amino  acids.  A
frameshift in exon 3 of survivin-3B (120aa) results in a truncated protein with a distinct C-
terminus. In the recently discovered variant 2α exon 1 and 2 are followed by an in frame stop 15
codon within intron 2, generating a protein of 74aa. The NES () is only encoded in survivin
wild-type, 2B and 3B, but is absent in survivin DeltaEx3 and 2α. Boxes represent exons, with
exon numbers and numbers of aa indicated below. B, position of the NES within the NMR
structure  of  human  survivin  (PDB  1XOX).  Ribbon  representation  of  the  backbone
superposition (residues 1-117). Residues 89-98 encompassing the NES are shown in a cyan 20
spacefill depiction. Critical amino acids for NES activity (89, 93, 96 and 98) are shown in red.Knauer et al.
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Supplementary Tables:
Table S1: Tumor stages and clinical characteristics of CRC patients examined by RT-qPCR
analysis
Case Staging Grading Age Sex Ratio
pT pN pM
1 T3 N1 M1 G2 67 M 6,24
2 T2 N0 M0 G1 58 M 3,83
3 T4 N1 M1 G3 64 M 2,23
4 T3 N2 M0 G2 65 M 5,40
5 T3 N0 M1 G2 76 M 6,69
6 T3 N1 M1 G2 56 F 9,09
7 T4 N2 M0 G3 76 M 4,60
8 T3 N1 M0 G2 77 M 12,48
Ratio:  ( )
( )
sample) (control ref
sample) (control target
ref
target
−
−
Δ
Δ
= CP
CP
E
E
RKnauer et al.
Table S2: Tumor stages and clinical characteristics of HNSCC patients examined by RT-
qPCR analysis
Case Localization Staging Grading Age Sex Ratio
pT pN
1 Oral cavity T4 N2 G2 51 M 2,13
2 Oral cavity T3 N1 G2 47 M 1,23
3 Oropharynx T3 N2 G2 56 M 2,96
4 Oral cavity T4 N1 G2 42 F 5,8
5 Larynx T4 N3 G3 56 M 5,04
6 Hypopharynx T3 N2 G2 49 M 0,62
7 Oropharynx T3 N1 G2 58 M 1,63
8 Oral cavity T1 N2 G3 57 M 0,45
9 Oral cavity T2 N3 G2 57 M 7,53
10 Oral cavity T2 N2 G2 47 M 4,81
11 Oral cavity T4 N2 G2 80 M 13,68
Ratio:  ( )
( )
sample) (control ref
sample) (control target
ref
target
−
−
Δ
Δ
= CP
CP
E
E
RKnauer et al.
Table S3: Collective results of the transport activity of survivin, survivin splice mutants and
survivin deletion mutants.
Export activity Import activity Protein    aa
tf mj mj
HsSurvivin 1-142 + (2, H, HN, CC) + (V, HN, CC) - (V, HN, CC)
HsSurvivin_NESmut 1-142 - (2, H, HN, CC) - (V, HN, CC) - (V, HN, CC)
survivin_sim-GFP 1-142 + (2, H, HN, CC) + (V, HN, CC) - (V, HN, CC)
survivin∆NES_sim-GFP 1-142 - (2, H, HN, CC) - (V, HN, CC) - (V, HN, CC)
RnSurvivin 1-142 + (H, N) + (V, N) n.d.
HsSurvivin2B 1-165 + (H, HN, CC) n.d. n.d.
HsSurvivinDEx3 1-137 - (H, HN, CC) n.d. n.d.
HsSurvivin3B 1-120 + (H, HN, CC) n.d. n.d.
HsSurvivin2α 1-74 - (H, HN, CC) n.d. n.d.
HsSurvivin1-119 1-119 + (H, HN, CC) n.d. n.d.
HsSurvivin1-88 1-88 - (H, HN, CC) n.d. n.d.
HsSurvivinNES 89-98 n.d. + (V, HN, CC) n.d.
HsSurvivinNESmut 89-98 n.d. - (V, HN, CC) n.d.
HsSurvivin93-104 93-104 n.d. - (V) n.d.
RnSurvivinNES 89-98 n.d. + (V, N) n.d.
2: 293T; H: HeLa; HN: 1624; CC: RKO; V: Vero; N: NIH3T3; tf: transient expression; mj:
microinjection; Hs: Homo sapiens; Rn: Rattus norvegicus; n.d., not done.Knauer et al.
Table S4: Overall clinical characteristics of CRC patients examined by ICH.
Survivin N/C N
n n (%) n (%)
Number of
specimens 263 239 (91) 24 (9)
Stage
pT2   24   24   0
pT3 239 215 24
pN0   39   34   5
pN1   81   68 13
pN2 132 129   6
pNx*   11     8   0
pM0 107 100   7
pM1 125 113 12
pMx*   31   26   5
Grade
G1   22   20   2
G2 218 198 20
G3   23   21   2
*status unknown in metastatic tumorsPUBLICATIONS
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Regulated nucleo-cytoplasmic transport is crucial for
cellular homeostasis and relies on protein interaction
networks. In addition, the spatial division into the
nucleus and the cytoplasm marks two intracellular
compartments that can easily be distinguished by
microscopy. Consequently, combining the rules for
regulated nucleo-cytoplasmic transport with autofluor-
escent proteins, we developed novel cellular biosen-
sors composed of glutathione S-transferase, mutants
of green fluorescent protein and rational combinations
of nuclear import and export signals. Addition of regu-
latory sequences resulted in three classes of biosen-
sors applicable for the identification of signal-specific
nuclear export and import inhibitors, small molecules
that interfere with protease activity and compounds
that prevent specific protein–protein interactions in liv-
ing cells. As a unique feature, our system exploits
nuclear accumulation of the cytoplasmic biosensors
as the reliable readout for all assays. Efficacy of the
biosensors was systematically investigated and also
demonstrated by using a fully automated platform for
high throughput screening (HTS) microscopy and
assay analysis. The introduced modular biosensors
not only have the potential to further dissect nucleo-
cytoplasmic transport pathways but also to be
employed in numerous screening applications for the
early stage evaluation of potential drug candidates.
Key words: apoptosis, cancer, export, Exportin 1/CRM1,
HIV-1 Rev, import, Jun/Fos, Myc/Max, p53/mdm2,
protein–protein interaction, Stat
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Cellular communication strictly depends on regulated
nucleo-cytoplasmic transport through the nuclear pore
complex (NPC), which is controlled by specific signals
and transport factors (1). Those include the proteins of
the NPC (nucleoporins), the RanGTPase, transport recep-
tors and specialized factors that promote the transport of
specific protein/RNA complexes (2). In general, active
nuclear import requires energy and is mediated by short
stretches of basic amino acids, termed nuclear localization
signals (NLSs), which interact with specific import recep-
tors [(2) and references within]. The best characterized
nuclear export signals (NESs) consist of a short leucine-
rich stretch of amino acids and interact with the export
receptor Exportin 1 [(3) and references therein]. Leucine-
rich NESs have been identified in an increasing number of
disease-relevant cellular and viral proteins implicated in
transcription control (4), cell cycle control (5) and RNA
transport (6). Although the orchestration of export is still
unclear, NESs can be grouped into specific classes
according to their activity in vivo (7). Because regulated
subcellular localization provides an attractive way to con-
trol the activity and stability of regulatory proteins and
RNAs, interfering with nucleo-cytoplasmic transport in
general as a novel therapeutic principle has recently
attracted major interest by academia and industry
[reviewed in (8,9)].
Regulated intracellular localization is also essential for the
controlled activity of site-specific proteases, which play
crucial roles in a variety of cellular functions. Deregulation
of key proteases is known to contribute to pathological
consequences. For several viruses, such as HIV, viral pro-
teases are essential for replication and thus are crucial drug
targets (10). Among the key mediators of apoptosis are also
proteolytic enzymes known as caspases. Given their cen-
tral role as death effector molecules, a great deal of interest
has recently focused on caspases as therapeutic targets for
various disease processes (11).
Because protein interaction networks are critical for all cel-
lular events including intracellular transport (1), identification
of specific protein interactions and characterization of their
physiological significance is one of the main goals of current
research in a wide range of biological fields. In addition,
abolishing or inducing specific protein–protein interactions
by molecular decoys offers tremendous possibilities for the
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1treatment of human diseases. Consequently, numerous
methods have been described to analyze protein–protein
interactions in vitro and in vivo [(8,12–14) and references
therein]. In cancer, cellular transformation and maintenance
of the transformed phenotype often depend upon the for-
mation of specific complexes. For example, the proto-
oncogenes jun and fos encode basic leucine zipper (bZip)
containing oncogenic transcription factors that bind DNA as
dimers and can promote malignant transformation [see (15)
and references therein]. Potential drug targets are also the
basic helix–loop–helix leucine zipper (bHLHZip) transcription
factors Myc and Max. Myc is associated with numerous
types of human cancers and must dimerize with the Max
protein for its oncogenic activity. Inhibitors that prevent Jun-
Fos or Myc-Max dimerization are thus currently under
intense investigation as potential anticancer drugs (16,17).
Likewise, the tumor-suppressor protein p53 forms an auto-
regulatory feedback loop with mdm2, in which the latter
inhibits p53 transcriptional activity and stimulates its degra-
dation [(18) and references therein]. Inhibition of the
p53–mdm2 interaction with synthetic molecules can lead
to the nuclear accumulation and the activation of p53 fol-
lowed by the death of the tumor cells from apoptosis (19).
As any biochemical data or potential drug therapies must
be effective at the cellular level, isolated proteins cannot be
regarded as representatives of complex biological systems,
and cell-based assays (CBAs) have to be employed to
complement in vitro data. Recently, several methods have
been developed to facilitate the implementation of high-
throughput CBAs (20). In particular, the advent of autofluor-
escent proteins (AFPs) [e.g. green fluorescent protein
(GFP)] as imaging tools, combined with novel computer-
driven automated image acquisition and pattern-recognition
systems, will help to make high-throughput screening a
rapid and facile process [referenced in (21)]. However, any
realistic applications of high-content (HC) and high-throughput
CBAs critically depend on robust and reliable biological
readout systems with a high signal to noise ratio. In this
context, the spatial and functional division into the nucleus
and the cytoplasm marks two dynamic intracellular com-
partments that can easily be distinguished by microscopy.
Facing the clear need for improved CBAs, we exploited
our knowledge of regulated nucleo-cytoplasmic transport
resulting in the development and application of modular
protein translocation biosensors tailored to investigate
signal-specific nuclear export and import, protease activity
and specific protein–protein interactions in living cells.
Results
Rational design of biosensors to investigate signal-
specific nucleo-cytoplasmic transport
Autofluorescent protein-based cellular assays for the iden-
tification of signal-specific nucleo-cytoplasmic transloca-
tion inhibitors should meet the following requirements:
The AFP-biosensor (i) should localize predominantly to
the cytoplasm, (ii) is efficiently shuttled between the
nucleus and the cytoplasm, (iii) should accumulate in the
nucleus following inhibition of nuclear export, (iv) should
allow the modular exchange of transport signals and (v) is
neither toxic nor affected by passive diffusion or post-
translational modifications in its intracellular localization.
Previously, we showed that the intracellular localization
of a glutathione S-transferase (GST)-GFP fusion strictly
depends on the presence of transport signals and is not
flawed by passive diffusion (22). In addition, GST-GFP is
highly fluorescent, non-toxic and stable. To design a
GFP-GST shuttle protein with a predominantly cytoplas-
mic steady-state localization, an appropriate combination
of NLS and NES had to be used. On the basis of our
kinetic classification studies (7), we choose the SV40
large T-antigen NLS (NLS) and the NESs from the HIV-1
Rev protein, protein kinase inhibitor (PKI), p53, the
MAPKK, STAT1 and the Bcr-Abl oncoprotein and investi-
gated their activities by microinjection of recombinant
GST-GFP-NLS or -NES fusion proteins, respectively.
The results (see Supplementary Table S1 available online
at http://www.traffic.dk/suppmat/6_7a.asp) indicated
that combining the SV40 NLS with the NESs from PKI
(PKINES), the HIV-1 Rev protein, STAT1, Bcr-Abl and
from MAPKK but not from p53 should result in predomi-
nantly cytoplasmic NLS-GFP/GST-NES shuttle proteins.
We confirmed this prediction by the transient expression
of selected fusion proteins (NLS-GFP/GST-PKINES ¼
PKINES-sensor; NLS-GFP/GST-RevNES ¼ RevNES-sensor;
NLS-GFP/GST-AblNES ¼AblNES-sensor; NLS-GFP/GST-
Stat1NES ¼ StatNES-sensor and NLS-GFP/GST-p53NES ¼
p53NES-sensor) in several cell lines (Figure 1A–D and
Supplementary Table S2 online for detailed values, avail-
able online at http://www.traffic.dk/suppmat/6_7a.asp).With
the exception of the p53-sensor, all sensor constructs dis-
played a predominantly cytoplasmic steady-state localization.
Of note, exchanging the positions of the NLS with the
RevNES or the PKINES-impaired NES activity (Figure 1C and
data not shown) resulting in strictly nuclear fusion proteins,
most likely due to sterical interference between the NES and
the GFP.
The continuous shuttling of the transport sensors
was confirmed by treatment with the export inhibitor
leptomycin-B (LMB), resulting in their nuclear accumula-
tion (Figure 1B,D and Supplementary Table S2 online for
detailed values, available online at http://www.traffic.dk/
suppmat/6_7a.asp). The activity of the biosensor appeared
not to be cell-type specific, and translocation of the bio-
sensors could also be detected in non-adherent K562 cells
(Figure 1D). In addition, the localization was not affected
by fixation and storage of the cells prior to analysis (see
Supplementary Table S2 online for detailed values, avail-
able online at http://www.traffic.dk/suppmat/6_7a.asp).
For HCS (high content screening)/HTS assays, cell lines
inducibly expressing the biosensor are essential. Thus,
Knauer et al.
2 Traffic 2005; 6: 1–13we generated cell lines, in which the expression of the
transport sensors could be induced by the addition of
doxycycline (Dox) (Tet-on system). The induced sensors
retained the desired property of an efficient cytoplasmic to
nuclear transition following LMB treatment (Figure 1E–G
and Supplementary Table S2 online for detailed values,
available online at http://www.traffic.dk/suppmat/
6_7a.asp).
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Figure 1: Transport biosensors to
detect interference with nuclear
export. A) Schematic representation
of the transport sensors. B) In trans-
fected cells, the indicated sensor pro-
teins localized predominantly to the
cytoplasm and accumulated in the
nucleus following leptomycin-B
(LMB) treatment. C) In contrast,
t h ep 5 3 N E Ss e n s o ro rt h eR e v N E S -
GFP/GST-NLS fusion (RevNES-G/
G-NLS) localized predominantly in
the nucleus. D) Cytoplasmic-nuclear
translocation of the AblNES sensor
was detectable also in non-adherent
leukemia cells. Scale bars, 10 mm.
Dashed lines mark the cell boundaries
visualized from the corresponding
phase-contrast images. E) Inducible
expression of transport sensors in
stable cell lines. Cells cultured in the
presence or absence of doxycycline
were recorded using identical camera
settings. Upon LMB-treatment, the
cytoplasmic RevNES sensor accumu-
lated completely in the nucleus
after 2 h. Scale bar, 100 mm. F)
Translocation assay performed on an
automated platform for high-through-
put cell screening microscopy and
assay analysis. The total nuclear fluor-
escence in at least 200 sensor-expres-
sing cells from two independent
experiments was recorded before
and after the treatment with LMB for
2 h. Mean values   SD from two
independent experiments are shown.
G) To quantify the cytoplasmic to
nuclear translocation, the percentage
of cytoplasmic and nuclear fluores-
cence of the indicated biosensors in
inducible cell lines was determined
before and after the treatment, and
t h em e a nt r a n s l o c a t i o ni n d e xT i was
calculated. Error bars, SD.
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Traffic 2005; 6: 1–13 3Next, we tested the inducible RevNES- and the AblNES-
sensor on an automated platform for high-throughput cell
screening microscopy and assay analysis. Figure 1F demon-
strates that cytoplasmic to nuclear translocation of the
sensors following LMB treatment could be accurately and
reproducibly quantitated in an automated fashion.
To further investigate whether the biosensors are superior
in analyzing signal-specific translocation compared with
full-length GFP-fusions of the corresponding proteins
from which the signals originated, we quantitated the
translocation index Ti (difference of cytoplasmic signal
before and after inhibition of export) for the respective
proteins. As shown in Figure 2A, Rev14-GFP, PKI-BFP
(blue fluorescent protein) and STAT1-GFP localized predo-
minantly to the cytoplasm following transient expression
in HeLa cells and accumulated to various degrees in the
nucleus following LMB treatment. However, the translo-
cation index for the corresponding biosensors was signifi-
cantly higher and reached a maximum already 2 h after
treatment in contrast to the full-length GFP-fusions
(Figure 2B and Supplementary Table S2 online for detailed
values, available online at http://www.traffic.dk/suppmat/
6_7a.asp).
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Figure 2: A) Transport biosensors
are superior in studying signal-
specific transport compared with
full-length green fluorescent pro-
tein (GFP)-fusion. In transfected
HeLa cells, Rev14-GFP, Stat1-GFP
and PKI-BFP localized predominantly
to the cytoplasm (upper panel) and
accumulated to various degrees in
the nucleus following treatment with
leptomycin-B (LMB) for 6 h (lower
panel). Scale bar, 10 mm. B) To quan-
tify the cytoplasmic to nuclear translo-
cation, the percentage of cytoplasmic
and nuclear fluorescence was deter-
mined in several cell lines before and
after treatment (see Supplementary
T a b l eS 1o n l i n ef o rd e t a i l e dv a l u e s ,
available online at http://www.
traffic.dk/suppmat/6_7a.asp), and the
mean translocation index Tiwas calcu-
lated. Error bars, SD. C) Transport
biosensors to identify import inhibi-
tors. Microinjection of Texas Red-
conjugated WGA into a RevNES
sensor-expressing cell (marked by the
asterisk) inhibited nuclear import and
prevented LMB-induced nuclear
accumulation of the sensor protein,
whichwasobservedforanon-injected
control cell (marked by the arrow).
Scale bar, 10 mm.
Knauer et al.
4 Traffic 2005; 6: 1–13To date, no specific small molecular weight nuclear
import inhibitors are available. To test whether the bio-
sensors can be used to also identify compounds inter-
fering with nuclear import, wheat germ agglutinin (WGA)
was microinjected into the nucleus of cells expressing
the RevNES-sensor, and cells were subsequently treated
with LMB. Wheat germ agglutinin interferes with nuclear
import by binding to nucleoporins (7). As depicted in
Figure 2C, nuclear import of the biosensor was inhibited
in injected cells in contrast to control cells. Thus, com-
pounds that preserve the cytoplasmic localization of the
biosensors after the subsequent addition of nuclear
export inhibitors can be annotated as nuclear import
inhibitors.
96-well plate assays to screen for drugs or proteins
that interfere with nucleo-cytoplasmic transport
To demonstrate the applicability of the transport sensors
for HTS assays, we performed screening experiments in
96-well plates. Expression of the respective transport
biosensors was induced by Dox, and cells were subse-
quently incubated with drugs, which previously have
been reported to affect nucleo-cytoplasmic transport
(see Supplementary Table S3 online for details, available
online at http://www.traffic.dk/suppmat/6_7a.asp).
Interestingly, of the tested substances, only the
Exportin 1 targeting compounds LMB and RatA caused
nuclear accumulation of all transport sensors. Although
prolonged treatment with taxol or nocodazol for 16 h
caused cell rounding and partial detachment, the trans-
port sensors still remained cytoplasmic (Supplementary
Figure S1A, available online at http://www.traffic.dk/
suppmat/6_7a.asp). To investigate whether drug treat-
ment affected nuclear import, compound treated cells
were subsequently incubated with LMB. The resulting
nuclear accumulation of the sensors indicated that the
tested substances did not significantly interfere with
import (Supplementary Figure S1A and Supplementary
Table S3 online for details, available online at http://
www.traffic.dk/suppmat/6_7a.asp).
The intracellular localization of a shuttle protein may also
be influenced in trans by interacting proteins or by pro-
teins interfering with the transport machinery. As an
example for a genetic screen, we investigated whether
translocation of the transport sensors was affected by
overexpressing proteins in trans. Transfection of several
expression constructs (see Supplementary Table S3 online
for details, available online at http://www.traffic.dk/
suppmat/6_7a.asp) revealed that the overexpression of
PKI-BFP and the C-terminal part of Nup214 affected
nuclear export as previously reported (7) and caused nuclear
accumulation of all sensor constructs (see Supplementary
Figure S1B and Supplementary Table S3, available online at
http://www.traffic.dk/suppmat/6_7a.asp). Transfected cells
were treated with LMB to investigate whether the
overexpression of the indicated proteins in trans interfered
with nuclear import. As summarized in Supplementary
Table S3, all sensor proteins accumulated in the nucleus
upon LMB treatment arguing against negative effects of
the overexpressed proteins on nuclear import.
Biosensors for protease and apoptosis research
The robust performance of the translocation sensors was
further exploited by the development into protease bio-
sensors. Weincorporated the poly(ADP-ribose)-polymerase
(PARP) cleavage site for Caspase 3 (CS3) N-terminal to the
Myc-epitope-RevNES resulting in an NLS-GFP/GST-
CS3-RevNES fusion protein (Casp3-sensor) (Figure 3A).
Upon transient expression, the Casp3-sensor localized
predominantly to the cytoplasm in HeLa cells (see
Supplementary Table S2 online for values, available online
at http://www.traffic.dk/suppmat/6_7a.asp). Induction of
apoptosis by treatment with staurosporin-induced caspase
activity, which resulted in the cleavage of the Myc-
epitope-RevNES and the subsequent nuclear accumula-
tion of the Casp3-sensor in early apoptotic, TdT-mediated
biotin – dUTP nick-end labelling (TUNEL)-positive cells
(Figure 3B). In non-apoptotic, TUNEL-negative cells, no
change in localization was observed (Figure 3B, cells
marked by the arrow). As a control, a construct containing
a non-functional Casp3 cleavage site (Casp3mut-sensor)
remained cytoplasmic under identical experimental condi-
tions, indicating that nuclear accumulation was not caused
by unspecific interference with nuclear export (Figure 3B).
Of note, in late apoptotic cells, the Casp3-sensor was
equally distributed throughout the cell due to the loss of
the integrity of the nuclear membrane (data not shown).
Proteolytic cleavage was verified by staining with an anti-
Myc antibody. The cytoplasmic Casp3-sensor was detect-
able by anti-Myc staining in non-apoptotic cells, whereas
caspase activation resulted in the cleavage of the Myc-
epitope-RevNES, and thus, the nuclear Casp3-sensor
could no longer be detected by the anti-Myc antibody
(Figure 3D). To underline the performance of the Casp3-
sensor, we performed a comparison with a commercially
available apoptosis indicator composed of the MAPKK
NES, CS3, GFP and three copies of the SV40 NLS
(MKNES-CS3-GFP-NLS). In contrast to the Casp3-sensor,
a significant amount of the MKNES-CS3-GFP-NLS was
already detectable in the nucleus prior to induction of
apoptosis (see Supplementary Table S2 online for values,
available online at http://www.traffic.dk/suppmat/
6_7a.asp), and the indicator accumulated less efficiently
in the nucleus after staurosporin treatment (Figure 3B).
Consequently, the nuclear translocation index was
significantly higher for the Casp3-sensor upon induction
of apoptosis (Figure 3C). This difference was most likely
caused by the passive diffusion of GFP in combination
with the weaker activity of the MAPKK NES compared
to the Rev NES (see Supplementary Table S1, available
online at http://www.traffic.dk/suppmat/6_7a.asp) and the
Translocation-Based Chemical Genetic Screening Assays
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Figure 3: Induction of apoptosis
resulted in proteolytic cleavage
and nuclear accumulation of the
Casp3-biosensor. A) Schematic
representation of the Casp3-sensor.
B) Cells expressing the indicated plas-
mids were treated with staurosporin
to induce apoptosis. In TdT-mediated
biotin–dUTP nick-end labelling-positive
apoptotic cells (red, lower panel), the
Casp3-sensor accumulated in the
nucleus in contrast to non-apoptotic
cells (marked by the arrow) (left
panel). The MKNES-CS3-GFP-NLS
protein accumulated less efficiently in
thenucleusanddisplayedadetectable
nuclear localization in non-apoptotic
cells (middle panel). As a control,
the Casp3mut sensor containing a
non-functional Casp3-recognition site
remained cytoplasmic (right panel).
Scale bar, 10 mm. C) To quantify the
cytoplasmic to nuclear translocation of
thebiosensors,thetranslocationindex
Ti was calculated. Mean values   SD
from two independent experiments.
D) The cytoplasmic Casp3 sensor
w a sd e t e c t a b l eb ys t a i n i n gw i t ht h e
anti-Myc antibody in non-apoptotic
cells. Caspase activation resulted in
the cleavage of the Myc-epitope-
RevNES, and thus, the Casp3 sensor
in the nucleus was no longer
detectable.
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6 Traffic 2005; 6: 1–13presence of three copies of the SV40 NLS in the
MKNES-CS3-GFP-NLS construct.
Facile cellular biosensors to visualize specific protein–
protein interaction in vivo
A facile and reliable system that allows visualizing protein
interactions in living cells applicable also for drug
screening CBAs has to fulfill the following criteria: (i) the
GFP-tagged molecule I (GFP-prey), although continuously
shuttling between the nucleus and the cytoplasm, should
localize predominantly to the cytoplasm, (ii) the BFP-
tagged molecule II (BFP-bait) should be confined to the
nucleus, (iii) upon specific protein interaction between
molecule I and II, the GFP-prey should redistribute to the
nucleus and colocalize with the BFP-bait, (iv) the system
should be reversible and should allow the modular
exchange of interaction domains (IDs) and (v) inhibitors/
inductors of protein interactions should prevent/induce the
cytoplasmic to nuclear translocation.
Because the RevNES translocation sensor fulfilled all the
quality criteria of a GFP-prey, we engineered a cassette that
allows the expression of any open reading frame (ORF) X
as a NLS-GFP/GST-X-RevNES fusion protein (GFP-prey).
Our previous work (23) demonstrated that a NES-deficient
HIV-1 Rev BFP fusion (RevM10-BFP) localized to the
nucleolus and thus represented an ideal frame to express
nucleolar anchored Y-BFP fusion proteins (BFP-bait).
To demonstrate that our system was applicable for the
analysis of protein IDs, we first tested the bZip IDs of Jun
and Fos and the bHLHZip IDs of Myc and Max in our
assay. We found that the NLS-GFP/GST-JunbZip-RevNES
fusion (GFP-prey_Jun) localized predominantly to the cyto-
plasm in the presence of the empty BFP-bait (Figures 4A
and 6C). In contrast, coexpression of the FosbZip-
RevM10-BFP protein (Fos_BFP-bait) resulted in the
colocalization of the GFP-prey_Jun fusion with the
Fos_BFP-bait at the nucleolus (Figures 4B and 6C).
Similar results were obtained for the Myc and Max
bHLHZip IDs (Figures 4A,B and 6C) and could be con-
firmed in MCF7, 293 and non-adherent K562 cells (data
not shown). As a control, we switched the Jun/Fos IDs in
the prey and bait constructs which resulted in a similar
prey-redistribution upon coexpression (Figure 4C, left
panel). Importantly, we did not observe protein interaction
upon coexpression of the GFP-prey_Jun together with the
Max_BFP-bait (Figures 4C, middle panel, and 6C) or of the
GFP-prey_Myc together with the Fos_BFP-bait
(Figures 4C, right panel, and 6C), which underlined the
specificity of the interaction assay. To further investigate
whether our system was also applicable for non-leucine
zipper mediated protein interactions, we tested the p53/
mdm2 IDs. The GFP-prey_mdm2 fusion localized to the
cytoplasm and colocalized with the p53_BFP-bait but not
with the empty BFP-bait at the nucleolus upon coexpres-
sion (Figures 4A,B and 6C).
The routine use of live cell assays to analyze protein–
protein interaction requires that the system is robust and
does not depend on demanding technological assay
platforms. We compared the translocation biosensors
to bimolecular fluorescence complementation (BiFC) by
cotransfecting equal amounts of the GFP-prey_Jun and
Fos_BFP-bait or the FosGC and JunGN expression plasmids
into HeLa cells together with a red fluorescent protein
(RFP) expression construct as the transfection control.
Quantitation of the number of RFP-positive cells also
displaying nuclear GFP-fluorescence, indicative for active
protein interaction (Figure 5A), revealed that not only the
number of individual protein interaction events but also
the average fluorescence signal was significantly higher for
the translocation assay (TA) compared with that for the
BiFC (Figure 5A,B). Equal transfection efficiencies and
expression levels were confirmed by immunoblot analysis
of the respective GFP-fusion proteins (data not shown).
The protein interaction assay is reversible and suited
for the identification of small molecule protein
interaction inhibitors (SMPIIs)
Besides efficacy and specificity, reversibility is an import-
ant criterion for cellular protein interaction assays. We
confirmed the reversibility of our assay by overexpressing
the untagged Fos leucine zipper (Fos bZip) in cells coex-
pressing GFP-prey_Jun and Fos_BFP-bait, which resulted
in a significantly reduced nucleolar colocalization of the
GFP-prey_Jun protein (Figure 6A,C). Similar results were
obtained in competition experiments for the Myc and Max
IDs using the untagged Max-bHLHZip (Figure 6C).
As a case study for the application of a SMPPII, we
attempted to disrupt the p53/mdm2 interaction by micro-
injection of a synthetic peptide (comP) or an inactive
scrambled control peptide (comPmut) into the nucleus of
GFP-prey_mdm2 and p53_BFP-bait coexpressing cells.
The comP peptide had been described as an inhibitor of
p53/mdm2 interaction in vitro (18). Injection of comP
interfered with p53/mdm2 ID interaction, resulting in a
significantly cytoplasmic redistribution of the GFP-
prey_mdm2, in contrast to non-injected cells or cells
injected with comPmut (Figure 6B, lower panel, and 6C).
Of note, comP injection had no effect on Jun/Fos com-
plexes (data not shown), excluding the possibility that the
GFP-prey_mdm2 redistribution was caused by comP-
mediated inhibition of nuclear import.
Discussion
Despite intense investigation, the detailed molecular
mechanism regulating the orchestration of nucleo-cytoplasmic
transport is still not completely understood. Thus, in
addition to biochemical studies, systematic cell-based
chemical-genetic screens need to be applied to unravel
novel regulatory mechanism and to clarify cargo
specificity.
Translocation-Based Chemical Genetic Screening Assays
Traffic 2005; 6: 1–13 7Although nucleo-cytoplasmic TAs using GFP-fusions have
been described (see (8), and references therein), this strat-
egy is not generally applicable for every protein and often
not suited for the development of systematic HCS/HTS
assays. Firstly, applications are hampered by either the
inability to generate cell lines stably overexpressing
the particular GFP-fusion protein due to its toxicity and/or
the inefficient cytoplasmic-nuclear redistribution, which
makes fast and reliable automatic detection and analysis
difficult. These limitations are exemplified by investigating
the cytoplasmic nuclear translocation of the HIV-1 Rev-,
the PKI- and the STAT1-GFP fusions. The lower Tis were
caused by the lack/inaccessibility of an efficient nuclear
import signal and/or interference by passive diffusion due
to the small size of the fusion proteins. Secondly, the GFP
TAs reported so far did not allow to discriminate whether
export inhibition was caused by unspecific interference
with the export machinery, by binding to the NES, by
induction of intramolecular conformational changes or
indirectly by affecting proteins that interact with the target
protein in trans. Kau et al. (24) used a FOXO1a immuno-
fluorescence translocation screen to identify compounds
that caused FOXO1a nuclear accumulation. Additional
assays were required to show that one class of com-
pounds was indirectly interfering with FOXO1a transport
by inhibiting PI3K/Akt signaling in general. The other class
of compounds reacted with Exportin 1 and thus repre-
sents unspecific export inhibitors similar to other drugs
Jun A
B
C
G
F
P
B
F
P
G
F
P
B
F
P
G
F
P
B
F
P
Myc mdm2
P
r
e
y
B
a
i
t
 
c
o
n
t
r
o
l
P
r
e
y
B
a
i
t
 
P
r
e
y
B
a
i
t
 
J
u
n
/
M
y
c
/
m
d
m
2
G
S
T
G
S
T
G
S
T
G
S
T
R
e
v
R
e
v
R
e
v
R
e
v
J
u
n
/
M
y
c
/
m
d
m
2
J
u
n
/
M
y
c
J
u
n
Jun
Hela
Hela
Hela
Jun
Jun
Fos
F
o
s
F
o
s
/
M
a
x
/
p
5
3
M
a
x
/
F
o
s
Fos
Fos
Max
Max
p53
Myc
Myc
mdm2
Figure 4: Application of the auto-
fluorescent protein-based inter-
action biosensors to visualize
specific protein–protein inter-
action in vivo. HeLa cells coexpres-
sing the indicated prey/bait proteins
were analyzed by fluorescence
microscopy. A)Thegreenfluorescent
protein (GFP)-prey proteins localized
predominantly to the cytoplasm
(upper panel), and no colocalization
was detectable by coexpression of
the empty BFP-bait proteins (lower
panel). B) In contrast, the GFP-prey
proteins accumulated in the nucleus/
nucleolus upon coexpression of the
matching BFP-bait interaction part-
ners. C) Domain swapping in the
GFP-prey/BFP-bait constructs also
resulted in efficient Fos/Jun protein
interaction (left column). No signifi-
cant colocalization was detectable
by coexpression of GFP-prey_Jun
and Max_BFP-bait or GFP-prey_Myc
and Fos_BFP-bait fusion proteins
(middle and right column). Scale
bars, 10 mm4. c: nuclear localization
signal, b: nuclear export signal.
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8 Traffic 2005; 6: 1–13reported (25,26). Exportin 1 inhibitors can most likely not
be used in target-specific therapeutic applications due to
their toxic side-effects by blocking all cellular Exportin
1-mediated transport pathways.Therefore, protein-specific
transport inhibitors are urgently needed. Because NESs
can be grouped into specific categories according to their
activity in vivo, these differences represent an attractive
opportunity to selectively interfere with export and the
biological functions of proteins by the generation of NES-
specific inhibitors. The developed sensor system allows
the modular integration of any specific transport signal into
a constant protein backbone to now identify signal-specific
inhibitors by a systematic screening of compound
libraries. In contrast to other assays (24,27), the sensors
were not restricted to a specific cell type, displayed a high
translocation index and allowed the generation of inducible
stable cell lines.
As a case study, we screened compounds that have been
reported previously to affect nucleo-cytoplasmic transport
including inhibitors of receptor signaling pathways
(24,28,29), drugs, which affected the cytoskeleton
(30,31), inhibitors of epigenetic regulators (32), transcrip-
tion inhibitors (6) and inductors of apoptosis (see
Supplementary Table S3, available online at http://
www.traffic.dk/suppmat/6_7a.asp). In summary, we
found that only drugs, which directly inactivated Exportin
1 inhibited nuclear export of all translocation sensors,
indicating that the other compounds tested neither
directly affected the transport machinery nor displayed
any specificity for transport signals.
Because intracellular transport of proteins is not only regu-
lated by specific signals but may also be influenced in
trans by interacting proteins or by proteins interfering
with the transport machinery, systematic genetic screens
can be used to identify novel proteins engaged in intracel-
lular transport networks. Of the randomly selected expres-
sion constructs, the overexpression of the C-terminal part
of Nup214 affected nuclear export of all sensor con-
structs. Although it was reported that Nup214 is involved
in the specific transport of the HIV-1 Rev protein (33) or of
STAT1 (4), our data support the previous notion that over-
expression of xFxFG-repeat containing nucleoporins
unspecifically inhibits the nuclear export machinery (34).
Thus, although suggested (9), components of the NPC
appear not to represent pathway-specific drug targets.
In conclusion, the designed transport sensors will allow
directly investigating the effects of drug treatment or of
over-expression/conditional knock-down of proteins on
general and signal-specific nucleo-cytoplasmic transport. The
sensorswerefunctionalinchemicalscreensandcouldalsobe
used on a fully automated platform for high-throughput
cell screening microscopy and assay analysis, which is an
essential requirement for their practical use in HTS assays.
To further exploit the common principle of cytoplasmic to
nuclear translocation, the transport sensors were developed
into protease biosensors. Because caspases are central
players in several pathological states, we investigated the
applicability of our principle by the generation of a caspase
biosensor. Numerous in vitro and in vivo caspase assays have
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Figure 5: The autofluorescent pro-
tein-based protein–protein inter-
action assay is superior to
bimolecular fluorescence comple-
mentation. HeLa cells were cotrans-
fected with 1 mgo fe a c ho ft h eg r e e n
fluorescent protein (GFP)-prey_Jun and
Fos_BFP-bait or the FosGC and JunGN
expression plasmids, respectively,
together with 1 mg of the red fluores-
cent protein (RFP)-expression plasmid
and analyzed by fluorescence micro-
scopy. Cells were recorded using iden-
tical camera settings. A significantly
higher percentage of RFP-positive
cells displaying also nuclear GFP-
fluorescencewasobservedforthetrans-
location assay (TA). A) Representative
fields are shown. B) To quantify the
number of protein interaction
events, 200 cells from three separ-
ate images were inspected, and the
number of RFP-positive cells, in
which nuclear GFP fluorescence
could be detected, was counted.
Mean values   SD from two indepen-
dent experiments. Scale bars, 100 mm.
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Traffic 2005; 6: 1–13 9been developed to date, including the application of
fluorochrome-labeled inhibitors of caspases (35), fluorescence
resonance energy transfer (FRET) (36) or even caspase-
mediated activation of luciferase in whole animals (37).
Analysis of caspase activity in intact cells, however, is
often limited to the measurement of end-point apoptosis
markers. In contrast, induction of apoptosis resulted in the
cleavage of the RevNES and the nuclear accumulation of
the Casp3-sensor already early in the cell death cascade. A
commercially available indicator that is also based on the
induction of nuclear accumulation upon proteolytic cleav-
age displayed a lower Ti and thus appears to be less
applicable for CBAs. Our results suggest the use of the
described protease biosensor to investigate caspase activ-
ity in real time and to study novel inhibitors or inductors of
apoptosis in the context of an intact cellular environment.
In addition, the modular composition of the translocation
sensor implies that the system is readily adaptable for use
with additional protease targets (e.g. HIV-1 protease).
A major emphasis of proteomic research and systems
biology is the mapping and validation of protein interaction
networks [(38,39) and references therein]. In addition, it
has been acknowledged that molecules, which modulate
protein–protein interactions may have great potential as
therapeutics (40). Methods to study protein interactions in
living cells or whole animals involve the yeast two hybrid
(YTH) system, inter- and intramolecular FRET, BiFC as well
as several split-enzyme complementation/reconstitution
assays [(41) and references therein]. Although these vari-
ous methods have been proven as valuable tools, several
intrinsic limitations apply [see (42) and references within].
For example, the YTH detects only protein interactions in
the nucleus of yeast cells, and potential interactions have
to be verified assiduously in mammalian cellular systems.
Although BiFC represents a powerful method, the effi-
ciency and signal intensity are low, which was also
demonstrated in our study. In addition, BiFC depends on
the proper orientation of the two AFP fragments, and the
likelihood of complementation is expected to decrease
with protein size and distinct intracellular localization of
the interaction partners, which will limit its application for
the characterization of high molecular weight complexes.
Moreover, BiFC as well as other reconstitution/comple-
mentation assays appear to be irreversible (12), which
hampers the screening for inhibitory protein interaction
decoys. Likewise, the efficiency of FRET in cellular assays
is often inefficient, affected by background fluorescence
and requires demanding technological assay and analysis
platforms in order to perform HTS. All these limitations do
not apply to the described AFP-based cellular ‘‘two
hybrid’’ interaction system, which proved to be effective
for different classes of protein IDs. The cytoplasmic to
nucleolar redistribution of the sensors was easily
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by the arrow). B) Application of a synthetic peptide competitor (comP) to inhibit the p53/mdm2 interaction. GFP-prey_mdm2- and
p53_BFP-bait-coexpressing cells were microinjected with the rhodamine-conjugated peptides and analyzed 4 h later. Injection of comP
interfered with protein interaction resulting in a significant cytoplasmic redistribution of GFP-prey_mdm2 (upper panel) in contrast to non-
injected cells (marked by the arrow) or cells injected with the control peptide comPmut (lower panel). Scale bars, 10 mm. C) To quantify
the degree of protein interaction, 200 cells coexpressing the indicated GFP-prey and BFP-bait proteins together with the indicated
competitors were inspected. The percentage of cells in which BFP and GFP colocalized in the nucleolus was determined. Mean
values   SD from two independent experiments.
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depend on specific linker sequences for functionality.
Importantly, the distinct intranuclear colocalization pat-
terns observed were characteristic for the IDs used,
and in the case of the Myc-Max Ids, a similar granular
pattern was exhibited as reported for full-length Myc-
Max heterodimers (43). This suggests that the IDs dis-
played by the prey/bait backbone can mimic the confor-
mation of the IDs in the full-length proteins in vivo. This
assumption is supported by the report of Berg et al. (44),
who used in vitro FRET assays to identify SMPPIIs inter-
fering with Myc/Max ID dimerization. Importantly, the
identified compounds also inhibited Myc-induced onco-
genic transformation but were not entirely specific and
also extended to Jun. Because we observe neither Myc/
Fos nor Max/Jun interaction, our in vivo assay could dis-
criminate between different classes of leucine zipper IDs
and therefore represents an ideal screening tool to iden-
tify ID-specific inhibitors. Besides specificity, reversibility
is an important issue in CBAs to identify potent SMPIIs.
Overexpression of the untagged Fos or Max IDs was able
to chase the respective prey fusion proteins of the Jun/
Fos or Myc/Max complexes, and microinjection of an in
vitro inhibitory peptide was able to successfully compete
with the p53/mdm2 ID interaction in vivo.
In addition, because the majority of GFP-prey fusions are
not expected to intrinsically localize to the nucleolus or
nuclear structures, our system is applicable for a wide
variety of proteins.
In summary, the assays presented proved flexible, robust,
facile and highly amenable to academic scale screens with
the potential to be employed in novel drug-screening appli-
cations, in particular, when combined with biochemical
assays. Efficient nuclear accumulation served as the reli-
able indicator for all biosensors (see Supplementary Figure
S2 online, available online at http://www.traffic.dk/
suppmat/6_7a.asp) and thus facilitates fully automated
image acquisition and data analysis using commercial
and academic microscopy assay platforms. The modular
composition of the biosensors guarantees their adoption
and thus application in numerous biological systems.
Methods
Plasmids
To construct pc3GFP/GST, the coding region for GST was polymerase
chain reaction (PCR) amplified using primers containing KpnI-restriction
sites, pGEX-GFP (45) as the template and cloned into the vector pc3-GFP
(45). Subsequently, complementary oligonucleotides encoding the SV40
NLS and the NES of the PKI, of the HIV-1 Rev, of the STAT1, of the Bcr-Abl
or of the p53 protein (see Supplementary Table S1, available online at
http://www.traffic.dk/suppmat/6_7a.asp) were cloned into the HindIII-/
BamHI-o rt h eKpnI-/EcoRI-restriction sites, respectively, to generate pNLS-
GFP/GST-PKINES, pNLS-GFP/GST-RevNES, pNLS-GFP/GST-StatNES,
pNLS-GFP/GST-AblNES, pNLS-GFP/GST-p53NES, pRevNES-GFP/GST-
NLS and pPKINES-GFP/GST-NLS. Plasmids pTRE-NLS-GFP/GST-RevNES,
pTRE-NLS-GFP/GST-Stat1NES and pTRE-NLS-GFP/GST-AblNES allow the
inducible expression of the GFP-biosensors. The cytomegalovirus-promoter
in the respective pc3 expression plasmids was therefore replaced by the
tetracycline-regulated promoter using HindIII/BamHI-restriction sites and
vector pTRE-d2EGFP.1 (BD Biosciences, San Jose, CA, USA) as the tem-
plate for PCR amplification. The protease sensor expression vector, pNLS-
GFP/GST-CS3-RevNES, was constructed by inserting the PARP Casp3
cleavage recognition site (CS3) (KRKGDEVDGVDE) N-terminal to the
RevNES using complementary oligonucleotides containing NotI- and
XhoI-restriction sites, and subsequently, the Myc-epitope was inserted
into the XhoI-restriction site using complementary oligonucleotides.
pNLS-GFP/GST-CS3m-RevNES encodes a fusion protein containing a
non-functional CS3 (KRKGAEVAGVDE). Plasmids pNLS-GFP/GST-
bZipJun-RevNES, pNLS-GFP/GST-bZipFos-RevNES, pNLS-GFP/GST-
HZipMyc-RevNES, GFP/GST-HZipMax-RevNES, pNLS-GFP/GST-p53-
RevNES and pNLS-GFP/GST-mdm2-RevNES encode NLS-GFP/GST-ID-
RevNES fusions, containing the IDs of human Jun (aa 222–331), of
human Fos (aa 118–209), of human Myc (aa 354–434), of the rat Max
(aa 13–93), of the human p53 (aa 2–42) and of the human mdm2 protein
(aa 1–118). The expression vectors were constructed by inserting the IDs
N-terminal to the RevNES by PCR amplifying the respective domains
(44,45) using oligonucleotides containing NotI- and XhoI-restriction sites.
pRevM10-BFP encodes a NES-deficient HIV-1 Rev-blue fluorescent fusion
protein (RevM10-BFP) (23). Plasmids pFos-RevM10-BFP, pJun-RevM10-
BFP, pMyc-RevM10-BFP, pMax-RevM10-BFP, pp53-RevM10-BFP and
pmdm2-RevM10-BFP encode N-terminal fusions of the respective protein
IDs and RevM10-BFP. Plasmids were constructed by PCR amplification
and cloning of the IDs 5´- to the Rev ORF by using oligonucleotides
containing KpnI-restriction sites. pc3Fos-bZip and pc3Max-HZip encode
the untagged Fos bZip or the Max bHLHZip IDs, respectively, and were
constructed by PCR amplifying the IDs using oligonucleotides containing
HindIII-/BamHI-restriction sites and cloning into pc3 (45). Nuclear export/
import signals (Supplementary Table S1, available online at http://
www.traffic.dk/suppmat/6_7a.asp) were cloned into the bacterial expres-
sion vector pGEX-GFP as described (7). For details on previously described
expression plasmids, see Supplementary Online Methods, available online
at http://www.traffic.dk/suppmat/6_7a.asp.
Cell culture, microinjection and fluorescence imaging
of cells
Vero, 293, MCF7, HLR9, HeLa and K562 human chronic myelogenous
leukemia lymphoblast cell lines were maintained under conditions
recommended by the American Type Tissue Culture. Cells were
transfected or microinjected and observed as described (46). Twelve-
bit black and white images were captured using a digital Axiocam CCD
camera (Carl Zeiss, Jena, Germany). Quantitation, image analysis and
presentation were performed using IPLab Spectrum (Scanalytics,
Fairfax, VA, USA) and Axiovision software (Carl Zeiss). The total cellular
GFP signal was measured by calculating the integrated pixel intensity in
the imaged cell multiplied by the area of the cell. The nuclear signal
was similarly obtained by measuring the pixel intensity in the nucleus.
Nuclei were marked by staining with Hoechst 33258 (Sigma Aldrich,
Munich, Germany) as described (45) or stained with TO-PRO
TM-3-iodide
(Molecular Probes, Eugene, OR, USA) according to the manufacturer’s
recommendations. The cytoplasmic signal was calculated by subtracting
the nuclear signal from the total cellular signal. All pixel values were
measured below the saturation limits and the background signal in an
area with no cells was subtracted from all values. To determine the
average intracellular protein localization, at least 200 fluorescent cells
from three separate images were examined. The number of cells exhib-
iting cytoplasmic (C; cytoplasmic signal >80% of the total cellular sig-
nal), cytoplasmic and nuclear (C/N) or nuclear (N; nuclear signal >80%
of the total cellular signal) fluorescence was counted, the percentages
of C, N/C and N cells were calculated, and standard deviations were
determined. To quantitate the efficiency of cytoplasmic to nuclear redis-
tribution, the difference between the percentages of the cytoplasmic
signal before (Cb)a n da f t e r( C a) the treatment was calculated in 100
cells resulting in the translocation index Ti. To quantify the degree of
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which BFP and GFP colocalized to the nucleus from three separate
images was determined with standard deviations.
To compare the protein translocation biosensors and BiFC, 200 cells from
three separate images were inspected, and the number of RFP-positive
cells in which nuclear GFP fluorescence could be detected using equal
CCD-camera settings was counted.
Automated image acquisition and analysis
For automated image acquisition on a fully automated screening micro-
scope, cells were seeded in Laboratory-Tek eight-well chamber slides
(Nunc, Wiesbaden, Germany). Following treatment, cells were fixed, and
nuclei were marked by staining with Hoechst 33258. Data acquisition and
analysis were performed as described (47). Briefly, images were acquired
with an Orca
TM-cooled CCD camera (Hamamatsu, Bridgewater, NJ, USA)
OLYMPUS IX81 microscope (Olympus Biosystems, Munich, Germany).
Camera and shutter were triggered via a real-time controller for fast data
acquisition and ultra precise camera integration. The set-up was controlled
by custom-made software (Olympus Biosystems). A cell detecting auto-
focus was used for every field of view. Cell detection during image acquis-
ition was based on object intensity, size (min, max) and contrast (frequency
analysis) information. The focal plane with the maximum number of ‘‘in
focus objects’’ was imaged. Relative z-shifts were used between the
different color channels to compensate focus differences. Images, contain-
ing also meta information (filter cubes, integration times and position),
were stored as TIFF files in a hierarchical file structure. Image analysis
was done with custom-made scripts written in Labview Vision
TM (National
Instruments, Munich, Germany & Olympus Biosystems). Cell nuclei detec-
tion was performed using the Labview Vision
TM threshold-based particle
feature. Cytosol was measured via symmetrical extension of the nucleus
(dilation), and ratios were generated accordingly. Detailed information can
also be found at www.embl.de/~liebel.
Generation of stable cell lines
To generate cell clones allowing the inducible expression of the GFP-
biosensors, HLR9 cells (HeLa Tet-On) transfected with the respective
pTRE expression vectors together with pBABE were grown in the pres-
ence of 500 mg/mL G418 and 2 mg/mL puromycin (Sigma Aldrich). Pooled
G418/puromycin-resistant colonies were cultured in medium containing
1 mg/mL Dox (Sigma Aldrich) to induce expression of the GFP-fusion pro-
teins. Fluorescent clones were isolated by fluorescence-activated cell sort-
ing and cloned twice by limited dilution.
96-well plate assays
HLR9 cell lines expressing the indicated transport sensors were cultured in
the absence of Dox and plated into black-walled 96-well clear-bottomed
plates (Corning, Acton, MA, USA) at a density of 3000 cells/well in Dox-
containingmedium(1 mg/mL).After16 h,cellsweretransfectedorincubated
in media containing the specified drugs (see Supplementary Table S3 online
for details, available online at http://www.traffic.dk/suppmat/6_7a.asp) and
inspectedby fluorescence microscopy. For eachexperiment,twowells were
drug treated, and each experiment was performed in duplicates.
Microinjection of synthetic peptides
The synthetic rhodamine B-conjugated fluorescent peptide comP (Ac-Met-
Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-NH2) or a scrambled control
peptide comPmut with the identical aa composition (Ac-Met-Tyr-Pro-Arg-
Met-Phe-Asp-Trp-Glu-Leu-Gly-Asn-NH2) (Thermo Electron, Waltham, MA,
USA) were microinjected for competition experiments at a concentration of
2 mg/mL. Microinjection of the synthetic peptides, IgG or Texas Red-
conjugated WGA (Molecular Probes) was performed as described (46).
Apoptosis assay
To induce apoptosis, cells were treated with staurosporin (1 mM) for 6 h.
Apoptosis was assessed by labeling free 3´OH ends in genomic DNA with
rhodamine-dUTP (TUNEL-staining) using the in situ cell death detection kit
(Roche Diagnostics, Basel, Switzerland).
Immunoprecipitation, immunoblotting and
immunofluorescence
5   10
5 HeLa cells were transfected with the indicated plasmids. Whole
cell lysates and immunoprecipitation of GST fusion proteins from cellular
lysates using a monoclonal anti-GST antibody (Abcam, Cambridge, UK) as
well as analysis of the complexes by SDS-PAGE and immunoblotting using
polyclonal anti-GFP antibodies (BD Biosciences) were performed as
described (46). Immunofluorescence was carried out according to standard
procedures as described previously (7). Myc-epitope-tagged proteins were
detected using a monoclonal antibody (Cell Signaling Technology, Beverly,
MA, USA).
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Supplementary Methods
Plasmids
Plasmid p3-Exportin 1-HA, encoding HA-tagged Exportin 1 (7), pc3-E1B55K, encoding the
Adenovirus type 5 E1B-55K protein (45), pc3-Vpr, encoding the HIV-1 Vpr protein (48), pc3-
GR, encoding the human glucocorticoid receptor alpha (48), pc3-PKI-BFP, encoding a PKI-
BFP fusion (7), pc3eIF-5A, encoding the eukaryotic initiation factor 5A (eIF-5A) (45), pc3p53,
encoding human p53 (45), pc3mdm2, encoding the human mdm2 protein (45), pc3-E1BAP5,
encoding the human E1B-AP5 protein (45), p3CANc/VSV-G, encoding the carboxy terminus
of CAN/Nup214 (7) have been described. Plasmid pBrev14-GFP produces a cytoplasmic
Rev-GFP mutant (Rev14-GFP) (23). pSTAT1-GFP encodes a human STAT1-GFP fusion (4).
pDS-RED-N1 encodes the red-fluorescent protein (RFP) (BD Biosciences). pBABE confers
puromycin  resistance.  pCaspase3-Sensor  (BD  Biosciences)  encodes  a  fusion  protein
composed of the mitogen-activated kinase kinase (MAPKK) NES (26), followed by CS3, GFP
and three copies of the SV40 NLS. pHA-CMV-bFosGC (FosGC) and pFLAG-CMV2-bJunYN
(JunGN), encoding the IDs of human Fos and Jun fused to a C- (aa 155-238) or N-terminal
(aa 1-154) fragment of GFP, respectively, have been described (12).Supplementary Online Tables
Supplementary Table S1
Sequence  and  activity  of  the  nuclear  transport  signals  quantified  by  microinjection  of
recombinant GST-GFP-NES or -NLS substrates.
Signal Sequence Import/export activity
SV40 NLS PPKKKRKVEDP 60+/- 5 min/neg.
PKI-NES LALKLAGLDI neg./5+/- 2 min
HIV-1 Rev NES LQLPPLERLTL neg./15+/- 3 min
STAT1 NES LAAEFRHLQL neg./20+/- 3 min
Abl NES LENNLRELQI neg./30+/- 5 min
MAPKK NES LQKKLEELEL neg./40+/- 3 min
p53 NES MFRELNEALEL neg./14+/- 1 h
Supplementary Table S2
Quantitation of the intracellular localization and of the translocation index Ti  of the tested
transport sensors in several cell lines (see Methods for details). H: HeLa, M: MCF-7, K:
K562, H9: HRL9; SP: staurosporin.
Sensor %C %C/N %N Ti (in %)
RevNES-sensor
96,8±2,4  (H),  95,1±2,9
(M), 89,6±4,1 (K)
2,3±1 (H), 3,1±2,0 (M),
6,4±2,9 (K)
0,9±0  (H),  1,8±1,1  (M),
4,0±1,6 (K)
RevNES-sensor
+LMB
0,7±0,5 (H), 1,0±0,9 (M),
2,5±1,3 (K)
2,7±1,4 (H), 1,9±1,2 (M),
6,2±2,0 (K)
96,6±1,2  (H),  97,1±3,5
(M), 91,3±2,7 (K)
93,1± 3,9 (H)
92,3±4,1 (M)
86,9±5,6 (K)
RevNES-sensor
(fixed cells)
97,1±2,1  (H),  94,8±3,9
(M), 88,3±5,2 (K)
2,3±1,5 (H), 2,7±1,4 (M),
8,6± 2,3 (K)
0,6±0,2 (H), 2,5±1,3 (M),
3,1±2,0 (K)
RevNES-sensor
+LMB (fixed cells)
1,2±0,3 (H), 2,3±1,1 (M),
2,3±1,4 (K)
2,3±0,8 (H), 3,5±1,8 (M),
8,0±2,0 (K)
96,5±1,4  (H),  94,2±4,1
(M), 89,7±3,4 (K)
92,5± 3,4 (H)
91,4±6,0 (M)
85,7±4,7 (K)
RevNES-
GFP/GST-NLS
1,8±0,9(H),  3,5±3,0  (M),
5,1±2,8 (K)
4,1±1,0 (H), 3,5±2,0 (M),
6,3±4,1 (K)
94,1±0,8  (H),  93,0±1,9
(M), 88,6±5,2 (K) n.d.
Rev14-GFP
21,3±3,3  (H),  22,5±5,3
(M), 30,7±2,0 (K)
75,1±4,9  (H),  73,0±4,2
(M), 66,9±6,9 (K)
3,6±3,9 (H), 4,5±2,0 (M),
2,4±2,0 (K)
Rev14-GFP
+LMB
1,0±0,7 (H), 3,2±2,4 (M),
5,7±2,3 (K)
30,2±3,9  (H),  35,9±5,4
(M), 45,7±2,1 (K)
68,8±2,8  (H),  60,9±6,4
(M), 48,6±7,2 (K)
73,7± 4,1 (H)
68,8±7,2 (M)
63,2±6,9 (K)
PKINES-sensor
97,7±2,3  (H),  95,0±3,3
(M), 88,8±4,2 (K)
2,0±1,0 (H), 3,7±1,0 (M),
10,1±4,3 (K)
0,3±0,0 (H), 1,3±0,9 (M),
1,1±0,7 (K)
PKINES-sensor
+LMB
0,5±0,3 (H), 1,1±1,1 (M),
3,5±2,8 (K)
1,9±1,2 (H), 3,4±2,3 (M),
7,4±4,0 (K)
97,6±3,9  (H),  95,5±1,1
(M), 89,1±5,2 (K)
91,4± 3,7 (H)
92,6±4,3 (M)
89,3±5,0 (K)
PKI-BFP
98,0±0,6  (H),  97,5±4,4
(M), 93,8±4,7 (K)
0,8±0,1 (H), 1,5±1,2 (M),
4,2±2,8 (K)
1,2±0,9 (H), 1,0±0,1 (M),
2,0±1,1 (K)
PKI-BFP
+LMB
1,0±0,5 (H), 0,9±0,3 (M),
1,8±1,2 (K)
98,5±2,8  (H),  97,6±3,7
(M), 94,9±2,2 (K)
0,5±0,1 (H), 1,5±0,7 (M),
3,3±1,7 (K)
45,9± 2,8 (H)
42,4±3,9 (M)
36,6±6,1 (K)
StatNES-sensor
80,3±3,3  (H),  82,6±4,9
(M), 78,4±5,2 (K)
15,0±1,0  (H),  13,9±2,5
(M), 17,5±3,7 (K)
4,7±2,0 (H), 3,5±2,1 (M),
4,1±3,4 (K)
78,3± 4,2 (H)
78,4±7,0 (M)StatNES-
sensor+LMB
0,9±0,5 (H), 1,4±0,9 (M),
2,3±1,6 (K)
6,4±2,5 (H), 5,5±2,2 (M),
8,1±3,3 (K)
92,7±3,7  (H),  93,1±4,0
(M), 89,6±5,1 (K)
65,8±8,7 (K)
STAT1-GFP
25,8±6,0  (H),  27,2±3,9
(M), 19,9±4,6 (K)
69,2±3,8  (H),  66,5±2,7
(M), 73,3±4,2 (K)
5,0±2,3 (H), 6,3±3,1 (M),
6,8±2,5 (K)
STAT1-GFP  +
LMB
3,3±1,3 (H), 2,1±1,3 (M),
4,8±2,7 (K)
93,3±6,2  (H),  96,7±5,9
(M), 91,5±6,7 (K)
3,4±1,0 (H), 1,2±0,5 (M),
3,7±3,4 (K)
31,8± 2,9 (H)
33,1±5,5 (M)
28,7±8,9 (K)
AblNES-sensor
80,7±3,3  (H),  78,6±2,5
(M), 79,7±5,1 (K)
16,1±3,1  (H),  17,7±4,2
(M), 15,3±4,4 (K)
3,2±1,0 (H), 3,7±1,6 (M),
5,0±2,8 (K)
AblNES-
sensor+LMB
2,1±0,3 (H), 1,6±0,3 (M),
4,0±2,0 (K)
13,4±2,5  (H),  14,7±3,9
(M), 16,1±6,2 (K)
84,5±4,0  (H),  83,7±5,3
(M), 79,9±6,2 (K)
81,9± 4,8 (H)
80,4±4,2 (M)
70,7±6,7 (K)
RevNES-
sensor+Dox
93,2±3,9 (H9) 4,1±2,7 (H9) 2,7±1,1 (H9)
RevNES-
sensor+Dox+LMB
2,9±0,9 (H9) 2,7±1,5 (H9) 94,4±3,8 (H9)
 91,7± 2,6 (H9)
StatNES-
sensor+Dox
81,3±5,6 (H9) 13,3±4,5 (H9) 5,4±2,2 (H9)
StatNES-sensor-
Dox+LMB
2,6±1,8 (H9) 8,7±3,0 (H9) 88,7±6,3 (H9)
 79,4± 5,1 (H9)
AblNES-
sensor+Dox
79,9±5,3 (H9) 16,5±6,4 (H9) 3,6±1,1 (H9)
AblNES-sensor-
Dox+LMB
4,1±2,4 (H9) 17,6±3,9 (H9) 78,3±7,0 (H9)
 77,3± 6,2 (H9)
Casp3-sensor 93,1±5,2 (H) 5,3±2,9 (H) 1,6±0,7(H)
Casp3-
sensor+SP
9,4±7,8 (H) 10,3±7,0 (H) 80,3±5,5 (H)
90,2± 2,9 (H)
MKNES-CS3-
GFP-NLS
80,2±5,7 (H) 11,9±4,1 (H) 7,9±4,8 (H)
MKNES-CS3-
GFP-NLS+SP
14,4±4,0 (H) 72,9±8,3 (H) 12,7±6,3 (H)
56,5± 4,9 (H)
Casp3mut-sensor 95,6±2,4 (H) 2,5±1,1 (H) 1,9±0,9 (H)
Casp3mut-
sensor+SP
93,8±3,8 (H) 3,4±2,0 (H) 2,8±1,3 (H)
5,0± 2,9 (H)Supplementary Table S 3
Collective assay results for the effects of compounds or overexpressed proteins on
nucleo-cytoplasmic transport.  Expression  of  the  indicated  translocation  sensor  was
induced by Dox. Cells were either incubated with the indicated compounds for 8 h and fixed
or transfected with the indicated plasmids (see Supplementary Methods for details) and
analyzed 16 h later by fluorescence microscopy. IH: inhibitor; -: no effect, +: inhibition of
transport. The main target protein of the kinase IHs is indicated in brackets.
RevNES-sensor StatNES-sensor AblNES-sensor
Interference with Substance
export import export import export import
Exportin1 IH
LMB + - + - + -
RatA + - + - + -
Transcription IH
ActD - - - - - -
DRB - - - - - -
Cytoskeleton IH
Taxol - - - - - -
Nocodazol - - - - - -
LAT-B - - - - - -
HDAC IH
TSA - - - - - -
VPA - - - - - -
Kinase IH
Wortmannin (PI(3)K) - - - - - -
LY294002 (PI(3)K) - - - - - -
Staurosporin (PKC) - - - - - -
SB203580 (p38-MAPK) - - - - - -
U-73122 (PLC) - - - - - -
IC261 (casein kinase) - - - - - -
STI571 (Bcr-Abl) - - - - - -
AG 1478 (EGFR) - - - - - -
UO126 (MEK) - - - - - -
Others
INFg  - - - - - -
CsA (calcineurin) - - - - - -
Rapamycin (mTOR) - - - - - -
Protein
p53 - - - - - -
PKI-BFP + - + - + -
Exportin 1 - - - - - -
E1B-AP5 - - - - - -
eIF-5A - - - - - -
RevM10BL - - - - - -
GR - - - - - -
Vpr - - - - - -
E1B55K - - - - - -
mdm2 - - - - - -
CANc + - + - + -Cells were treated with the following chemicals: LMB (10 nM), interferon gamma (IFNg) (10
ng/ml),  wortmannin  (20  µM),  actinomycin  D  (ActD)  (5  µM),  5,6-
dichlororibofuranosylbenzimidazole  (DRB)  (5  µM),  taxol  (2  mM),  nocodazol  (50  µg/ml),
latrunculin-B (LAT-B) (1 µM), rapamycin (50 nM), cyclosporin A (2 µM), staurosporin (1 µM)
were purchased from Sigma (Sigma-Aldrich, Munich, Germany). Inhibitors NL-71-101 (20
µM), LY294002 (50 µM), IC261 (20 µM), SB203580 (20 µM), AG 1478 (10 µM), U-73122 (2
µM), valproic acid (VPA) (5 mM) and trichostatin A (TSA) (200 nM) were purchased from
Calbiochem  (St.  Louis,  MO,  USA).  Ratjadone  A  (10  nM)  was  purchased  from  Alexis
Biochemicals (San Diego, CA, USA), UO126 (50 µM) from Promega (Madison, WI, USA) and
STI571 (20 µM) was provided by Novartis (Basel, Switzerland).Supplementary Figures
Supplementary Figure S1
Application of transport biosensors to identify compounds or proteins that interfere
with nucleo-cytoplasmic transport. Expression of the RevNES sensor was induced by Dox
and (A) cells were incubated with taxol or nocodazol or (B) transfected with the PKI-BFP or
the CanC expression plasmids (3 µg each) together with 0.3 µg of the RFP expression
plasmid and analyzed by fluorescence microscopy. (A) Inhibition of microtubule metabolism
resulted in cell rounding but did not block nuclear export (upper panel) nor interfered with
nuclear import (lower panel). (B) Overexpression of PKI-BFP or CanC inhibited nuclear
export and resulted in the nuclear accumulation of the RevNES-sensor. Scale bars, 10 µm.
Supplementary Figure S2
Nuclear  translocation  of  the  biosensors  as  the  principle  for  cell  based  screening
applications. The cellular biosensors are composed of GST, GFP and rational combinations
of nuclear import and export signals. Addition of regulatory sequences resulted in three
classes of biosensors applicable for the identification of signal specific nuclear transport
inhibitors, small molecules that interfere with protease activity and compounds that modulate
protein-protein  interactions  in  living  cells.  Nuclear  accumulation  of  the  cytoplasmic
biosensors serves as the indicator, which can be induced by interference with nuclear export,
induction of protease activity or formation of highly specific protein complexes.Supplementary Figure S1Supplementary Figure S2PUBLICATIONS
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190Development of an Autofluorescent Translocation
Biosensor System To Investigate Protein-Protein
Interactions in Living Cells
Shirley K. Knauer* and Roland H. Stauber
Georg-Speyer-Haus, Paul-Ehrlich-Strasse 42-44, D-60596 Frankfurt, Germany
Protein-protein interactions are crucial for all cellular
events. To analyze protein-protein interactions in live
mammalian cells, we developed novel protein transloca-
tion biosensors composed of glutathione S-transferase,
mutants of GFP, and a rational combination of nuclear
import and export signals. Nuclear accumulation of the
cytoplasmic biosensors served as the reliable indicator,
which was induced by the formation of protein complexes
and could easily be detected by fluorescence microscopy.
The efficacy of the system was systematically investigated
by mapping the p53/mdm2 protein interaction interface.
Specificity and general applicability of the biosensors were
confirmed by studying additional classes of protein inter-
action domains (IDs), e.g., the leucine zipper IDs of Jun/
Fos and the coiled-coil ID of Bcr-Abl in different cell lines.
Importantly, we found that, in comparison to protein
complementation assays, our system proved highly ef-
ficient and reversible and thus suited for the identification
of molecular decoys to prevent specific protein-protein
interactions in living cells. Reversibility was demonstrated
in competition experiments by overexpressing the specific
IDs or by the application of a p53/mdm2 protein interac-
tion inhibitor. Thus, besides the convenient mapping of
protein IDs in living cells, the modular translocation
system has great potential to be employed in numerous
cell-based assays for the identification of small-molecule
protein interaction inhibitors as potential novel therapeu-
tics.
Cellular homeostasis and communication strictly require
regulated protein-protein interaction networks. Identification of
these interactions and characterization of their physiological
significance is one of the main goals of current research in a wide
range of biological fields.1,2
In addition, abolishing or inducing specific protein-protein
interactions by molecular decoys offers tremendous possibilities
for the treatment of human diseases.3 In cancer, cellular trans-
formation and maintenance of the transformed phenotype often
depend on the formation of high molecular weight complexes
(HMWCs). For example, the proto-oncogenes jun and fos encode
oncogenic transcription factors that bind DNA as dimers and can
promote malignant transformation by activating or repressing gene
expression (see ref 4 and references therein). As Jun and Fos
are members of the basic leucine zipper (bZip) protein family,
their dimerization is mediated by a parallel association of bZip
IDs. Inhibitors that prevent Jun-Fos dimerization and thus DNA
binding are currently under intense investigation as potential
anticancer drugs.5
Likewise, the importance of protein interactions is further
exemplified by the leukemia-inducing oncoprotein BCR-Abl. Oli-
gomerization of BCR-Abl is mediated by the N-terminal coiled-
coil region of BCR, and targeting this oligomerization domain by
peptides was shown to inhibit the leukemic activity of BCR-Abl
(ref 6 and references within).
In addition, the tumor-suppressor protein p53 forms an auto-
regulatory feedback loop with mdm2, in which the latter inhibits
p53 transcriptional activity and stimulates its degradation (ref 7
and references therein). Inhibition of the p53-mdm2 interaction
with synthetic molecules can lead to the nuclear accumulation
and the activation of p53 followed by the death of the tumor cells
from apoptosis.8
Therefore, modulating protein-protein interactions in general
as a novel therapeutic principle has recently attracted major
interest by academia and industry (reviewed in ref 3).
To date, numerous methods have been described to analyze
protein-protein interactions in vitro, in cell culture, and in vivo.9
Besides biochemical techniques, these include the yeast two-
hybrid (YTH) system, several split-enzyme complementation/
reconstitution assays (ref 10 and references therein), fluorescence
resonance energy-transfer (FRET),1,11 and bimolecular fluores-
cence complementation (BiFC) (see refs 12 and 13). Although
* To whom correspondence should be addressed. E-mail: s.knauer@
em.uni-frankfurt.de. Phone: (+49) 69 63395-149. Fax: (+49) 69 63395-145.
(1) Ozawa, T.; Kaihara, A.; Sato, M.; Tachihara, K.; Umezawa, Y. Anal. Chem.
2001, 73, 2516-2521.
(2) Mendelsohn, A. R.; Brent, R. Science 1999, 284, 1948-1950.
(3) Arkin, M. R.; Wells, J. A. Nat. Rev. Drug Discovery 2004, 3, 301-317.
(4) Vogt, P. K. Nat. Rev. Cancer 2002, 2, 465-469.
(5) Berg, T. Angew. Chem., Int. Ed. 2003, 42, 2462-2481.
(6) Beissert, T.; Puccetti, E.; Bianchini, A.; Guller, S.; Boehrer, S.; Hoelzer, D.;
Ottmann, O. G.; Nervi, C.; Ruthardt, M. Blood 2003, 102, 2985-2993.
(7) Chene, P. Mol. Cancer Res. 2004, 2,2 0 -28.
(8) Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.;
Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. Science
2004, 303, 844-848.
(9) Meng, J. J.; Rojas, M.; Bacon, W.; Stickney, J. T.; Ip, W. Methods Mol. Biol.
2005, 289, 341-358.
(10) Paulmurugan, R.; Umezawa, Y.; Gambhir, S. S. Proc. Natl. Acad. Sci. U.S.A.
2002, 99, 15608-15613.
(11) Wehrman, T.; Kleaveland, B.; Her, J. H.; Balint, R. F.; Blau, H. M. Proc.
Natl. Acad. Sci. U.S.A. 2002, 99, 3469-3474.
(12) Hu, C. D.; Kerppola, T. K. Nat. Biotechnol. 2003, 21, 539-545.
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interactions, several intrinsic limitations apply (see ref 1 and
references within). For example, the YTH detects only protein
interactions in the nucleus of yeast cells, and FRET and BiFC
require demanding technological assay platforms.
In particular, since biologically relevant protein-protein inter-
actions or any potential drug therapy targeting protein interactions
must be effective at the cellular level, cell-based assays (CBAs)
have to be employed to complement in vitro data. Recently, several
methods have been developed to facilitate the implementation of
CBAs.14 However, for any realistic application of high-content
(HCS) and high-throughput screening (HTS), CBAs depend on
robust and reliable biological readout systems with a high signal-
to-noise ratio.
Facing the clear need for facile cellular protein-protein
interaction assays, the present study describes a novel biosensor
system that has been tailored to also meet crucial requirements
of cell-based HCS/HTS assays. Combining autofluorescent pro-
teins as imaging tools with regulated nucleocytoplasmic transport
resulted in a mammalian two-hybrid protein translocation biosen-
sor (PTB) system, composed of a shuttling GFP-tagged molecule
I (GFP-prey) and a nucleolar anchored blue fluorescent protein
(BFP)-tagged molecule II (BFP-bait). The expression of active
protein IDs as fusions with the prey/bait constructs allowed the
co-localization of the GFP-prey with the BFP-bait, resulting in
cytoplasmic to nuclear prey translocation. Thus, our system
exploited the spatial division of the cell into the nucleus and the
cytoplasm as two intracellular compartments that can easily be
distinguished by microscopy. In contrast to existing protein
interaction assays, the presented strategy proved highly efficient,
flexible, and reversible and thus represents a straightforward
approach to characterize novel protein IDs and to identify low
molecular weight protein interaction inhibitors in living cells.
EXPERIMENTAL PROCEDURES
Plasmids. To construct pc3GFP/GST, the coding region for
GST was PCR amplified using primers containing KpnI-restriction
sites, pGEX-GFP15 as the template, and cloned into the vector pc3-
GFP.15 Subsequently, complementary oligonucleotides encoding
the SV40 NLS and the NES of the HIV-1 Rev were cloned into
the HindIII-/BamHI- or the KpnI-/EcoRI-restriction sites to gener-
ate pNLS-GFP/GST-RevNES. Plasmids pNLS-GFP/GST-bZipJun-
RevNES (GFP-prey_Jun), pNLS-GFP/GST-bZipFos-RevNES (GFP-
prey_Fos), pNLS-GFP/GST-BCR-RevNES (GFP-prey_BCR), pNLS-
GFP/GST-p53-RevNES (GFP-prey_p53), and pNLS-GFP/GST-
mdm2-RevNES (GFP-prey_mdm2) encode NLS-GFP/GST-ID-
RevNES fusions, containing the interaction domains (IDs) of
human Jun (aa 222-331), human Fos (aa 118-209), and human
BCR (aa 1-72), of the human p53 (aa 1-42) and the human
mdm2 protein (aa 1-118). The expression vectors were con-
structed by inserting the IDs N-terminal to the RevNES by PCR
amplifying the respective domains15,16 using oligonucleotides
containing NotI- and XhoI-restriction sites. pRevM10-BFP (BFP-
_bait) encodes a NES deficient HIV-1 Rev-BFP fusion protein
(RevM10-BFP).17 Plasmids pFos-RevM10-BFP (Fos_BFP-bait),
pJun-RevM10-BFP (Jun_BFP-bait), pBCR-RevM10-BFP (BCR_BFP-
bait), pp53aa1-131-RevM10-BFP (p53 aa 1-131_BFP-bait),
pp53aa132-262-RevM10-BFP (p53 aa 132-262_BFP-bait),
pp53aa263-393-RevM10-BFP (p53 aa 263-393_BFP-bait), pp53-
RevM10-BFP (p53_BFP-bait), and pmdm2-RevM10-BFP
(mdm2_BFP-bait) encode N-terminal fusions of the respective IDs,
the human p53 protein aa 1-131, aa 132-262, or aa 263-393 fused
to RevM10-BFP. Plasmids were constructed by PCR amplification
and cloning of the IDs 5¢ to the Rev ORF by using oligonucleotides
containing KpnI-restriction sites. pc3Fos-bZip and pc3BCR_ID
encode the untagged Fos bZip or the BCR aa 1-72, respectively,
and were constructed by PCR amplifying the IDs using oligo-
nucleotides containing HindIII-/BamHI-restriction sites and clon-
ing into pc3.15 The plasmid pNLS-EYFP/GST-bZipJun-RevNES
(YFP-prey_Jun) was constructed by replacing the GFP with the
ORF of the yellow fluorescent protein (YFP) by PCR amplification
and cloning using pEYFP-N1 (BD Biosciences) as template and
oligonucleotides containing BamHI-/KpnI-restriction sites. Plasmid
pc3p53, encoding human p53,15 pc3mdm2, encoding the human
mdm2 protein,15 pHA-CMV-bFosYC (FosYC), and pFLAG-CMV2-
bJunYN (JunYN), encoding the IDs of human Fos and Jun fused
to a C- or N-terminal fragment of YFP, respectively,18 have been
described. pDS-RED-N1 encodes the red fluorescent protein (RFP)
(BD Biosciences).
Cell Culture, Microinjection, and Fluorescence Imaging
of Cells. 293, HeLa or Vero cell lines were maintained in DMEM
medium (GIBCO) supplemented with 10% (v/v) fetal calf serum
and 2 mM glutamine at 37 °C and 5% CO2. Cells were transfected
with Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions and analyzed 16 h later as described to avoid
potential artifacts caused by protein overexpression.19 Twelve-bit
black and white images were captured using a digital Axiocam
CCD camera (Zeiss) and appropriate excitation and emission
filters to detect GFP, YFP, or BFP fluorescence.20 Quantitation,
image analysis, and presentation were performed using IPLab
Spectrum (Scanalytics) and Axiovision software (Zeiss). The total
cellular GFP signal was measured by calculating the integrated
pixel intensity in the imaged cell multiplied by the area of the
cell. The nuclear signal was similarly obtained by measuring the
pixel intensity in the nucleus. To quantify the degree of protein
interaction, the percentage of 200 BFP- and GFP-positive cells in
which BFP and GFP co-localized to the nucleus from three
separate images was determined with standard deviations (SD).
To compare PTB and BiFC, 200 cells from three separate images
were inspected, and the number of cells in which nuclear YFP
fluorescence could be detected with equal CCD camera settings
was counted. Nuclei were marked by staining with TO-PRO-3-
iodide (Molecular Probes) according to the manufacturer’s recom-
mendations. All pixel values were measured below the saturation
(13) Yu, H.; West, M.; Keon, B. H.; Bilter, G. K.; Owens, S.; Lamerdin, J.;
Westwick, J. K. Assay Drug Dev. Technol. 2003, 1, 811-822.
(14) Hemmila, I. A.; Hurskainen, P. Drug Discovery Today 2002, 7, S150-156.
(15) Kra ¨tzer, F.; Rosorius, O.; Heger, P.; Hirschmann, N.; Dobner, T.; Hauber,
J.; Stauber, R. H. Oncogene 2000, 19, 850-857.
(16) Berg, T.; Cohen, S. B.; Desharnais, J.; Sonderegger, C.; Maslyar, D. J.;
Goldberg, J.; Boger, D. L.; Vogt, P. K. Proc. Natl. Acad. Sci. U.S.A. 2002,
99, 3830-3835.
(17) Stauber, R. H.; Afonina, E.; Gulnik, S.; Erickson, J.; Pavlakis, G. N. Virology
1998, 251,3 8 -48.
(18) Hu, C. D.; Chinenov, Y.; Kerppola, T. K. Mol. Cell. 2002, 9, 789-798.
(19) Heger, P.; Lohmaier, J.; Schneider, G.; Schweimer, K.; Stauber, R. H. Traffic
2001, 2, 544-555.
(20) Stauber, R. H.; Horie, K.; Carney, P.; Hudson, E. A.; Tarasova, N. I.;
Gaitanaris, G. A.; Pavlakis, G. N. BioTechniques 1998, 24, 462-471.
B Analytical Chemistrylimits, and the background signal in an area with no cells was
subtracted from all values.
Drug Treatment. Cells were treated with 0.2 íM nutlin-3
(Alexis Biochemicals) for 8 h.
Immunoblotting. 5  105 HeLa cells were transfected with
the indicated plasmids. Whole cell lysates, analysis of the
complexes by SDS-PAGE, and immunoblotting using a polyclonal
anti-GFP antibody (BD Biosciences) and a polyclonal anti-â-actin
antibody (Sigma Aldrich) were performed as described.19
RESULTS
Rational Design of PTBs To Visualize Specific Protein-
Protein Interaction in Living Cells. A facile and reliable system
that allows visualization of protein interactions in living cells
applicable also for drug screening CBAs has to fulfill the following
criteria: (1) The GFP-tagged molecule I (GFP-prey), although
continuously shuttling between the nucleus and the cytoplasm,
should localize predominantly to the cytoplasm. (2) The BFP-
tagged molecule II (BFP-bait) should be confined to the nucleus.
(3) Upon specific protein interaction between molecule I and II,
the GFP-prey should redistribute to the nucleus and co-localize
with the BFP-bait (Figure 1b). (4) The system should be reversible
and should allow the modular exchange of interaction domains.
(5) Inhibitors/inductors of protein interactions should prevent/
induce the cytoplasmic to nuclear translocation.
Previously, we showed that the intracellular localization of a
GST-GFP fusion strictly depends on the presence of nucleocy-
toplasmic transport signals and is not flawed by passive diffusion.19
In addition, GST-GFP is highly fluorescent, nontoxic, and stable.
To design a GFP-GST shuttle protein with a predominantly
cytoplasmic steady-state localization, an appropriate combination
of nuclear import (NLS) and nuclear export signals (NES) had to
be used. Based on our kinetic classification studies,19 we choose
the SV40 large T-antigen NLS (SV40NLS) and the NES from the
HIV-1 Rev protein (RevNES). Subsequently, we engineered a
cassette that allows the expression of any ORF X as a NLS-GFP/
GST-X-NES fusion protein (GFP-prey) via cloning into the unique
NotI-/XhoI-restriction sites of the expression vector (Figure 1a).
Our previous work17 demonstrated that a NES deficient HIV-1 Rev-
Figure 1. (a) Schematic representation of the domain organization of the GFP-prey and BFP-bait proteins. The GFP-prey is composed of the
SV40 NLS, GST, GFP and the HIV-1 RevNES. The BFP-bait comprises a fusion of the HIV-1 RevM10BL protein fused to BFP. Unique restriction
sites for the cloning of interaction domains are indicated. (b) Principle of the translocation based protein-protein interaction assay. GFP-prey
fusions are continuously shuttling between the nucleus and the cytoplasm and do not interact with nucleolar BFP-bait proteins lacking matching
IDs. In contrast, in case of efficient protein interaction, coexpression of a GFP-prey-ID1 fusion together with an ID2-BFP-bait protein results in
translocation of the prey, being tethered to the nucleolus by the bait. Filled forward triangle, NLS; filled reverse triangle, NES.
Figure 2. PTB-based mapping of the mdm2 protein interaction
interface on p53. HeLa cells coexpressing the indicated prey/bait
proteins were analyzed by fluorescence microscopy. The GFP-prey-
mdm2 protein localized predominantly in the cytoplasm, and no co-
localization was detectable by coexpression of the empty BFP-bait
protein (left panel). In contrast, coexpression of the p53 aa 1-131,
but not of aa 132-262 or aa 263-393_BFP-bait induced the
cytoplasmic to nuclear translocation of GFP-prey_mdm2, indicative
for protein-protein interaction. Scale bars, 10 ím.
Analytical Chemistry CBFP fusion (RevM10-BFP) localized to the nucleolus and thus
represented an ideal frame to express nucleolar anchored Y-BFP
fusion proteins (BFP-bait) by cloning into the unique KpnI-
restriction site of the expression vector. Of note, the distinct
emission and excitation spectra of the used GFP and BFP
mutants20 allowed the detection of the localized GFP-prey and the
BFP-bait independently from each other in the same cell.
Mapping the mdm2 Protein Interaction Interface on p53.
To demonstrate that our system was applicable for the identifica-
tion of protein IDs, we first expressed the mdm2 aa 1-118, known
to mediate p53 binding, as a GFP-prey_mdm2 fusion. As expected,
the GFP-prey_mdm2 fusion localized to the cytoplasm and did
not co-localize with the empty BFP-bait at the nucleolus upon
coexpression in HeLa, 293 or Vero cells (Figure 2, left panel and
data not shown). Next, we expressed the p53 aa 1-131, 132-
262, or 263-393 in the context of the BFP-bait construct. Following
transient expression, the p53-bait fusions were correctly tethered
to the nucleolus. Although protein expression increased over time,
the observed prey/bait-translocation patterns were similar when
inspected at 16, 24, or 26 h posttransfection (data not shown).
However, only the p53 aa 1-131 induced the cytoplasmic to
nuclear translocation of the GFP-prey_mdm2 indicative of efficient
protein interaction (Figure 2). Similar results were observed in
293 and Vero cells (data not shown). Since the p53/mdm2 ID
has previously been assigned to the p53 aa 1-42,7 our PTB could
be successfully applied for the protein ID identification. Of note,
we have not experienced limitations of our system due to protein
size, since we used the PTB system to analyze homomultimer-
ization of prey/bait proteins with 180 kDa in size (unpublished
observation).
PTBs Are Generally Applicable and Specific. Subsequently,
we confirmed the performance of our system by analyzing
additional structurally unrelated protein IDs. As representatives
of the basic bZip protein ID family we examined the bZip IDs of
Jun and Fos. Expression of GFP-prey_Jun revealed a cytoplasmic
localization even in the presence of the empty BFP-bait (Figure
3a, left panel, and Figure 4b). In contrast, coexpression of the
Fos_BFP-bait resulted in nuclear translocation and co-localization
Figure 3. Application of PTBs to visualize specific protein-protein
interaction in living cells. HeLa cells coexpressing the indicated prey/
bait proteins were analyzed by fluorescence microscopy. (a) The GFP-
prey-Jun/BCR proteins localized predominantly in the cytoplasm
(upper panel) and no co-localization was detectable by coexpression
of the empty BFP-bait proteins (lower panel). (b) In contrast, the GFP-
prey proteins accumulated in the nucleolus upon coexpression of the
matching BFP-bait interaction partners. (c) No significant co-localiza-
tion was detectable by coexpression of GFP-prey_Jun together with
BCR_BFP-bait or of GFP-prey_BCR and the Fos_BFP-bait fusion
proteins. Dashed lines mark the cell boundaries visualized from the
corresponding phase-contrast images. Scale bars, 10 ím. Filled
forward triangle, NLS; filled reverse triangle, NES.
Figure 4. Superiority of AFP-based protein-protein interaction
assay to bimolecular fluorescence complementation. HeLa cells were
cotransfected with 1 íg of each of the GFP-prey_Jun and Fos_BFP-
bait or the FosYC and JunYN expression plasmids and analyzed by
fluorescence microscopy (see Experimental Procedures). Cells were
recorded using identical camera settings. (a) A significantly higher
percentage of cell displaying nuclear GFP fluorescence indicative for
protein interaction was observed using the PTB assay. Mean values
( SD from two independent experiments are shown. Error bars, SD.
(b) In addition, randomly selected cells displayed a higher fluores-
cence intensity on average in the PTB assay. Scale bars, 10 ím. (c)
Equal expression levels of the indicated fusion proteins were verified
by Western blot analysis of cellular lysates using a polyclonal anti-
GFP antibody. â-Actin served as the loading control.
D Analytical Chemistryof the GFP-prey_Jun fusion with the bait at the nucleolus (Figure
3b, left panel, and Figure 4b). Similar results were observed when
swapping the Jun/Fos IDs in the prey/bait constructs (data not
shown). As a further example for a non-leucine zipper protein ID,
we investigated the N-terminal coiled-coil oligomerization interface
of the BCR-Abl protein. The steady-state localization of the GFP-
prey_BCR was cytoplasmic, and as required, no co-localization
was induced upon coexpression of the empty BFP-bait (Figure
2a, right panel, and Figure 4b). Importantly, although the BCR-
Abl ID is able to form homodimers, coexpression of the BCR_BFP-
bait still resulted in a significant co-localization of the GFP-
prey_BCR at the nucleolus (Figure 2b, right panel, and Figure
4b). Importantly, we did not observe protein interaction upon
coexpression of the GFP-prey_Jun together with the BCR_BFP-
bait (Figure 2c, left panel, and Figure 4b) or of the GFP-prey_BCR
together with the Fos_BFP-bait (Figure 2c, right panel, and Figure
4b), which underlines the specificity of the interaction assay. All
results could be confirmed in 293 and Vero cells (data not shown).
PTB Assay Is facile and Highly Efficient. A prerequisite for
the routine use of live cell assays to detect protein-protein
interaction is that the system is robust and does not require
demanding technological assay platforms. Consequently, we
compared our translocation assay to BiFC as another fluorescence
microscopy-based assay system. BiFC is based on the fluorescence
complementation between two nonfluorescent fragments of GFP
when brought together by the interaction between proteins IDs
fused to each fragment.
To compare the performance of the two assay systems, we
cotransfected equal amounts of the GFP-prey_Jun and Fos_BFP-
bait or the FosYC and JunYN expression plasmids into HeLa cells
and quantitated the number of cells displaying nuclear GFP
fluorescence indicative for active protein interaction (Figure 4a).
Using identical CCD camera settings, not only the number of
individual protein interaction events but also the average fluores-
cence signal was significantly higher for the PTB assay when
compared to BiFC (Figure 4a,b). Similar transfection efficiencies
and expression levels were confirmed by immunblot analysis
(Figure 4c).
PTB Assay Is Reversible and Suited for the Identification
of Small-Molecule Protein Interaction Inhibitors. Besides
efficacy and specificity, reversibility is an important criterion for
cellular protein interaction assays, in particular when applied for
HCS/HTS to identify SMPIIs. Thus, we confirmed the reversibility
of our assay by overexpressing the untagged ID of p53 (ID p53)
in cells coexpressing the GFP-prey_mdm2 and p53_BFP-bait,
which resulted in a significantly reduced nucleolar co-localization
of the GFP-prey_mdm2 protein (Figure 5a,c). Similar results were
obtained in competition experiments for the BCR-Abl ID using
the untagged BCR aa 1-72 (Figure 5b,c).
As a case study for the application of a SMPPII, we attempted
to disrupt the p53/mdm2 interaction by the use of nutlin-3, which
had been described as a synthetic inhibitor of p53/mdm2
interaction in vitro and in vivo.8 Treatment of transfected HeLa
cells resulted in a significant cytoplasmic redistribution of the GFP-
prey_mdm2 fusion, due to interference with p53/mdm2 interaction
(Figure 5c). Of note, nutlin-3 treatment had no effect on Jun/Fos
or BCR/BCR mediated translocation (data not shown), excluding
the formal possibility that the GFP-prey_mdm2 redistribution was
caused by nutlin-3-mediated inhibition of nuclear import.
Figure 5. Reversibility of the PTB assay and suitability for the identification of SMPIIs. (a) Overexpression of the untagged p53 ID in GFP-
prey_mdm2 and p53_BFP-bait coexpressing cells competes with p53/mdm2 interaction. RFP served as the transfection control. In RFP positive
cells, expression of the competitor partially relieved the nucleolar accumulation of GFP-prey_mdm2, in contrast to nontransfected cells (marked
by the arrow). (b) Overexpression of the untagged BCR ID in GFP-prey_BCR and BCR_BFP-bait coexpressing cells competes with BCR ID
interaction. RFP served as the transfection control. In RFP positive cells, expression of the competitor relieved the partially nucleolar accumulation
of GFP-prey_BCR in contrast to nontransfected cells (marked by the arrow). Scale bars, 10 ím. (c) To quantify the degree of protein interaction,
200 cells coexpressing the indicated GFP-prey and BFP-bait proteins together with the indicated competitors/compound were inspected. The
percent of cells in which BFP and GFP co-localized at the nucleolus was determined. Mean values ( SD from two independent experiments.
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This study validates the advantages of the AFP-based protein
translocation biosensors as a straightforward approach to inves-
tigate protein-protein interactions in live cells. Recently, it has
become clear that molecules that inhibit specific protein-protein
interactions have great potential as therapeutics with new modes
of action3. Consequently, numerous methods have been developed
to analyze protein-protein interactions in vitro, in cell culture,
and in vivo (see ref 21 and references therein). Paulmurugan et
al.10 reported a noninvasive system to detect protein-protein
interaction in whole animals based on the reconstitution of split
luciferase fragments. However, the experimental procedures
required to quantify luciferase activity argue against its routine
use in high-throughput CBAs. Fluorescence methods to study
protein interactions in living cells involve inter- and intramolecular
FRET as well as BiFC.12 In contrast to in vitro FRET applications,
the use of FRET in cellular assays is often inefficient, affected by
background fluorescence, and requires demanding technological
assay and analysis platforms in order to perform HTS. Although
BiFC represents a powerful method, the efficiency and signal
intensity is low, which could be also demonstrated in our study.
In addition, BiFC depends on the proper orientation of the two
AFP fragments, and the likelihood of complementation is expected
to decrease with protein size and distinct intracellular localization
of the interaction partners, which will limit its application for the
characterization of HMWCs. Moreover, BiFC as well as other
reconstitution/complementation assays appears to be irreversible18
which hampers the screening for inhibitory protein interaction
decoys. All these limitations do not apply to the described AFP-
based cellular “two-hybrid” interaction system. We showed that
the cytoplasmic to nuclear/nucleolar redistribution was easily
detectable, highly specific, and reversible for the IDs investigated.
In contrast to FRET, no specific linkers connecting the IDs to
the prey/bait backbone were required. Importantly, the distinct
intranuclear (co)localization patterns observed were characteristic
for the IDs used and, in the case of the Jun-Fos IDs, exhibited a
similar granular pattern as reported for full length Jun-Fos
heterodimers.18 This suggests that the IDs displayed by the prey/
bait backbone can mimic the conformation of the IDs in the full
length proteins in vivo. Besides specificity, reversibility is an
important issue in CBAs in order to identify potent SMPIIs. Since
overexpression of the untagged Fos or BCR ID was able to chase
the respective prey fusion proteins out of the Jun/Fos or BCR/
BCR complexes, our interaction system fulfills this criterion.
Importantly, as a bona fide application of a SMPII treatment with
nutlin-3 was able to successfully compete with p53/mdm2 ID
interaction in living cells. Thus, the introduction of the AFP-based
PTB system, combined with novel computer-driven, automated
image acquisition and pattern-recognition systems, will help to
realize cell-based high-throughput SMPIIs identification. Already
to date, the defined disease relevant targets are numerous (see
refs 5 and 21) and are expected to multiply by the systematic
analysis of the human proteom.
In conclusion, the assay presented proved flexible, robust,
facile, and highly amenable to academic-scale screens with the
potential to be employed in novel HCS/HTS applications. Since
the majority of GFP-prey fusions are not expected to intrinsically
localize to the nucleolus, our system is applicable to also map the
IDs of novel proteins. The modular composition of the PTB
guarantees their application in numerous biological systems and
will not only help to elucidate basic biological mechanisms but
also stimulate the screening and discovery of pharmaceuticals that
modulate protein-protein interactions as novel therapeutic strate-
gies.
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